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I. SUMMARY 
I. 1 Summary 
Haemotrophic mycoplasmas (HM), small, cell wall-less, uncultivable bacteria, reside on 
the surface of mammalian red blood cells (RBCs). They were first described in the early 
20th century as Eperythrozoon and Haemobartonella species within the group of Ricket-
tsia. In the late 1990s, they were reclassified as Mycoplasma species within the group of 
Mollicutes. In most animal species, a HM infection is accompanied by haemolytic anae-
mia, and clinical signs may include decreased exercise tolerance, lack of appetite, poor 
weight gain, and infertility. 
Although HM infections have already been studied in several domesticated and wild 
animals, almost nothing is known about possible infections in horses. First indications 
of the existence of horse-specific HM parasites and their infection of horses in the Lune-
burg Heath (Northern Germany) were reported by owners presenting horses showing 
the aforementioned clinical signs. Blood samples of these animals were analysed for 
HM using microscopy, PCR, and 16S rRNA sequencing, and the first molecular proof, 
that HM infections do occur in horses, was shown. 
The clinical significance of HM infections in horses was evaluated. Blood samples from 
horses of one breeding farm were analysed haematologically and screened using PCR 
and microscopy. For a more sensitive and unambiguous diagnostics, a specific SYBR 
green I real-time PCR assay was developed. A high prevalence of 33.2 % and a mean 
blood load of 1.67 x 107 cells/mL blood were observed. Infected horses older than one 
year showed no significant blood parameter changes, while those younger than one year 
showed a significant reduction in red blood cell count, haematocrit, and haemoglobin 
concentration, indicating a haemolytic anaemia. In horses, HM infections frequently 
displayed a subclinical course of disease, with relatively low concentrations of bacteria 
in blood. A severe course of disease with pronounced clinical signs and anaemia may 
only develop in young, stressed, or immunocompromised animals. 
Generally, the current classification of HM in the Mycoplasma-cluster in the Mollicutes 
group was confirmed, and within HM’s group, two subclusters were found (‘haemofe-
lis-group’ and ‘haemominutum-group’). In Northern Germany, two HM isolates were 
found in cattle: M. wenyonii and ‘CM haemobovis’. The novel equine HM isolate be-
longs to the ‘haemofelis-group’ and shows 97-98 % 16S rRNA identity to ‘CM haemo-
bovis’. 
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I. 2 Zusammenfassung 
Hämotrophe Mykoplasmen (HM) sind kleine, zellwandlose, unkultivierbare Bakterien 
auf der Erythrozyten-Oberfläche von Säugetieren. Sie wurden Anfang des 20. Jahrhun-
derts erstmals beschrieben und als Eperythrozoon oder Haemobartonella innerhalb Ri-
ckettsia klassifiziert. In den späten 1990iger wurden sie als Mykoplasmen (Mollicutes) 
reklassifiziert. In den meisten Tierarten ist eine HM-Infektion durch hämolytische Anä-
mie, Leistungsabfall, Appetitlosigkeit, Gewichtsverlust und Infertilität gekennzeichnet. 
Obwohl HM-Infektionen in vielen Haus-, Nutz- und Wildtieren beschrieben wurden, ist 
bisher fast nichts über eine mögliche equine Infektion bekannt. In der Lüneburger Heide 
(Norddeutschland) wurde wiederholt von anämischen Pferden mit oben genannter 
Symptomatik berichtet. Blutproben dieser Tiere wurden auf das Vorkommen von HM 
mithilfe von Mikroskopie, PCR und 16S rRNA-Sequenzierung untersucht. Dabei konn-
te der Erreger erstmals zweifelsfrei molekularbiologisch im Blut von Pferden nachge-
wiesen werden. 
Um die klinische Relevanz einer HM-Infektion beim Pferd zu untersuchen, wurden so-
wohl große Blutbilder angefertigt, als auch Mikroskopie und PCR durchgeführt. Zur 
sensitiveren und zweifelsfreien Diagnostik wurde ein spezifischer SYBR green I real-
time PCR Assay entwickelt. Dabei wurde eine relativ hohe Prävalenz (33.2 %) mit einer 
durchschnittlichen Bakterienanzahl von 1.67 x 107 Zellen/mL Blut gefunden. Während 
bei infizierten Pferden älter als ein Jahr keine signifikanten Veränderungen im Blutbild 
beobachtet wurden, zeigten infizierte Pferde unter einem Jahr signifikante Reduzierun-
gen der Erythrozytenzahl, des Hämatokrit und der Hämoglobin-Konzentration. Dies 
deutet auf eine hämolytische Anämie hin. Im Grossen und Ganzen scheint diese Infek-
tion in Pferden eher subklinisch mit einer nur geringen Anzahl von Bakterien im Blut zu 
verlaufen, während die akute Verlaufsform mit ausgeprägter Symptomatik und Anämie 
nur in jungen, gestressten oder immunkompromitierten Tieren vorzukommen scheint. 
Im Allgemeinen wurde die Eingruppierung der HM in die Gruppe der Mollicutes inner-
halb des Mykoplasmen-Clusters bestätigt. Es wurden zwei Subcluster innerhalb der HM 
gefunden (‘haemofelis-’ und ‘haemominutum-Gruppe’). In Norddeutschland wurden in 
einer anämischen Rinderherde zwei verschiedene HM Isolate gefunden: M. wenyonii 
und ‘CM haemobovis’. Das neue equine HM Isolat gehört zur ‘haemofelis-Gruppe’ und 
zeigt auf Ebene der 16S rRNA eine 97-98 %ige Identität zu ‘CM haemobovis’. 
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II. INTRODUCTION 
II.1 The genus Mycoplasma 
Mycoplasmas are the smallest self-replicating bacteria known thus far (0.3-1.0 µm), 
near the theoretical minimum cell size limit of 0.15 µm (195, 256, 259, 261). Mycoplas-
mas’ genomes range in size from 580 kb (M. genitalium, 89) to 1359 kb (M. penetrans, 
272) and code for up to only 700 proteins (258). Mycoplasmas are also characterised by 
a low GC % content (23-41 %, 195) and unusual codon usage (261, 262). Due to their 
small size, they pass through common bacterial filters and were therefore not detected 
until 1898 (‘microbe de la péripneumonie’, 234). In 1929, NOWAK introduced the desig-
nation ‘Mycoplasma’ (237). Although gliding motility was reported for some species 
(e.g. M. pneumoniae, M. gallisepticum, and M. pulmonis) (195), most mycoplasmas are 
non-motile. In mycoplasmas, a cell wall is missing, leading to various cell and colony 
shapes (fried-egg shaped colonies, pear-shaped or flask-shaped cells, terminal tip struc-
tures, and filaments) (256, 261). Cell shapes are governed by cytoskeleton-like struc-
tures (261, 262), but may be influenced by culture and procession conditions (195). Un-
til the first genomic analysis in the 1960s, the scientific consensus was that mycoplas-
mas may represent L-forms of bacteria (bacteria which have lost their cell wall) (218). 
Genomic analyses, however, revealed no relationship to known cell-walled bacteria for-
ming L-forms (262). 
Their stringent nutritional requirements render them difficult to cultivate, so many spe-
cies have not yet been cultivated (8, 261), hampering research and diagnostics. Several 
explanations for this phenomenon were offered based on results from genomics experi-
ments. Both, M. genitalium and M. pneumoniae, lack genes for amino acid synthesis 
(89, 124, 260), requiring very complex media including various growth supplements 
(256, 262). Due to their small genomes, mycoplasmas do not have an extensive metabo-
lism; they only have enzymes for energy production. Furthermore, mycoplasmas have a 
limited respiratory system, as they lack quinones, cytochromes, and parts of the citric 
acid cycle (250, 256, 258, 260, 261). Despite their small genomes and stringent environ-
mental requirements, mycoplasmas are widely distributed and common pathogens due 
to their high level of adaptation to certain tissues in various hosts (plants, insects, ani-
mals, and humans) (8, 255, 256, 337). They rely on an obligate parasitic lifestyle and 
occur as extra- and intracellular parasites (261, 262). 
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II.2 Haemotrophic mycoplasmas 
II.2.1 Overview 
Haemotrophic mycoplasmas (HM) are extraordinary members of the large group of my-
coplasmas due to their obligate intra- or extracellular parasitism of mammalian red 
blood cells (RBCs) (106, 136, 172, 210). Deformity and destruction of RBCs caused by 
attached HMs lead to mild to severe haemolytic anaemia (136, 210). Since HMs require 
special growth conditions, in vitro cultivation has not yet been successful, although an 
in vitro maintenance system for M. suis was proposed (235). Thus, researchers still rely 
on ethically questionable experimental infections of splenectomised or otherwise immu-
nocompromised animals to analyse HM’s physiology, pathogenesis, and immunology 
(34). 
First representatives of HMs were discovered in 1928 in Germany, when SCHILLING ob-
served roundish RBC parasites in mice and named them Eperythrozoon coccoides 
(275). In 1939, TYZZER & WEINMAN detected Haemobartonella muris in mice (342). 
Since then, many novel Eperythrozoon and Haemobartonella species in several animal 
hosts were found all over the world (210). In the late 1990s, Eperythrozoon and Haemo-
bartonella species were reclassified as Mycoplasma species within the Mollicutes class 
(e.g. 219, 220, 265; Ch. II.2.7., p. 22). An increasing number of case reports within the 
past several years demonstrate how HM infections are not restricted to farming and 
companion animals (e.g. pigs, cattle, dogs, and cats) anymore; HM isolates were also 
found in wild animals such as lions (108) and capybara (350). Furthermore, novel spe-
cies in cats (360), cattle (314), sea lion (351), and deer (355) were detected. 
HM infections merit further study due to their economic and scientific impact. In live-
stock husbandries, HM infections can lead to important economic losses: decreased 
weight gain in pigs, decreased wool production in sheep, and decreased fertility (53, 
136, 210, 212). Undetected latent HM infections in laboratory animals may cause inter-
ferences and bias of experiments (e.g. dog (164), mice (25, 99, 245, 266, 275), rats (75), 
and primates (64, 221)). 
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II.2.2 Pathogenesis and clinical signs 
HMs induce a disease known by several names (‘eperythrozoonosis’ (122, 263, 292), 
‘haemobartonellosis’ (35, 192), ‘infectious anaemia’ (116, 136), and ‘haemoplasmosis’ 
(315)), but each describes more or less the same clinical manifestation. The incubation 
period varies from days to several weeks (312). The most prominent clinical sign in in-
fected animals is haemolytic anaemia; HMs attach to RBCs, which are then deformed 
and destroyed (136, 138, 210). Further possible clinical signs are summarised in Table 
II-1 (pp. 9-10). 
HM infection severity can vary from mild to life-threatening. Severity could possibly be 
linked to the number of bacteria in blood (182, 325), although this point remains a sub-
ject of contention (322, 361). Furthermore, a subclinical course of disease and chronic 
infection states have been reported, and infections may persist chronically for years un-
til an outbreak is induced (85, 86, 136, 194, 210, 289, 292). Chronic infections are typi-
cally observed in non-splenectomised, immunocompetent animals (210). Splenectomy 
or immunocompromisation of latent infected animals can induce severe disease (35, 
99). Chronically infected animals may represent HM reservoirs and could possibly 
spread the infection to other animals. Mainly immunocompromised, stressed, pregnant, 
and juvenile or old animals are affected (99, 105, 136, 199, 210, 311, 336). Severity of 
disease can also be affected by interference with concurrent infections, e.g. anaplasmo-
sis (Anaplasma marginale, A. ovis) (112, 139, 140), piroplasmosis (Theileria sp., Babe-
sia sp.) (65, 139, 245), virus infections (29, 46, 57, 86, 95, 103, 105), and co-infections 
of multiple HM species (154, 202, 323, 361). Additionally, interactions of mycoplasmas 
with the host immune system should be considered (261). 
HMs adhere to RBCs in a multifactorial process involving many accessory proteins 
(261), and they can attach to RBCs via fibrillary structures (64, 247, 376). In M. galli-
septicum, M. imitans, M. genitalium, M. pneumoniae, and M. alvi, a terminal tip struc-
ture was detected (30, 39, 124, 256, 261, 285), but this structure is absent in M. hominis, 
M. fermentans, M. pulmonis, and M. suis (40, 106, 261, 376). Attachment of M. pene-
trans induces a cytoskeletal rearrangement in the host cell (97). Adhesion proteins in 
M. pneumoniae and M. genitalium have also been observed and characterised (89, 124, 
125, 261). RAZIN stated that there may be a “conserved family of mycoplasmal cytadhe-
sins” (261). It appears that metabolic exchange between HMs and RBCs occurs, as 
“close contact seems to be crucial for the life cycle of this bacterium” (136). In 2007, 
HOELZLE et al. proposed MSG1 (M. suis GAPDH-like protein 1), a protein highly 
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similar to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as a putative adhesion 
protein of M. suis (135). GAPDH is an enzyme involved in glycolysis, and hypoglycae-
mia is well connected with M. suis metabolism (119, 235, 294). Massive metabolic dis-
turbances were observed in pigs as well as in sheep. In these cases, increased lactate and 
pyruvate concentrations alongside decreased bicarbonate concentrations in blood lead to 
severe blood acidosis (119, 120, 148). Hypoglycaemia was also observed in llamas 
showing peak parasitaemia (6, 199). Parasitaemia can range in infection severity, from 
barely detectable to more than 85 % of RBCs affected (163). Each RBC can carry up to 
twenty or more HM cells. Attached HMs lead to deformation of RBC membrane, and 
affected RBCs display pits, trenches, invaginations and indentations (163, 219, 252, 
265, 316, 376), which induce a type-II autoimmune reaction and lead to a Coombs’ po-
sitive immune mediated haemolytic anaemia (35, 136, 192). In pigs (M. suis; 138, 156, 
276), mice (M. coccoides; 150), cats (M. haemofelis; 328, 380), and dogs (M. haemoca-
nis; 17), high titres of IgM cold agglutinins were found. IgM cold agglutinins are either 
directed as auto-antibodies against RBC surface antigens or against bacteria attached to 
the RBC surface. In the latter case, destruction of RBCs would be a side effect. Activity 
of cold agglutinins may directly result in clinical signs such as acrocyanosis and pallor 
(17, 35, 48, 136, 156, 276, 377, 380). Additionally, HMs could directly damage RBCs. 
Our institute has performed initial studies which support the existence of this pathway; 
warm auto-reactive IgG antibodies were found in M. suis-infected pigs, which are speci-
fically directed against porcine actin, leading to eryptosis and resulting in severe haemo-
lytic anaemia (78). 
Since HM are not cultivable, pathogenicity studies of HM are complicated and the exact 
mechanism of adhesion, attachment, invasion, and destruction of RBCs is an active area 
of research. 
 
 Table II-1 Clinical signs of HM infections 
Clinical Sign HM species References 
abortion M. suis 210 
acrocyanosis M. suis 118 
anaemia ‘CM haemolamae’, M. ovis, M. suis, M. haemofelis, M. wenyonii, ‘CM turicensis’ 6, 36, 53, 122, 136, 137, 210, 263, 312, 360 
anorexia ‘CM haemolamae’, M. suis, M. haemofelis, M. wenyonii 6, 136, 210, 212, 263 
bacteraemia M. suis, M. haemofelis 312, 377 
bile-coloured faeces M. suis 118 
cardiac murmurs M. haemofelis 312 
collapse ‘CM haemolamae’ 210 
cyanosis M. suis 118 
decreased exercise tolerance M. ovis 36, 53, 210 
decreased milk production M. suis, M. wenyonii 136, 210, 293 
decreased wool production M. ovis 36, 53 
dehydration M. haemofelis 312 
depression ‘CM haemolamae’, M. suis, M. haemofelis 6, 210, 312 
diarrhoea ‘CM haemolamae’ 6, 263 
dyspnoea ‘CM haemolamae’, M. suis 6, 118 
oedema M. wenyonii 212 
enteritis M. suis 118 
fever M. suis, M. haemofelis, M. wenyonii 118, 136, 210, 212, 312 
hepatomegaly M. suis 169 
hyperkalaemia ‘CM haemolamae’ 6 
hypoglycaemia M. suis, M. ovis, ‘CM haemolamae’ 6, 119, 184, 199, 210, 294, 306 
hypoproteinaemia ‘CM haemolamae’ 263 
hypothermia M. haemofelis 312 
icterus M. suis, M. ovis, M. haemofelis 122, 136, 169, 210, 312 
ill-thrift M. suis, M. ovis 36, 53, 136, 210 
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 Table II-1 continued 
Clinical Sign HM species Reference 
immune suppression M. suis 136, 377 
inappetence M. suis, ‘CM haemolamae’, M. haemofelis 6, 118, 136, 312 
infertility M. suis, M. wenyonii 136, 210, 212 
lethargy M. haemofelis, ‘CM haemolamae’, M. wenyonii 210, 212 
lymphadenopathy M. wenyonii 210, 293 
metabolic acidosis ‘CM haemolamae’ 6 
pale mucous membranes M. ovis, M. haemofelis 210, 312 
parasitaemia of RBCs M. ovis, ‘CM haemolamae’, M. haemofelis 6, 136, 137, 210, 312 
petechial haemorrhages ‘CM haemolamae’ 6 
poor body condition ‘CM haemolamae’ 263 
poor maternal behaviour M. suis 136, 210 
poor weight gain M. suis, M. ovis 36, 53, 136, 210 
pyrexia M. suis 210 
rough haircoat M. wenyonii 210, 293 
skin pallor M. suis 118, 136 
splenomegaly M. suis, M. haemofelis 169, 312 
tachycardia M. wenyonii, M. haemofelis 212, 312 
tachypnoea M. wenyonii, ‘CM haemolamae’, M. haemofelis 6, 212, 312 
unthriftiness ‘CM haemolamae’, M. suis 6, 136 
weakness ‘CM haemolamae’, M. ovis, M. haemofelis 6, 137, 312 
weight loss M. ovis, ‘CM haemolamae’, M. wenyonii, M. haemofelis 137, 210, 263, 312 
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II.2.3 HM infection of different animal species 
HM infections occur in a variety of animal hosts, as listed in Table II-2. 
Table II-2 Haemotrophic Mycoplasma species and their hosts in chronological order of their first 
isolation 
Species Synonym  Host animal Reference 
M. coccoides E. coccoides Rodents 224, 275 
M. haemocanis H. canis, B. canis Dog 167, 208 
M. wenyonii E. wenyonii Cattle 2, 219 
 H. bovis, B. bovisa,b Cattle 66 
M. ovis E. ovis Sheep, Goat 223, 226 
M. haemomuris H. muris Rodents 220, 222, 342 
M. suis E. suis Pig, wild boar 1, 69, 128, 169, 220, 222, 296 
 E. parvuma,b Pig 297, 299 
M. haemofelis H. felis, E. felis Cat, wild felids 45, 82, 220, 222, 365 
 E. teganodesa,b Cattle 143 
 E. tuomiia,b,c Cattle 339, 343 
 H. procyonia,b Racoon 90 
 E. mariboria,b Fruit bat 76 
‘CM haemolamae’  Alpaca, Llama 199, 208, 263 
‘CM haemominutum’  Cat, wild felids 86, 365 
‘CM haemobovis’  Cattle 139, 314 
‘CM haemodidelphis’  Opossum 207, 208 
‘CM kahanei’  Squirrel monkey 221 
‘CM haematoparvum’  Dog 165, 308, 309 
‘CM turicensis’  Cat, wild felids 360, 365 
‘CM haemocervae’  Sika deer 355 
‘CM erythrocervae’  Sika deer 355 
‘CM haemozalophi’  Sea lion 351 
a
 = not affiliated in the ‘Approved Lists of Bacterial Names’ (http://www.bacterio.cict.fr/; 287); b = no 
DNA available; c =  observed on the surface of thrombocytes 
II.2.3.1 Rodents 
The first HM species to be discovered was M. coccoides (formerly E. coccoides; 224), 
and it became the type species of the former genus Eperythrozoon (275). M. coccoides 
induces an intense parasitaemia resulting in haemolytic anaemia in rodents (48, 98, 332, 
333). 
A second HM species in rodents was described in 1939 by TYZZER & WEINMAN (342) 
and characterised in detail by RIKIHISA et al. in 1997 (265). M. haemomuris (formerly 
H. muris) shows 89 % and 85 % 16S rRNA identity to M. haemofelis and ‘CM haemo-
minutum’, respectively, so a reclassification as a Mycoplasma species was proposed 
(265). M. haemomuris exhibits a higher pathogenic potential than M. coccoides and may 
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induce fatal disease or chronic carrier states in albino rats, albino mice, wild mice, and 
hamsters. 
In Brazil, an HM isolate was found in capybaras (Hydrochaeris hydrochaeris) that is 
closest related to M. coccoides (92 % 16S rRNA sequence identity) and ‘CM turicensis’ 
(91 %). Detection of a new species was postulated, but no name was given (350). 
II.2.3.2 Dog 
In 1928, an anaemia-inducing infective agent similar to Bartonella was found in dogs 
(167). Since then, cases of canine ‘haemobartonellosis’ have been reported worldwide 
(18, 103, 179), although infections do not play a significant role in healthy dogs (17, 32, 
164). Recently, H. canis was reclassified as M. haemocanis (208). Despite M. haemoca-
nis’ 99 % 16S rRNA sequence identity to M. haemofelis (208), sequence information of 
rnpB gene shows less similarity (26, 243, 324). Thus, one could justify that both HM 
isolates represent distinct species (26, 243), as it was suggested by cross-infection stu-
dies (84). LUMB’S cross-infection studies showed that cats may act as asymptomatic car-
riers of M. haemocanis: He transmitted blood of dogs diseased with ‘haemobartonello-
sis’ into cats. The cats remained asymptomatic, but susceptible dogs became anaemic 
after blood transfusion of these cats (189). 
In 2004, a second canine HM species, ‘CM haematoparvum’ (165, 308, 309), was dis-
covered. This novel species is most closely related to ‘CM haemominutum’ (94 % 16S 
rRNA identity) and exhibits only slight similarity to M. haemocanis (165, 308, 309). In-
vestigations concerning differences in pathogenicity are currently underway. 
II.2.3.3 Pig 
“A rickettsia-like or anaplasmosis-like disease in swine” was first described by KINSLEY 
(169) and DOYLE in 1932 (69). Since this agent displayed striking morphological simi-
larities with then-known RBC parasites (E. wenyonii, E. ovis), it was named E. suis in 
1950 (296-298), only to later be reclassified as M. suis (1, 220, 222, 265). Currently, 
scientific consensus pins M. suis as the cause for ‘porcine eperythrozoonosis’ (122, 
298), also known as ‘infectious anaemia of the pig’ (136). The clinical manifestation va-
ries from subclinical to mild anaemia to severe life-threatening course of disease (122, 
136, 292), causing high economic losses in pig husbandries (136). 
A second, smaller pig-infecting species besides the well-researched M. suis (174) is 
known to infect pigs, E. parvum, but this organism appears to have no clinical relevance 
(13, 270, 281, 297, 299, 345). 
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II.2.3.4 Cattle 
In cattle, five HM species are known: M. wenyonii (2, 219), E. teganodes (9, 112, 143), 
E. tuomii (339, 343), H. bovis (33, 66), and ‘CM haemobovis’ (129, 139, 314). 
ADLER & ELLENBOGEN discovered the first HM species in cattle, E. wenyonii, in 1934 
(2). In 1963, KREIER & RISTIC showed that M. wenyonii cannot be transmitted to other 
species (172), although sheep can act as paratenic host (144). In 1997, E. wenyonii was 
one of the first species to be reclassified as a Mycoplasma species (219). 
‘CM haemobovis’ was first detected in Switzerland (139) and Japan (314) in the begin-
ning of the 21st century. Based on 16S rRNA analysis, a closer relationship to M. hae-
mofelis (95 %) than to M. wenyonii (84 %) was found (139, 202). TAGAWA et al. used 
analysis of clinical signs and haematological measurements to determine that this novel 
species is more pathogenic than M. wenyonii (315). Also, concurrent M. wenyonii and 
‘CM haemobovis’ infections have been reported (315). 
In the pre-sequencing era, three more HM species of cattle were described by means of 
morphological and infectious criteria: E. teganodes (9, 112, 143), E. tuomii (339, 343), 
and H. bovis (33, 66). E. teganodes and H. bovis were found to be more free in the plas-
ma in comparison to E. wenyonii (33, 143). E. tuomii, on the other hand, attaches to the 
surface of thrombocytes (339, 343). These three species were clearly distinct form 
E. wenyonii as shown by cross-immunity tests and immunogenic and morphological dif-
ferences (144, 340). HOYTE found no difference in pathogenicity between E. wenyonii 
and E. teganodes (143). Today, these three species have no clinical impact (33, 162). 
Due to missing DNA of E. teganodes, E. tuomii, and H. bovis, their classification can-
not be confirmed by sequencing of phylogenetic marker genes. Thus, they were not in-
cluded in the ‘Approved List of Bacterial Names’ in contrast to E. wenyonii (129, 287). 
UILENBERG proposed that ‘CM haemobovis’ may demonstrate one of these earlier de-
scribed HM species (348). However, this statement cannot be conclusively proven with-
out DNA. 
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II.2.3.5 Cat 
Feline HM species are among the best-researched HM species. There are three known 
feline HM species: M. haemofelis (82), ‘CM haemominutum’ (85, 86), and ‘CM turi-
censis’ (360), which are distributed worldwide and can infect both domestic and wild 
felids (108, 344, 354, 365). The species can be clearly distinguished by 16S rRNA se-
quences (85, 205, 265, 320) and differ in pathogenicity (85, 154, 328, 359, 361). 
M. haemofelis may cause severe life-threatening haemolytic anaemia (‘feline infectious 
anaemia’) (21, 116). It was first described by CLARK in 1942 as E. felis (45) and FLINT 
& MOSS in 1953 as H. felis (82), when they found cats contracted with infectious anae-
mia. Cross-infection studies revealed no infectivity for rats, mice, swine, cattle, sheep, 
and dogs (295). 
FOLEY et al. found an HM-like organism in a cat co-infected with feline leukaemia vi-
rus. This organism was much smaller than the already known M. haemofelis (H. felis) 
and was initially described as ‘H. felis small form’ (‘H. felis California strain’; 0.3 µm) 
to distinguish it from the then-known ‘H. felis large form’ (‘H. felis Ohio strain’; ca. 
0.6 µm) (85, 265). RIKIHISA et al. proposed that these two isolates demonstrate two dis-
tinct species, as they only share 85 % 16S rRNA sequence identity and also significant-
ly differ in pathogenicity (86, 154, 265). The name ‘CM haemominutum’ was establi-
shed for the ‘H. felis small form’ (86) and M. haemofelis for the ‘H. felis large form’ 
(220, 222). Infections with ‘CM haemominutum’ result in minor clinical signs or may 
be even asymptomatic. Blood parameters are not or only slightly changed, but stay 
within the reference range (85, 86, 359). 
Recently, a third feline HM species was described by WILLI et al. (360). The species re-
ceived the name ‘CM turicensis’, because it was first isolated in Zurich (‘Turicum’) 
(360). Since then, ‘CM turicensis’ infections have been reported in domestic and wild 
felids worldwide (91, 361, 362, 364, 365). Their pathogenic potential strongly depends 
on additional factors like co-infection with other HM species or viruses, immunosup-
pression, and host susceptibility. ‘CM turicensis’ seems to be of lower pathogenicity 
than M. haemofelis but higher compared to ‘CM haemominutum’ (311, 360, 364). 
Concurrent infections with two or three feline HM species have been reported in domes-
tic (91, 154, 325, 361, 362) and wild felids (108, 365). 
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II.2.3.6 Sheep and goat 
E. ovis was first described in 1943 (153) and reclassified in 2004 as M. ovis (223). It 
displayed a high 16S rRNA sequence identity (95%) with M. wenyonii (223), and was 
shown to have a broader host range infecting also goats, blesbok, eland, and deer (51, 
172, 223, 227, 304). However, M. ovis cannot induce disease in dogs, guinea pigs, rab-
bits, and cattle, although the pathogen can persist in bovine blood for a brief time (144, 
226). 
Recently, HORNOK et al. found an ovine HM isolate showing a 17 bp deletion in the 16S 
rRNA sequence compared to the classical M. ovis isolate. If this difference is sufficient 
to designate a new species, then it will be called ‘CM haemovis’ (140). 
II.2.3.7 Llama and alpacas 
In 1990, first indications of an HM species exclusive to llamas and alpacas were repor-
ted in the USA (199, 263). Based on the observation of coccoid and ring-shaped baso-
philic organisms on the surface of RBCs and free in the plasma, REAGAN et al. conclu-
ded that, due to morphological similarities to M. wenyonii, this may represent a novel 
Eperythrozoon species (263). 16S rRNA sequencing indeed revealed the discovery of a 
novel species, and ‘CM haemolamae’ designation was introduced (199, 208). Clinical 
manifestations vary from asymptomatic to severe disease with fatal outcome. REAGAN 
et al. reported in their study that mainly young animals were affected (263). 
II.2.3.8 Human and primate HM 
Also in monkeys (64, 221, 246, 247) and humans, first indications of HM infections 
were found. In humans, ‘haemoplasmosis’ occurs mostly in conjunction with concurrent 
diseases, like systemic lupus erythematosus (158), AIDS (67, 72), mononucleosis (254), 
and, in one case, a multiple sclerosis patient co-infected with Bartonella sp. (313). 
M. suis was found amongst farm workers in China (375) and humans in Inner Mongolia 
(373). Thus, a zoonotic potential of HM should be kept in mind. TASKER et al. aimed to 
design a real-time PCR assay for detection of all known HM species (329). They tested 
blood of about 1000 patients for presence of HM and found only one sample to be posi-
tive. However, they failed to detect HM in DNA isolated from blood smears obtained 
from previous studies in which presence of HM in human blood was proposed using cy-
tological analysis (44, 102, 373). Thus, reports of human ‘haemoplasmosis’ only based 
on evaluation of stained blood smears without molecular confirmation should be viewed 
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with caution (329). Nonetheless, CHALKER et al. proposed a new human HM species: 
‘CM haemohominis’ (41). 
II.2.3.9 Further HM species/ isolates 
Novel HM species were described in racoon (H. procyoni) (90), opossum (‘CM haemo-
didelphis’) (207, 208), flying fox (E. mariboi) (76), sea lion (‘CM haemozalophi’) 
(351), and sika deer (‘CM haemocervae’, ‘CM erythrocervae’) (355). In reindeer (304), 
HM-like organisms were found, but the species was not identified. 
II.2.3.10 Situation in horses 
Previously, little was known about possible HM infections in horses. Initial observa-
tions of possible infection can be traced back to 1978, when GRETILLAT reported a puta-
tive ‘haemobartonellosis’ outbreak in Nigeria (101). Horses showed the following clini-
cal signs: general weakness, hyperthermia, inappetence, dyspnoea, anoxia, pale mucous 
membranes, profuse sweating after some minutes of trot, petechia, mild jaundice, epis-
taxis after exercise, joint and muscle pain, stumbling, and painful and swollen lymph 
nodes. Severe manifestations were observed in horses that were already stressed. HM-
like particles of approx. size of 0.3 µm diameter were found on the surface of erythro-
cytes in May-Grünwald and Giemsa-stained peripheral blood smears (101). After this 
first indication of HM infection in horses in 1978, nothing about this kind of infection in 
horses was reported until 2001, when TARELLO published a case report about the 
‘equine fatigue syndrome’ in combination with detection of small coccoid eperythrocy-
tic bacteria (318). The nature of these bacteria, however, was not elucidated. Later, a 
puative HM infection of German horses was reported based on cytology (93, 230, 231). 
The syndrome reported by TARELLO resembled the previously reported unspecific clini-
al signs, signifying possible HM infection in other animal species. In all four of these 
caes, suspected diagnosis was only made by monitoring unspecific clinical signs and a 
miroscopic appearance resembling HM infection. Proof of HM infections in horses by 
molecular diagnostic techniques remains to be seen. 
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II.2.4 Transmission 
Exact transmission pathways for natural HM infections remain unclear, although several 
transmission routes have been proposed in scientific literature. 
II.2.4.1 Blood-sucking arthropods 
Blood-sucking arthropods involved in transmission of HM may include fleas, hard ticks, 
and mosquitoes (220), as in the case of rickettsia and spiroplasmas (141, 264, 301). 
Hyalomma anatolicum possibly transmits M. wenyonii (162). M. haemocanis may be 
transmitted by the tick Rhipicephalus (R.) sanguineus (283), M. haemomuris via the 
mouse louse Polyplax (P.) spinulosa and the flea Xenosylla cheopis (22), and M. cocco-
ides via the mouse lice P. spinulosa (74) and P. serrata (22). The rat louse P. spinulosa 
was also proposed as vector for ‘CM haemominutum’ (75, 220). Transmission of M. su-
is via flies (Stomoxys (S.) calcitrans), mosquitoes (Aedes (Ae.) aegypti) and lice (Hae-
matopinus suis) was proposed (253, 291, 292). M. ovis may be transmitted via ticks 
(Haemaphysalis plumbeum, R. bursa) (232), mosquitoes (Ae. camptorhynchus, Culex 
annulirostris, Anopheles annulipes) (54, 142, 228), stable flies (S. calcitrans) (239), and 
keds (Melophagus (Me.) ovinus) (239). Besides ticks, M. haemofelis and ‘CM haemo-
minutum’ may be transmitted by the cat flea Ctenocephalides felis (160, 177, 284, 363), 
even though experimental transmission studies were not conclusive (372). 
Different arthropod species may vary in capability to harbour and transmit HM. MASON 
& STATHAM showed that stable flies would be more effective vectors than ticks, as ticks 
only transmit one or two RBCs, while stable flies can transmit up to 400 RBCs (197). 
Transmission via haematophagous arthropods is corroborated by findings of geographi-
cal variations in HM infection prevalence (95, 165, 310, 358, 361). Incidences of canine 
HM are higher in countries with higher mean annual temperatures, where R. sanguineus 
is endemic (11, 23, 165, 283). Therefore, the frequency of infection may be hypothetic-
cally related to the abundance of the relevant transmission vectors. 
‘CM haemominutum’ was found in unfed Ixodes (I.) ovatus ticks in Japan (319) and 
M. haemofelis in I. ricinus (273). However, a large study analysing almost 2000 ticks in 
Switzerland revealed no HM positive results in unfed Ixodes sp., but in some Ixodes sp. 
and Rhipicephalus sp. which were directly collected from animals (363). OVERAS (239) 
and FOOGIE & NISBET (87) infected sheep with the stable fly (S. calcitrans) and head 
lice (Linognathus ovillas) resulting in HM infection in sheep, but transmission under na-
tural conditions was not shown. Transmission via removed sheep keds (Me. ovinus) 
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from HM infected sheep and injection into healthy sheep did not result in visible infec-
tion (87, 226). 
Presence of HM in wild animals (108, 128, 350, 351, 355, 365) lead to the assumption 
that wild species may serve as reservoir hosts. 
II.2.4.2 Direct transmission 
In cats, direct transmission via bites and scratches during fighting seems to govern natu-
ral infection. Feline HMs were detected in saliva, salivary glands, gingival, claw beds, 
and faeces of infected cats (58, 105, 215, 360, 363). This hypothesis is substantiated by 
the higher prevalence of HM infection in male cats, cats with outdoor access, and cats 
with bite abscesses (105, 271, 325, 361). However, oronasal and subcutaneous transmis-
sion of ‘CM turicensis’ via saliva and oral transmission of blood failed, while subcuta-
neous exposure of ‘CM turicensis’ infected blood resulted in PCR positive animals, 
even though overt clinical signs were absent (215). Similar results have been found for 
canine HM (164, 236). 
II.2.4.3 Vertical transmission 
First indications of in utero or lactogenic transmission was reported for pigs (24, 121), 
sheep (104), cats (114), and llamas (6, 81). YANG et al. detected HM in cord blood of 
human newborns (373). However, the hypothesis of vertical transmission has not yet 
been systematically proven. 
II.2.4.4 Iatrogenic transmission 
Iatrogenic transmission via contaminated needles, surgical instruments, blood transfu-
sion, tattoo needles, ear tagging, tail docking, and shearing frequently occur (6, 38, 64, 
122, 157, 179, 210, 223, 305). Also transmission of bovine HM via automatically rota-
ting brushes may be possible (139). 
M. suis and M. haemofelis can be experimentally transmitted via subcutaneous, intrave-
nous, intraperitoneal, and oral inoculation (83, 136). 
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II.2.5 Diagnostics 
II.2.5.1 Microscopy 
Since molecular diagnostic tools are a rather recent invention and HM are not cultiva-
ble, HM diagnosis was previously performed with microscopic evaluation of peripheral 
blood smears stained with Romanowsky, Wright or Giemsa staining solution. They are 
based on a differential blood staining principal: various blood cells exhibit different 
staining properties based on the pH during staining procedure (28, 274). 
Staining with acridine orange can improve sensitivity but a fluorescence microscope is 
required for evaluation (28, 109, 288, 321). 
Improvement of diagnostic methods revealed the shortfalls of these staining methods, 
poor sensitivity (less than 20 %) and specificity (133, 154, 182, 321, 359). Staining pre-
cipitates, Heinz-, Pappenheimer-, and Howell-Jolly bodies can be confused with HM 
(114, 239, 321), and species differentiation is virtually impossible (321). Further, for 
‘CM turicensis’ it was reported that the blood loads were too low for detection of HM 
on the surface of RBCs (361, 367). A recent discovery showed that bacteria can detach 
from RBCs in EDTA anti-coagulated blood, leading to an underestimation of parasitae-
mia (5). 
II.2.5.2 Splenectomy 
Parasitaemia of RBCs only occurs during the acute phase of infection. Usually, chronic 
infections cannot be diagnosed via microscopy (5, 118, 209, 239). Before DNA extrac-
tion and PCR methods were available, animals suspected of asymptomatic or chronic 
course of disease are forced to undergo splenectomy. If the animal becomes anaemic, 
and HM could be revealed on RBCs in peripheral blood smears, a HM infection was 
confirmed (118, 210). An alternative, less ethically sound method of diagnosis, is to 
transmit suspected animals’ blood to susceptible animals. For HM-positive animals, 
subsequent infection produces anaemia, and a parasitaemia of RBCs can be observed 
(34, 136, 275, 332, 333). 
II.2.5.3 Polymerase chain reaction (PCR) 
In the 1990s, the first conventional PCR diagnostic assays specific to HM were deve-
loped based on the 16S rRNA gene: M. suis (206), M. haemocanis (32, 358), feline HM 
(49, 154, 205), and M. haemomuris (378). Also, assays based on other genes were pub-
lished, e.g. on a M. suis specific 1.8 kb genomic fragment (131) or the rpoB gene (111). 
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Up to now, PCR is the “method of choice” (364), as it is well-suitable for detection of 
HM in blood of acute, latently infected, and asymptomatic animals (136). 
PCR diagnostics were greatly improved by the development of quantitative real-time 
PCR assays, which improved the speed, ease, and sensitivity of HM diagnosis (133, 
182, 190, 201, 325, 358). No elaborate post-PCR steps are required anymore (190). Flu-
orescent labelling of primer (TaqMan system) or amplified DNA (SYBR green I sys-
tem) enable visualisation in real-time (190). This technique exhibits low contamination 
risk due to a closed tube system, allows standardisation, and is easily reproducible (136, 
190, 364). Automation facilitates high throughput in daily routine diagnostics and 
makes prevalence studies possible. 
However, specific PCR primers can only be designed if the sequence or part of a se-
quence of at least one gene is known. 16S rRNA, for example, is well-suited for compa-
rative sequence analysis due to its hyper-variable and conserved regions across all eu-
bacteria. Universal 16S rRNA oligonucleotides are available which amplify the 16S 
rRNA gene of most eubacteria. WILLI et al. reported the development of a SYBR green 
I real-time PCR assay which is suitable for detection of all known HM species (366). 
This assay may be useful to screen for hitherto unknown HM species in animal blood 
samples. Amplicons may be sequenced for further analysis and species identification. 
II.2.5.4 Serology 
Serological methods enable screening of a high sampling number at low costs. This is 
crucial for e.g. livestock husbandries who wish to affordably screen their populations. 
However, development of serological detection methods is hindered by unculturability 
of HM (136). As antigens are derived from experimentally infected animals, purifica-
tion is very elaborate, and preparations may contain host antigens. Nevertheless, six im-
munogenic proteins were identified for M. suis: HspA1, GroEL, enolase, pyruvate dehy-
drogenase, RNA helicase, and actin-analogous protein (132, 134, 136), and several test-
ing methods were established for M. suis diagnosis: (i) a complement fixation assay 
(CFA; 10, 279, 300), (ii) an indirect haemagglutination assay (IHA; 290), and (iii) an 
enzyme-linked immune assay (ELISA; 126, 145, 279). For M. ovis, (i) an indirect im-
munofluorescent antibody test (IFAT; 146, 149, 229), (ii) a CFA (50), and (iii) an 
ELISA (176) were reported. A Western immunoblot antibody test for feline HM was 
published (5), and WOLF-JACKEL et al. described a recombinant antigen for serological 
investigation of feline HMs (370). 
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II.2.6 Therapy 
Since mycoplasmas lack cell walls, they are resistant to penicillin and its derivates but 
susceptible to tetracyclines and other antibiotics which are not targeted against the cell 
wall, e.g. inhibitors of the gyrase (220). 
Pigs were traditionally treated with tetracyclines (oxytetracycline, doxycycline) and ar-
senic derivatives (diminazen aceturate). Auxiliary treatment of clinical signs by admi-
nistration of glucose and iron dextran is helpful in therapy of M. suis infections. How-
ever, complete elimination of bacteria from blood by use of tetracyclines is not possible 
(100, 122, 136). 
In sheep, treatment with tetracyclines (oxytetracycline, chlortetracycline) and arsenic 
derivatives leads to a reduction of bacteria in blood but not to a complete elimination 
(92, 227). Using imidocarb dipropionate, M. ovis may be completely removed, although 
recrudescence of infection and race-dependent side-effects may be observed (147). A 
supplementary diet was prescribed to improve general health condition of infected 
sheep (36). 
The three feline HM species vary in their therapeutic susceptibility. No therapy tested 
thus far (tetracycline: doxycyline; fluoroquinolon: enrofloxacin, marbofloxacin) was 
able to completely eliminate bacteria from blood of infected cats, but severity of clinical 
signs and bacterial blood loads were reduced (20, 68, 85, 209, 321, 326, 327, 361). Azi-
thromycin was not effective (359). In severe cases of anaemia, a blood transfusion may 
be indicated (321). In some M. haemofelis infections, administration of glucocorticoids 
(e.g. prednisolone) may be required, but interfering infections should be ruled out (321). 
Dogs with an HM infection are treated with oxytetracycline or doxycycline (42, 209). 
In llamas, tetracycline therapy lead to health improvements, but bacteria was not com-
pletely eliminated from blood, resulting in an asymptomatic carrier state (336). 
The best ‘therapy’ remains the prevention of blood transmission in animal husbandries 
by better hygiene, control of endo- and ectoparasites (36), removal of asymptomatic 
carrier animals (PCR testing), and screening of blood donor animals (209, 361). 
No vaccine is available, although immunogenic proteins of M. suis have been described 
(127, 134). Health condition and immune status can be improved by supplementation of 
e.g. iron and copper (92). GRETILLAT also reported in 1978, that horses having access to 
good quality feed showed less severe manifestations of ‘haemobartonellosis’ (101). 
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II.2.7 Taxonomy of haemotrophic mycoplasmas 
The first representatives of the haemotrophic mycoplasmas (HM) were found in the be-
ginning of the 21st century and were classified as members of the genus Bartonella 
(167), Haemobartonella (342), or Eperythrozoon (275). Since then, several anaemia in-
ducing parasites of mammalian RBCs were found (Tab. II-1, pp. 9-10) and sorted into 
the genera Haemobartonella or Eperythrozoon, respectively. Species names were given 
according to host, as strict host specificity was assumed (220). In the pre-sequencing 
era, bacteria were classified using morphological and infectious criteria. Due to their 
small size, gram-negative staining features, and suspected transmission via blood-suck-
ing arthropods, HMs were originally classified within the group of Anaplasmataceae in 
the class of Rickettsia (268). Differentiation of Haemobartonella and Eperythrozoon 
was somewhat arbitrary, as it relies solely on morphological and infectious criteria. 
While Eperythrozoon species frequently form ring forms and are more often found free 
in the plasma, Haemobartonella species do not assume a ring form and occur only 
rarely free in the plasma (210, 220). Electron microscopy studies revealed that the fine 
ultrastructures of both genera are fundamentally similar. Cross-infection studies were 
performed to discriminate HM species from each other (52, 144, 172, 189, 199). 
In 1965, TANAKA et al. first proposed that these two genera may belong to the class of 
Mollicutes because they share important characteristics like unculturability, lack of in-
tracellularity, lack of a cell wall and flagellae, and resistance to penicillin but susceptibi-
lity to tetracyclines (316). When the first 16S rRNA sequences of Haemobartonella sp. 
and Eperythrozoon sp. were available in the 1990s, their closer relationship to the genus 
Mycoplasma within the group of Mollicutes was proven. Reclassification of Haemobar-
tonella and Eperythrozoon species as Mycoplasma species was then suggested (208, 
219, 220, 222, 224, 265). 
The class of Mollicutes is grouped within the clostridial subdivision of the gram-posi-
tive bacteria exhibiting a low GC % content and is phylogenetically diverse, comprising 
an increasing number (currently more than 180) of species in eight genera (Mycoplas-
ma, Ureaplasma, Spiroplasma, Acholeplasma, Anaeroplasma, Asteroplasma, Mesoplas-
ma, and Entomoplasma) (218, 258, 261, 338, 368). One of the most striking features of 
Mollicutes is the absence of a cell wall. Mycoplasmas are the most rapidly evolving 
bacterial lineage, and they show an unusual mode of evolution, the so called “degenera-
tive evolution” (369), descending from Clostridia. Through reductive evolution, they 
have lost many genes. Today, they represent bacteria with the smallest reported ge-
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nomes, consisting of essential genes only (217, 218, 225, 357, 368). An alternative hy-
pothesis suggested that mycoplasmas are descendants of primitive ancestral cells that 
existed before the development of cell walls and represent one of the most primordial 
organisms (258). However, the aforementioned “degenerative evolution” hypothesis has 
been supported by rRNA and tRNA sequencing showing structures which more closely 
resemble gram-positive than gram-negative bacteria (218, 258, 368). For a detailed re-
view concerning the phylogenetic theories of Mollicutes, refer to RAZIN (258). 
The HMs form a distinct cluster within the genus Mycoplasma (219, 265), which is 
most closely related to the ‘fastidiosum-cluster’ (M. fastidiosum, horse; M. cavipharyn-
gis, guinea pig) (155). Both clusters belong to the ‘pneumoniae-group’, which includes 
the human pathogens M. pneumoniae, M. penetrans, and M. genitalium (155, 208, 219, 
220, 357). 
Analysis of additional phylogenetic marker genes (e.g. rnpB) confirmed the proposed 
classification and close relationship to the ‘pneumoniae-group’ (243, 324), although dif-
ferences with the previously published Mycoplasma classifications were found (324, 
357). Analysis of the rnpB gene afforded better resolution of closely related species, as 
it shows a higher rate of variation (317). M. haemocanis and M. haemofelis cannot be 
distinguished by 16S rRNA sequencing, but rnpB sequences revealed two distinct clus-
ters (26, 324). 
Two groups were able to be differentiated within the HM cluster based on 16S rRNA 
and rnpB sequence analyses: ‘haemofelis’- und ‘haemominutum-group’ (243). A cha-
racteristic truncation of 10 bp (position 453-481, E. coli numbering) was found in the 
16S rRNA sequence of members of the ‘haemofelis-cluster’ (155, 208). WILLI specula-
ted that HM species from different clusters may differ in pathogenicity (364). However, 
this requires further study. 
UILENBERG et al. have questioned the reclassification of HM, because HM and non-HM 
show higher 16S rRNA identities than members of well-defined genera such as Staphy-
lococcus and Streptococcus or Clostridium and Bacillus (346, 347). Additionally, HM 
exhibit unique properties (habitat, uncultivable, and suspected vector transmission). 
That is why UILENBERG et al. suggested that HM (Eperythrozoon as well as Haemobar-
tonella sp.) should be placed in their own genus named Eperythrozoon beside the genus 
Mycoplasma (including the non-haemotrophic Mycoplasma sp.) within the family of 
Mycoplasmataceae within the genus Mollicutes (346, 347). He pointed out that the 
transfer of Eperythrozoon species to Mycoplasma species does not follow the rules of 
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nomenclature, as the genus name Eperythrozoon was assigned earlier (1928) than the 
genus Mycoplasma (1929) (224, 237, 275, 346, 347). Though the reclassification would 
violate naming conventions. However, exceptions can be made “where strict adherence 
to the rules of nomenclature would produce confusion or would not result in nomencla-
tural stability” (Judical Commission of the International Committee on Systematics of 
Prokaryotes, Appendix 8). An exception was requested by NEIMARK et al. (224). 
II.3 Anaemia in Horses 
II.3.1 Anaemia 
Anaemia is characterised by decreased mass of RBCs, low haematocrit, and/or decreas-
ed haemoglobin concentrations leading to diminished oxygen transport capabilities. Cli-
nical signs of anaemia may include pallor of mucous membranes, exercise intolerance, 
weight loss, weakness, fatigue, rapid exhaustion, dyspnoea on exertion, tachypnea, ta-
chycardia, mitral valve murmur, hypoxia, haematuria, proteinuria, and icterus. Equine 
anaemia occurs concurrently with certain diseases or pathological changes, including 
blood loss, increased RBC destruction, and inadequate RBC production. Horses do not 
release reticulocytes or other juvenile forms of RBCs into the bloodstream. Thus differ-
entiation of regenerative (in case of blood loss and haemolysis) and non-regenerative 
anaemia (in case of malfunctioning RBC production) is hampered. Anaemia can be ca-
tegorised according to RBC morphology, haemoglobin concentration, mean corpuscular 
volume (MCV), mean corpuscular haemoglobin (MCH), and mean corpuscular haemo-
globin concentration (MCHC) (80, 94, 178, 213, 341). 
However, changes in erythrocytic indices are rare in horses, and mostly a normochro-
mic, normocytic anaemia is diagnosed (80, 175). In this case, RBCC is lowered, but 
cells appear morphologically normal. Anisocytosis and polychromasia are rarely obser-
ved in cases of equine anaemia (213). Either RBC production is reduced (e.g. chronic 
inflammatory or neoplastic diseases) or RBC degradation is increased (e.g. haemolytic 
anaemia). In normochromic, normocytic anaemia, MCV, MCH, and MCHC remain at 
normal levels (80, 175, 178, 341). 
Hyperchromic and macrocytic anaemia result from a deficiency in certain vitamins (e.g. 
vitamin B12, folic acid) and result in restricted production of RBCs. Since these vitamins 
are needed for DNA synthesis, there is not enough DNA for cell division, and RBCs do 
not divide and remain as enlarged cells (megaloblasts). However, vitamin B12 and/or fo-
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lic acid deficiencies are very rare in horses. MCV is increased and MCH and MCHC are 
decreased (175). 
Hypochromic and microcytic anaemia can be induced by iron deficiencies, when cells 
undergo additional cell division due to low haemoglobin concentrations. Iron deficien-
cy, however, does virtually not occur in horses, since adult horses have sufficient iron 
stored in tissues. MCV, MCH, and MCHC are decreased, while RBCs are smaller and 
show a greater central pallor. Deficiency may be caused by increased loss of iron due to 
unrecognised chronic bleedings, increased haemolysis, or insufficient absorption. Also, 
this type of anaemia may be induced by chronic diseases, immune mediated diseases, 
and acute or chronic infections (175, 178, 341). 
In horses, haemorrhage and haemolytic anaemia have the most important clinical signi-
ficance (175). 
II.3.2 Haemolytic anaemia 
Haemolytic anaemia is characterised by increased intra- and/or extravascular destruc-
tion of RBCs before they reach their physiological age of three to five months, when 
RBC destruction is not compensated by newly produced RBCs. Poikilocytosis is fre-
quently observed due to increased RBC fragility. RBCs can be damaged by corpuscular 
(e.g. defective RBC membrane, haemoglobin molecules, or enzymes) or extracorpuscu-
lar (e.g. microangiopathetic processes, drugs, toxins, immune mediated diseases, and 
damages due to parasites, bacteria, and viruses) reasons (80, 175, 178, 213, 330, 341). 
Due to destruction of RBCs, plasma levels of potassium, unconjugated bilirubin, and 
iron are increased. Increasing bilirubin concentrations in blood may lead to icterus. Also 
haemoglobinuria and proteinuria may occur. MCH and MCHC are usually increased 
due to elevated free haemoglobin levels. 
In autoimmune haemolytic anaemia, RBC destruction is initiated by binding of autoch-
thonous IgG and/or IgM antibodies to the surface of RBCs. In the first case, IgG antibo-
dies attach to the surfaces of RBCs, thereby removing RBCs from circulation, resulting 
in extravascular haemolysis. These antibodies exhibit the strongest reactivity close to 
37 °C. Haemograms of warm autoimmune haemolytic anaemia often show variable hae-
moglobin and haematocrit values but elevated MCV and WBCCs (94, 341). 
In the second case, RBCs agglutinate due to attachment of so-called cold agglutinins 
(IgM auto-antibodies) at low temperatures. This attachment leads to acrocyanosis, 
where haemolysis is induced via binding of cold auto-antibodies in the cooler peripheral 
circulation (94, 183, 341). Cold agglutinins by definition exhibit their strongest reactivi-
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ty at temperatures near 4 °C and show decreased binding at higher temperatures. IgM-
induced haemolysis can occur intra- or extravascularly (94). Cold autoimmune haemo-
lytic anaemia can be induced idiopathically or as a result of Mycoplasma infections (e.g. 
M. suis in pigs (138, 377), M. pneumoniae in humans (43, 77)). In haemograms, slightly 
decreased haemoglobin and haematocrit values will be detected, while the leukocyte 
and platelet numbers are usually normal. Due to RBC clumping, the MCV can be artifi-
cially increased, while the apparent RBC count is decreased (94). 
Additionally, a mixed-type (both IgG and IgM bind to the RBCs) and a drug-induced 
immune haemolytic anaemia (e.g. due to high-dose penicillin, N-propyl disulfide of red 
maple leaf) are known (94). 
II.3.3 Anaemia inducing diseases and infections 
Anaemia may be induced due to vitamin deficiencies (e.g. iron, folic acid, or vitamin 
B12), certain diseases and pathological changes (e.g. immune mediated diseases, infec-
tions, or tumours), or intoxications (e.g. drugs or red maple leaf) (27, 80, 175, 178, 213, 
330, 331, 341). 
Equine infectious anaemia (EIA) is caused by a virus, which is passed on by blood-
sucking arthropods. Since these insects prefer warm and humid regions, EIA is not en-
demic in Germany. In cold regions, infections can be imported through foreign horses 
or horses with travel history in endemic regions. Viruses attach to RBCs and induce an 
immune-mediated haemolysis leading to severe anaemia. Infection is accompanied by 
neutropenia and lymphocytosis (282, 330). 
Babesia caballi and Ba. equi (synonym: Theileria equi; equine piroplasmosis) are pro-
tozoan parasitizing equine RBCs transmitted by ticks. Although a small number of 
RBCs may be infected, Babesia caballi can lead to severe anaemia (178). The disease is 
not endemic in Germany but is common in North- and South America and parts of East- 
and South Europe (330). 
Ehrlichia equi is a bacterium belonging to the class of Rickettsia, which parasites in 
leucocytes and is presumably transmitted by ticks. Although their haemograms exhibit 
only unspecific changes and clinical sings resembling EIA, ehrlichiosis can be clearly 
diagnosed due to typical morula-like inclusions in the cytoplasm of eosinophils and ba-
sophils. Only sporadic cases of ehrlichiosis are reported in Germany (330). 
Rarely, haemolysins of Staphylococcus sp., Clostridium sp., or Leptospira sp. can in-
duce haemolytic anaemia in horses (330). 
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III. GOAL OF THIS THESIS 
III.1 HM in horses 
In Northern Germany, especially in the region of the Luneburg Heath, several horse ow-
ners reported horses showing inhibited development, apathy, shaggy fur, and poor over-
all health. These unspecific clinical signs were sometimes accompanied by slight anae-
mia. Thorough clinical examinations revealed no cause for these unspecific clinical 
signs, and other infective agents resulting in anaemia (e.g. Theileria sp., Babesia sp., or 
EIA virus) were determined not to be the underlying cause. In peripheral blood smears, 
HM-like particles of an approx. size of 0.3-0.4 µm were observed (DR. MICHAEL 
DIECKMANN & DR. MARGIT WINKLER, pers. comm.). 
 
The goals of this thesis research were to: 
(i) prove by use of molecular diagnostic techniques that HMs infect horses, 
(ii) develop a specific diagnostic tool, 
(iii) investigate the clinical significance of this type of infection in horses, and 
(iv) further characterise this novel infective agent. 
III.2 Phylogenetic analysis of novel HM isolates 
In the second part of this thesis, the current HM classification was re-evaluated and no-
vel HM isolates from horses, cattle, wild boars, and llamas were classified and their 
phylogenetic position clarified. 
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IV. MATERIAL & METHODS 
IV.1 Blood sample collection 
IV.1.1 Blood sample collection of horses 
Blood samples were collected from horses’ vena jugularis externa (Vacuette Greiner 
Bio-One tube system) and anti-coagulated with EDTA, Citrate, or Alsever’s solution. 
Figure IV-1 and Table IV-1 summarise the horse blood samples collected during this 
study; a detailed overview is given in the appendix (Tab. VIII-1, pp. 165-175; also com-
pare DIECKMANN et al., 2010 (62) & 2011 (63); pp. 134-136 & 140-164). All horses ori-
ginated from the Luneburg Heath (Northern Germany) without travelling history, if not 
indicated otherwise. 
 
Figure IV-1 Workflow of sample procession. Initially, 34 samples were collected for molecular proof 
of the existence of HM in horses in 2008; samples were analysed using PCR and acridine orange stained 
peripheral blood smears (AO). After the successful proof, eleven samples were re-collected for morpholo-
gical characterisation due to scanning electron microscopy (SEM). In 2009, 117 samples were collected 
to evaluate the clinical significance of equine HM infections; complete blood counts (CBC) were prepar-
ed, and samples were analysed by PCR and microscopy of Giemsa (GI) and acridine orange stained peri-
pheral blood smears. HM positive samples were used to establish a SYBR green I real-time PCR assay 
specific to the novel equine HM isolate. This assay was then used for specific diagnostics (purple arrow-
heads). 
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Table IV-1 Summary of horse blood samples (n = 283) analysed during this study 
Time period Number Origin of samples 
Spring 2008 34 Luneburg Heath, Northern Germany; MD 
Summer 2008 11 Luneburg Heath, Northern Germany; MD 
Autumn/Winter 2008 8 Luneburg Heath, Northern Germany; MD 
November 2009 117 Luneburg Heath, Northern Germany; MD 
December 2009 23 Luneburg Heath, Northern Germany; MD 
Autumn 2008 & 2009 72 Switzerland; Negative controls 
Winter 2009/2010 18 synlab.vet, Geesthacht, Northern Germany 
MD = Samples collected by DR. MICHAEL DIECKMANN. 
Gender and pregnancy
Gender unknown
7%
Gelding
17% Pregnancy unknown
17%
Pregnant
9%
Stallion
22%
Non pregnant
28%
 
Age
< 1 year
22%
1-3 years
31%
Age unknow n
9%
> 20 years
3%
11-20 years
14%
4-10 years
21%
 
Figure IV-2 Characteristics of horse samples (n = 211) collected during this study. Distribution of 
gender, pregnancy status and age is outlined. Horses from the negative collective are not shown. 
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Blood of 211 horses was analysed: 114 mares (54.0 %), 35 geldings (16.6 %), and 47 
stallions (22.3 %) were included. Fifteen horses’ gender was not known (7.1 %). The 
mean age was 5.7 years (range: nine months to 26 years). 175 of the horses were warm 
blood breeds (82.9 %; mainly Hanoverian (70.1 %)). Further, there were four German 
riding ponies (1.9 %), one Shetland pony (0.5 %), one tinker (0.5 %), three Friesian 
(1.4 %), one thoroughbred (0.9 %), one Arabian (0.5 %), and one Pinto (0.5 %) inclu-
ded into the study. Twenty-four horses’ breed was unknown (11.4 %) (Fig. IV-2, p. 31). 
To establish a negative control group, 72 blood samples from healthy Swiss horses were 
included (Tab. IV-I (p. 31) & VIII-2 (pp. 176-179)). These samples were tested negative 
for any HM infection by a SYBR green I real-time PCR assay comprising all known 
HM species (366). The mean age of the negative horse collective was 12.1 year (range: 
nine months to 39 years). Twenty-eight females (38.9 %) and 40 males (55.6 %) were 
included. Gender of four horses and pregnancy status were unknown. Twenty-eight 
warmblood horses (38.9 %), five Draft (6.9 %) horses, four Thoroughbreds (5.6 %), 
twenty ponies (27.8 %), and nine horses of various breeds (12.5 %) were included. Six 
horses’ breed (8.3 %) was unknown. 
From selected horses a complete blood count was prepared (synlab.vet) (Tab. VIII-1, 2 
& 3; pp. 165-187). 
IV.1.2 Blood sample collection of cattle 
For details about the collection procedure see HOELZLE et al., 2011 (130); pp. 137-139). 
Blood was collected from twenty animals showing the following clinical signs: anae-
mia, decreased milk production, infertility, and lameness. 
IV.1.3 Blood sample collection of wild boars 
A total of 359 EDTA-anti-coagulated blood samples from wild boars were included. 
Animals were hunted in the time period from December 2007 to January 2008 in South 
Germany. For details see HOELZLE et al., 2010 ((128); pp. 129-133).  
 Table IV-2 Composition, preparation, and cultivation condition of used culture media 
Medium Gassner agar Colombia blood agar Chocolate agar LB medium LBZ agar 
Composition/ 
preparation    
37 g LB broth, ad 1 L 
H2OMQ; autoclaving: 15 min, 
121 °C 
37g LB agar, ad 1 L H2OMQ; 
autoclaving: 15 min, 121 °C; 
chilling to 50 °C; 1 mL am-
picillin (100 mg/mL)a, 1 mL 
X-Gal (80 mg/mL)b, 1 mL 
IPTG (1 mmol/L)a 
Reference Oxoid AG, Pratteln, CH 
Cultivation 37 °C, aerobic, 24 h 37 °C, 5 % CO2, 48 h 37 °C, aerobic, 24 h 37 °C, aerobic, 24 h 
 
     
Medium PPLO agar PPLO broth SP4 broth SP4 agar modified RPMI broth 
Composition/ 
preparation 
10.5 g PPLO agar, 195 mL 
H2OMQ; autoclaving: 15 min, 
121 °C, 75 mL horse serumc 
30 mL yeast extract (with 
K2PO4), 1 mL thallium ace-
tate (10 %), 2.25 mL NAD 
solution (1 %), 0.75 mL 
penicillind 
10.5 g PPLO broth, 195 mL 
H2OMQ; autoclaving: 15 min, 
121 °C, 75 mL horse serumc 
30 mL yeast extract (with 
K2PO4), 1 mL thallium ace-
tate (10 %), 2.25 mL NAD 
solution (1 %), 0.75 mL 
penicillin (final concentration 
500 U/mL)d 
11 g PPLO broth, 10 g tryp-
tone, 5 g glucose, 625 mL 
H2OMQ; adjust pH: 7.5; auto-
claving: 15 min, 121 °C; 
50 mL mycoplasma growth 
supplement (10x, CMRL 
1066), 35 mL yeast extract 
solutione 100 mL yeastolate 
(2 %), 170 mL foetal bovine 
serumc 
11 g PPLO agar, 10 g tryp-
tone, 5 g glucose, 625 mL 
H2OMQ; adjust pH: 7.5; auto-
claving: 15 min, 121 °C; 
50 mL mycoplasma growth 
supplement (10x, CMRL 
1066), 35 mL yeast extract 
solutione, 100 mL yeastolate 
(2 %), 170 mL foetal bovine 
serumc 
500 mL RPMI 1640 (with L-
glutamine), 5 mL HEPES 
buffer (1 M), 5 mL sodium 
pyruvate (100 mM), 5 mL 
non-essential amino acids 
(100x), 1 mL haemin 
(7.5 mg/mL)f; adjust pH: 7.0 
Reference 73 ATCC medium 988 371 
Cultivation 37 °C, 5 % CO2, up to six weeks 
All media were sterile filtered with a pore size of 0.2 µm; medium components were purchased from Difco or Gibco, a ampicillin (Sigma-Aldrich) and IPTG (Chemie Brun-
schwig AG) were solved in H2OMQ; b X-Gal (Chemie Brunschwig AG) was solved in DMF; c heat-inactivated at 56 °C for 1 h; d Hoechst; e 250 g Baker’s yeast, ad 1 L H2OMQ; 
f
 solved in 0.01 M NaOH; ATCC = American Type Strain and Culture Collection 
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IV.2 Cultivation 
Gassner-, Colombia-blood-, chocolate-, SP4-, and PPLO-agar plates as well as PPLO-, 
SP4-, and modified RPMI-broth were each inoculated with 10 µL EDTA-anti-coagula-
ted horse blood and incubated, as outlined in Table IV-2 (p. 33). Additionally, blood 
culture systems (Oxoid) were inoculated with 10 mL of fresh horse blood and incubated 
for six weeks at 37 °C. Liquid cultures and blood cultures were checked weekly for mi-
crobial growth due to subcultivation on Gassner-, Colombia-blood-, chocolate, SP4-, 
and PPLO agar plates, in addition to PCR targeting universal regions of the 16S rRNA 
gene (Ch. IV.6.2., p. 38) and microscopy of Gram- and Giemsa-stained samples (Ch. 
IV.3, p. 34). 
Transformed Escherichia coli cells were grown on LBZ agar plates (Tab. IV-2; 
Ch. IV.7, p. 40). 
For longer storage of bacterial cultures, glycerol stocks were prepared. 1 mL mid-log 
culture was mixed with 1 mL glycerol solution (65 % glycerol (v/v), 0.1 M MgSO4, 
0.025 M Tris (pH 8.0)), frozen rapidly and stored at -80 °C. 
IV.3 Microscopy 
IV.3.1 Optical microscopy 
IV.3.1.1 Preparation of peripheral blood smears 
Peripheral blood smears were produced using the wedge method, as described by LA-
TIMER & RAKICH (178). One drop of blood was placed on a glass slide (SuperFrost, 
Menzel), and a second slide was drawn backwards into the drop of blood. Then, the 
spreader slide was rapidly and smoothly moved forward before air-drying. 
IV.3.1.2 Giemsa staining 
Peripheral blood smears were fixed in methanol (Roth) for 5 min and incubated for 2 h 
in Giemsa staining solution (190 mL H2OMQ (buffered by Sörensen phosphate buffer 
(Merck)), 10 mL Giemsa solution (Merck), incubation for 10 min at RT, sterile filtra-
tion (pore size 0.2 µm)). The slides were washed twice for 1 min in buffered H2OMQ and 
air-dried. 
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IV.3.1.3 Acridine Orange staining 
Peripheral blood smears on glass slides (SuperFrost, Menzel) were fixed in EtOH100 % 
(Fluka) for 1 min, air-dried, and incubated in acridine orange staining solution (0.02 %) 
for 1 h in the dark. Afterwards, the slides were rinsed with Aquabidest and air-dried. Stai-
ned samples were analysed using fluorescence microscopy (Olympus BX50). 
IV.3.1.4 Gram staining 
Samples were spread on glass slides (SuperFrost, Menzel), fixed by heat, and stained 
with crystal violet (R1; BioMérieux) for 3 min at RT. The staining solution was discar-
ded; slides were stained with lugol solution (R2; BioMérieux) for 2 min at RT, and then 
rinsed with Aquabidest. After decolourisation in EtOH100 % (Fluka) until blue clouds were 
no longer washed away, the slides were rinsed with Aquabidest and stained in safranin 
(R3; BioMérieux) for 30 s. 
IV.3.2 Scanning electron microscopy 
For fixation, 100 µL of fresh anti-coagulated blood was mixed with 2.5 mL PBS-GB 
(1x PBS, 10 mM glucose, 0.1 % BSA (Sigma-Aldrich)) and incubated at 37 °C for 
15 min. Slowly, 2.5 mL PFA-GA (1x PBS, 4 % PFA (Sigma-Aldrich), 0.01 % GA (Sig-
ma-Aldrich)) were added drop-wise. Occasionally, the tube was closed and carefully in-
verted. After incubation for 2 h the samples were centrifuged for 2 min at 500 g. The su-
pernatant was then discarded, and the pellet was resuspended in 5 mL 1x PBS (storage 
up to several weeks at 4 °C was possible). Before the blood samples were spotted onto 
slides, they were centrifuged for 2 min at 500 g. The supernatant was discarded; the pel-
let was resuspended in 10 mL 0.5 M sodium cacodylate buffer, and centrifuged for 
5 min at 500 g. Then the supernatant was discarded, and the pellet was resuspended in 
1 mL 0.05 M sodium cacodylate buffer. Afterwards, a 100 µL cell suspension were set-
tled on carbon coated cover slips (Assistant) using a Cytospin 2 centrifuge (Shandon, 
Dako-Diagnostica) for 2 min at 1200 rpm. Samples were dehydrated in increasing con-
centrations of acetone (from 70 % to 100 %). Due to critical point drying (BAL-TEC 
CPD 030, Critical Point Dryer), acetone was replaced by CO2. Finally, the slides were 
mounted on aluminium stubs, which were sputtered rotating at 45 ° with 4 nm of plati-
num/carbon using the BAL-TEC MED 020 coating system and analysed on a Zeiss Su-
pra 50 VP scanning electron microscope. 
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IV.4 General methods for preparation of DNA 
IV.4.1 Purification of genomic DNA 
IV.4.1.1 BEL lysis 
400 µL of blood was mixed with BEL buffer (1 M Tris (pH 7.4), 1 M MgCl2, 500 µL 
Triton X-100, 1 M sucrose, ad 50 mL H2OMQ) at a 1:1 ratio and centrifuged at 
10000 rpm (Eppendorf Mikrozentrifuge) for 1 min. The supernatant was discarded, and 
the pellet was resuspended in 400 µL BEL buffer and centrifuged again. The BEL buf-
fer wash was repeated so long as the pellet remained colourless. Then, the pellet was re-
suspended in 400 µL 1x PBS. 
IV.4.1.2 DNA purification 
Genomic DNA was prepared by BEL lysis and adjacent purification using several met-
hods. DNA was stored at -20 °C until use. 
First, the phenol extraction method was used. The BEL-lysed pellet was resuspended in 
400 µL 1x PBS and digested by Proteinase K: 45 µL 10 % SDS (Sigma-Aldrich), 
22.5 µL TEN buffer (100 mM Tris, 10 mM EDTA, 1 M NaCl, pH 7.4), and 10 µL Pro-
teinase K (50 U/mL, Roche) were added and incubated for 2 h at 56 °C. Afterwards, 
400 µL phenol (Rotiphenol, Roth) were added, and the tube was inverted approx. 100x 
before incubation for 20 min on ice and centrifugation for 5 min at 10000 rpm and RT 
(Eppendorf Mikrozentrifuge). The supernatant was detached and phenol extraction was 
repeated. Again, the supernatant was detached and mixed with 400 µL IAC (Sigma-Al-
drich). The tube was then inverted approx. 30x and centrifuged for 5 min at 10000 rpm 
and RT. The supernatant was removed and IAC extraction was repeated. Finally, the 
DNA was precipitated using EtOH. To do this, the supernatant was mixed with 40 µL 
NaAc and 800 µL EtOH100 % (Fluka), incubated for 30 min at -70 °C (alternatively for 
24 h at -20 °C), and centrifuged for 30 min at 15000 rpm and 4 °C (Heraeus Biofuge 
Stratos, Fisher Scientific). The supernatant was discarded. Then, the pellet was washed 
in 400 µL EtOH70 %, centrifuged for 30 min at 15000 rpm (Heraeus Biofuge Stratos) and 
4 °C, and the supernatant was discarded. The pellet was air-dried and resuspended in 
20 µL H2OMQ. 
Second, three commercial kits were used to isolate DNA according to manufacturer’s 
instructions: Sigma Gene Elute Bacterial Genomic DNA Kit (Sigma-Aldrich), the Qia-
gen DNeasy blood & tissue kit (Qiagen), and the MagNAPure System (Roche).  
IV. MATERIAL & METHODS 37 
Third, the Looxster® Kit (SIRS-Lab) was used to selectively enrich bacterial DNA rat-
her than eukaryotic DNA. 
IV.4.2 Purification of plasmid DNA 
Isolation of plasmid DNA was carried out with the GeneEluteTM Plasmid Miniprep Kit 
(Sigma-Aldrich) according to the manufacturer’s protocol. 
IV.4.3 Analysis of purity and concentration of DNA 
DNA concentration measurements were performed by detecting absorption at 260 nm 
(BioPhotometer, Vaudaux Eppendorf). Additionally, 5 µL of DNA was applied on an 
1 % agarose gel to check purity. 
IV.5 Agarose gel electrophoresis 
Gel electrophoresis was used to verify size, purity, and concentration of nucleic acids. 
Standard ladders were used to evaluate fragment size and to estimate concentration of 
samples (100 bp DNA ladder, 1 kb DNA ladder; New England Biolabs). 
The appropriate amount of agarose (AGAROSE Standard Molecular Biology Grade, 
Eurobio) was dissolved in 1x TAE buffer (Sigma-Aldrich) and boiled. Per 100 µL TAE-
agarose-solution, 3 µL EtBr (Merck) was added, and the gel was cast in a gel chamber. 
Additionally, 3 µL of EtBr per 100 mL running buffer (1x TAE) were added in the gel 
chamber. Samples were mixed 1:10 with 10x loading dye. For DNA fragments with size 
greater than 500 bp, a bromphenol blue buffer (0.25 % bromphenol blue, 30 % glycerol; 
running dye front: 500 bp) was used, and a xylene-cylene blue buffer (0.25 % xylene-
cylene, 30 % glycerol; running dye front: 1200 bp) was used for smaller fragments. 
Electrophoresis was performed with a constant current of about 100-120 mA for about 
20-45 min. The agarose gel was photographed on an UV transilluminator. 
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IV.6 In vitro DNA amplification by polymerase chain reaction 
IV.6.1 Primer 
The primers used in this study were constructed using the following rules and were 
checked by OligoAnalyzer 3.1 (Integrated DNA Technologies, Coralville, USA; 
http://eu.idtdna.com/analyzer/applications/oligoanalyzer/default.aspx). 
- Keep GC%-content around 50 % 
- Set length between 17-28 nucleotides and avoid distinct secondary structures 
- Put a ‘C’ at the 3’-end ideally 
- Ensure forward and reverse primer have approx. dissociation temperatures 
- Avoid more than three identical bases in a row 
All oligonucleotides used in this study are listed in Table IV-4 (p. 39) and were synthe-
sised and purified by Eurofin MWG Operon (Ebersberg, GER). 
IV.6.2 Conventional PCR 
All PCR reactions were performed in a mastercycler gradient (Eppendorf) or in a ther-
mal cycler (Type 2400, Applied Biosystems) using the Taq DNA polymerase (Roche), 
and all reagents were kept on ice. 2 µL of template DNA was mixed with 23 µL of mas-
ter mix no. 1 and 25 µL of master mix no. 2 (Tab. IV-3). 
Table IV-3 Standard 50 µL protocol using the Taq DNA polymerase (Roche) 
Component Concentration [µL] No. Temperature Time 
master mix no. 1    
H2OMQ  21.6 1x 95 °C 2 min 
dNTPs 10 mM 0.4 94 °C 30 s 
Primer for 100 pmol/µL 0.5 x °C 45 s 
Primer rev 100 pmol/µL 0.5 
35-40x 
72 °C y 
   1x 72 °c 10 min 
master mix no. 2    
H2OMQ  19.75    
Buffer 10x 5    
Taq  0.25    
No. = number of cycles, x = primer dependent annealing temperature, y = elongation time dependent on 
the fragment length 
 
 Table IV-4 Oligonucleotide primers and probes used in this study 
Name Application 5’-sequence-3’ TM [°C] GC [%] Reference 
27F F, 1 CAGAGTTTGATCCTGGCTCAG 59.8 52.4 L. HOELZLE (IVB)a 
1492R R, 1 TACGGYTACCTTGTTACGACTT 57.5 43.2 L. HOELZLE (IVB)a 
h1f F, 1 CAGCCRCAATGGGATTGA 54.8 52.8 L. HOELZLE (IVB)a 
h2f F, 1 GGCCCATATTCCTRCGGGAAG 62.8 59.5 L. HOELZLE (IVB)a 
h1r R, 1 TAGTTTGACGGGCGGTGTGTA 59.8 52.4 L. HOELZLE (IVB)a 
h2r R, 1 ACRGGATTACTAGTGATTCCA 54.9 40.5 L. HOELZLE (IVB)a 
Mh_F4 F, 1 AGCAGCAGTAGGGAATCTTC 57.3 50.0 314 
Mh_R3 R, 1 TTCAAGGAGGCGAATTGCAG 57.3 50 314 
80F1 F, 2 GAGGAAAGTCCRYGCTWGCAC 61.8 57.1 W. LUDWIG (TUM)a 
290R1 R, 2 TCCCYTACCRAAATTTRGGTTTCT 58.4 39.6 W. LUDWIG (TUM)a 
SYBR_For F, 3 AGCAATRCCATGTGAACGATGAA 58.0 41.3 366 
SYBR_Rev1 R, 3 TGGCACATAGTTTGCTGTCACTT 58.9 43.5 366 
SYBR_Rev2 R, 3 GCTGGCACATAGTTAGCTGTCACT 62.7 50 366 
MycHorse_F1 F GCAAGCGCAGGCGGATGTG 63.1 68.4 This study 
MycHorse_F2 F GCGCAGGCGGATGTGTAAG 61.0 63.2 This study 
MycHorse_F3 F, 3 CAGGCGGATGTGTAAGTTC 56.7 52.6 This study; 63 
MycHorse_R1 R GCCTAAGCGTCAATTATGGCC 59.8 52.4 This study 
MycHorse_R2 R CCTAAGCGTCAATTATGGCC 57.3 50.0 This study 
MycHorse_R3 R, 3 CGCCTCCGGTGTTCTTAAAC 59.4 55.0 This study; 63 
M13uni F, 4 GTAAAACGACGGCCAG 50.7 56.3 TOPO TA Cloning Kitb 
M13rev R, 4 CAGGAAACAGCTATGAC 47.0 47.1 TOPO TA Cloning Kitb 
EUB 5 GCTGCCTCCCGTAGGAGT 55.0 66.7 7 
NON-EUB 5 ACTCCTACGGGAGGCAGC 55.0 66.7 352 
F = forward primer, R = reverse primer, 1 = 16S rRNA PCR, 2 = rnpB PCR; 3 = SYBR green I real-time PCR, 4 = colony screen of transformed E. coli cells, 5 = CARD-FISH 
probes labelled with HRP; IUPAC codes: Y = C or T, R = A or G, W = A or T; IVB = Institute of Veterinary bacteriology, University of Zurich; TUM = Technische Universität 
München; a = personal communication; b = Invitrogen 
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IV.6.3 Gradient PCR 
In order to evaluate the optimal annealing temperature of newly designed oligonucleo-
tide primers, gradient PCR was performed in a mastercycler gradient (Eppendorf) with a 
gradient in the annealing temperatures of about 10 °C using a 50 µL standard protocol 
(Tab. IV-3, p. 38). 
IV.6.4 Purification of PCR fragments 
PCR products were purified from remaining nucleotides, polymerases, primers, and 
salts using the QIAquick PCR Purification Kit (Qiagen). The manufacturer’s protocol 
was followed. 
IV.6.5 Quality control of PCR products 
All PCR products were checked qualitatively and quantitatively by agarose gel electro-
phoresis. 
IV.6.6 Real-time PCR 
IV.6.6.1 Universal HM screening SYBR green I real-time PCR assay 
The universal HM screening SYBR green I real-time PCR assay (366) was performed to 
check negative control samples for HM infection. 
IV.6.6.2 SYBR green I real-time PCR assay specific for the equine HM isolate 
During this study, a SYBR green I real-time PCR assay specific to the novel equine HM 
isolate was developed and published ((63); pp. 140-164). 
IV.7 PCR fragment cloning 
Amplified DNA fragments were cloned with the TOPO TA Cloning Kit (Invitrogen). 
One Shot® chemical competent E. coli Top10 cells were used in conjunction with the 
pCR® 2.1-TOPO® cloning vector. To insert the fragments into the cloning vector, 4 µL 
purified PCR product, 1 µL vector, and 1 µL salt solution were mixed and incubated for 
15 min at RT. Then, the mixture was added to frozen competent cells and incubated for 
20 min on ice. Cells were heat-shocked at 42 °C for 30 s and incubated in 250 µL pre-
warmed S.O.C. medium for 1 h at 37 °C while shaking. 70 µL and 200 µL of transfor-
med bacteria were plated on LBZ agar plates each (Ch. IV.2, p. 34) and incubated for 
16 h at 37 °C. Clones were picked, incubated in 50 µL LB medium (Tab. IV-2, p. 33; 
supplemented with ampicillin at a final concentration of 100 µg/mL) for 1 h at 37 °C. A 
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colony screen PCR using 2 µL bacterial culture as template, M13 primers, and a stan-
dard protocol was performed (Ch. IV.6.2., p. 40). 
IV.8 Sequencing of DNA 
Sequencing was performed by Eurofin MWG Operon (Ebersberg, GER). 
IV.9 CARD FISH 
PERNTHALER et al. and SCHÖNHUBER et al.’s protocol (242, 278) were used with slight 
modifications. 
IV.9.1 Preparation of samples and slides 
50 µL EDTA-anti-coagulated blood was incubated in 2.5 mL PBS-GB (1x PBS, 10 mM 
glucose (Sigma-Aldrich), 0.1 % BSA (Sigma-Aldrich)) for 15 min at 37 °C. Afterwards, 
1 mL blood-PBS-GB was incubated in 1 mL PFA-GA (1x PBS, 8 % PFA (Sigma-Al-
drich), 0.02 % GA (Sigma-Aldrich)) for 24 h at 4 °C, centrifuged for 2 min at 500 g, 
and resuspended in 1x PBS. 
Ten-well slides (Erie Scientific Company, Diagnostic Microscope Slide) were coated 
with 20 µL poly-L-lysine (25 µg/mL; Roth) per well for 1 h at RT and rinsed with 
H2OMQ. 10 µL of fixed blood were applied to each well and air-dried at 37 °C. Samples 
were dehydrated using an EtOH series (50 %, 80 %, and 100 %): 20 µL per well, each 
for 3 min at RT. Finally, each well was incubated in 20 µL EtOH100 % (Fluka), and the 
slides were air-dried at 37 °C. 
IV.9.2 Permeabilisation and enzymatic pre-treatment 
Each well was incubated in 50 µL permeabilisation buffer (100 mM Tris/HCl (pH 7.5), 
50 mM EDTA (pH 8.0), 1 mg lysozyme (Roche), ad 100 mL H2OMQ) for 30 min at 
37 °C, rinsed with H2OMQ, and the remaining liquid was removed by filter paper before 
air-drying the slides at 37 °C. Endogenous peroxidases were inactivated by incubation 
in 20 µL 0.01 M HCl per well for 10 min at RT, slides were washed in H2OMQ and 
EtOH96 %, air-dried at 37 °C, and incubated in 20 µL 3 % H2O2 per well for 10 min at 
RT. Finally, the slides were washed in H2OMQ and EtOH96 % and air-dried at 37 °C. 
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IV.9.3 Hybridisation and washing 
Hybridisation buffer (0.9 M NaCl, 20 mM Tris/HCl (pH 8.0), 35 % formamide (Roth), 
10 % dextran sulphate (Sigma-Aldrich), 1 % blocking buffer (Roche), 0.02 % SDS 
(Sigma-Aldrich)) was prepared freshly each time. SDS was added last to avoid precipi-
tation with the concentrated NaCl. The buffer was heated to 40-60 °C and shaken until 
dextran sulphate was completely dissolved. The probe solution (50 ng/µL) was mixed 
with hybridisation buffer at a 1:100 ratio. 50 µL hybridisation buffer (cooled to 35 °C) 
were applied per well. Then, the samples were incubated for 20 min at 35 °C, and the 
hybridisation buffer was removed with filter paper. 50 µL fresh hybridisation buffer 
were added and incubated for 2 h at 35 °C. Incubation was performed in a humidity 
chamber inlayed with blotting paper soaked with the remaining hybridisation buffer 
without the probe. 
The hybridisation buffer was removed, and the slides were quickly and carefully rinsed 
with washing buffer (33.6 mM NaCl, 20 mM Tris/HCl (pH 8.0), 5 mM EDTA (pH 8.0), 
0.01 % SDS). The wells were covered with washing buffer, and then the slides were 
transferred to a humidity chamber inlayed with blotting paper soaked with washing buf-
fer and incubated for 25 min at 37 °C. The washing buffer was removed with filter pa-
per, the slides were incubated in PBS-T (1x PBS supplemented with 0.05 % Triton X-
100 (Sigma-Aldrich)) for 15 min at RT, carefully rinsed with H2OMQ, and the remaining 
liquid was removed with filter paper. 
IV.9.4 Tyramide signal amplification 
After hybridisation, the slides were immediately transferred to the substrate mix (1:10 
tyramide-Cy5:amplification buffer (TSATM Fluorescence system; NEN® Life Science 
Products) in the dark. 10 µL of amplification buffer were added per well before incuba-
tion for 20 min at RT. Slides were briefly placed onto blotting paper, washed in PBS-T 
for 10 min, in excess H2OMQ and then in EtOH100% for 1 min at RT, and air-dried. 
IV.9.5 Counterstaining 
IV.9.5.1 DAPI 
Cells were stained with 20 µL DAPI (1 µL stock solution (100 µg/mL), ad 20 mL 
1x PBS; Sigma-Aldrich) per well for 5 min at RT, washed three times in 1x PBS, once 
in EtOH80 %, and air-dried. 
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IV.9.5.2 Glycophorin A stain 
Due to cross-reactivity of porcine and equine membrane components, RBC surfaces 
were stained using a purified mouse anti-pig CD235a (glycophorin A) monoclonal anti-
body (1:100, PharMingen, BD Biosciences) for 45 min at 37 °C, followed by FITC-
conjugated goat anti-mouse IgG (1:100, Sigma) for 45 min at 37 °C. After, slides were 
washed three times in 1x PBS and air-dried. 
IV.9.6 Microscopy and image analysis 
Cover slips (22x50 cm, Menzel) were mounted by use of 1 drop glyzergel + DABCO 
(Invitrogen) per well. Samples were analysed using a Leica SP2 confocal microscope. 
IV.10 Statistical analysis 
Data were compiled and analysed using Excel (Microsoft) and R Foundation for Statis-
tical Computing (R version 2.11.1). Categorical values (gender, anaemia, clinical status, 
pregnancy, type of housing) were analysed by Fisher’s exact test and continuous variab-
les (age, haematological parameter) using the Mann-Whitney U-test. Correlation of hae-
matocrit and blood loads was assessed by the Spearman rank correlation coefficient (rs). 
Differences were considered statistically significant if P ≤ 0.05. 
IV.11 Phylogenetic analysis 
Phylogenetic analyses were carried out applying the ARB software package (187). Se-
quences were aligned using the ClustalW tool, and the alignment was refined manually. 
Reference sequences were obtained from GenBank 
(http://www.ncbi.nlm.nih.gov/nucleotide/). For 16S rRNA genes, seed alignment with 
corresponding secondary structure annotation was provided by DR. WOLFGANG LUDWIG 
(TU München). Trees were calculated using a neighbour joining and a maximum likeli-
hood approach (RAxML) in combination with similarity filters of 0 %, 25 %, and 50 % 
(185), respectively. Trees were re-sampled 1000 times. Only sequences longer than 
1200 bp were taken in consideration for tree calculation. Shorter sequences were added 
after initial tree calculation using a maximum parsimony approach. 
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V. RESULTS 
V.1 Haemotrophic mycoplasmas in horses 
V.1.1 Clinical signs 
Horses infected with HM displayed unspecific clinical signs including reduced general 
health, apathy, reduced performance, exercise intolerance, asthenia, and weight loss. In 
young horses, developmental retardation may occur. Changes in vital parameters (pulse, 
respiration, temperature) were not usually detected. In 27 of 156 samples, for which a 
complete blood count was available (17.3 %), a normocytic, normochromic anaemia 
was found, and a microcytic, hypochromic anaemia was observed in twelve cases 
(7.7 %). 
V.1.2 Haematological analysis 
V.1.2.1 Complete blood counts 
Correlation between HM infection and anaemia was examined through analysis of com-
plete blood counts from 156 samples collected during Autumn and Winter 2009 and 
2010 (no. 001-007, 010-012, 014, 015, 020-026, 029-031, 036, 048-157; Tab. VIII-1, 
pp. 165-175). Results of haematological values are summarised in Table V-1 (pp. 46-
50) and Figure V-1 (pp. 51-54). Detailed presentation of blood counts can be found in 
Table VIII-3 (pp. 180-187). 
V.1.2.2 Comparison of blood counts of HM infected and non-infected horses 
Haematological parameters for PCR positive and PCR negative (SYBR green I real-
time PCR specific for equine HM; Ch. IV.6.6.2, p. 40; (63); pp. 140-164) horses are 
compared in Table V-1 (pp. 46-50) and Figure V-1 (pp. 51-54). To establish reference 
ranges, the data obtained by LATIMER & RAKICH (178) was used. In PCR positive hor-
ses, RBCC and MCHC were significantly lowered (P = 0.00042 and P = 0.03434, res-
pectively). Changes in other blood parameters were not as significant, although the data 
exhibited slight decreases in haemoglobin concentration (P = 0.08337), absolute num-
ber of eosinophils (P = 0.06017), and relative number of eosinophils (P = 0.09826) in 
infected animals. Decreases in RBCC and haemoglobin concentration may indicate hae-
molytic anaemia. 
 
 Table V-1 Summary of results of complete blood counts 
Parameter Ref. range Mean Range Median 1st Qu 3rd Qu       
 All samples (n = 118)     
Leucocytes 6.0-12.0 G/L 9.64 3.60-14.30 9.80 7.73 11.18       
Erythrocytes 6.0-12.0 T/L 8.79 6.54-13.38 8.84 8.28 9.28       
Haemoglobin 100-180 g/L 128.0 94.0-212.0 128.0 120.0 137.0       
Haematocrit 0.32-0.48 L/L 0.34 0.26-0.52 0.34 0.32 0.37       
MCV 34-58 fL 39.41 30.90-50.80  35.42 43.18       
MCH 13-19 pg 14.63 11.70-17.90 14.50 13.30 15.80       
MCHC 31-37 g/dL 37.25 32.60-41.00 37.30 36.40 38.08       
Thrombocytes 100-600 G/L 171.4 83.0-320.0 164.5 131.0 198.2       
Neutrophils 30-75 % 46.25 20.00-66.00 48.00 40.25 53.00       
Neutrophils abs. 3000-6000 /µL 4346 1332-8400 4246 3686 4972       
Lymphocytes 25-60 % 46.05 23.00-74.00 44.00 37.00 53.50       
Lymphocytes abs. 1500-5000 /µL 4574 1736-9870 4313 3000 5548       
Monocytes 1-8 % 4.27 0-8.00 4.00 4.00 5.00       
Monocytes abs. 0-100 /µL 401.4 0-1120.0 376.0 288.5 494.2       
Eosinophils 1-10 % 2.77 0-7.0 3.0 2.0 4.0       
Eosinophils abs. 0-800 /µL 255.0 0-756.0 240.5 145.0 364.8       
Basophils 0-3 % 0.65 0-4.00 1.00 0.00 1.00       
Basophils abs. 0-300 /µL 60.65 0-564 63 0 96.75       
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 Table V-1 continued 
Parameter Ref. range Mean Range Median 1st Qu 3rd Qu Mean Range Median 1st Qu 3rd Qu P* 
 All samples of horses over one year (n = 87) All samples of horses under one year (n = 31) 
Leucocytes 6.0-12.0 G/L 9.18 3.60-14.10 9.20 7.45 10.80 10.91 7.50-14.30 10.90 9.70 11.95 P = 0.00014* 
Erythrocytes 6.0-12.0 T/L 8.71 6.54-13.38 8.80 8.17 9.21 9.00 7.09-10.65 9.03 8.36 9.55 P = 0.03635* 
Haemoglobin 100-180 g/L 132.7 112.0-212.0 132.0 124.0 140.0 114.8 94.0-131.0 114.0 109.5 121.5 P < 0.00001* 
Haematocrit 0.32-0.48 L/L 0.36 0.31-0.52 0.36 0.34 0.38 0.31 0.26-0.35 0.31 0.29 0.32 P < 0.00001* 
MCV 34-58 fL 41.35 33.40-50.80 41.00 37.15 44.40 33.98 30.90-38.30 33.60 32.70 34.85 P < 0.00001* 
MCH 13-19 pg 15.33 12.90-17.90 15.30 14.20 16.35 12.71 11.70-13.90 12.70 12.40 13.10 P < 0.00001* 
MCHC 31-37 g/dL 37.18 32.60-41.00 37.20 36.30 38.05 37.45 35.80-39.30 37.70 36.70 38.05 n. s. 
Thrombocytes 100-600 G/L 158.7 83.0-272.0 153.0 128.5 186.5 207.1 103.0-320.0 201.0 166.0 247.0 P = 0.00005* 
Neutrophils 30-75 % 48.31 24.00-66.00 50 44 54 40.48 20-60 41 34 46 P = 0.00004* 
Neutrophils abs. 3000-6000 /µL 4321 1332-6825 4224 3777 4749 4416 2356-8400 4601 3354 5302 n. s. 
Lymphocytes 25-60 % 43.47 23-74 42 36 48 53.29 32-74 52 46 60 P < 0.00001* 
Lymphocytes abs. 1500-5000 /µL 4122 1736-9870 3686 2743 4761 5842 3450-9408 5424 4669 6702 P < 0.00001* 
Monocytes 1-8 % 4.25 0-7 4 4 5 4.32 0-8 4 3 6 n. s. 
Monocytes abs. 0-100 /µL 378.8 0-810 360 289 444 465 0-1120 456 312 572 P = 0.0084* 
Eosinophils 1-10 % 3.17 0-7 3 2 4 1.65 0-5 2 0 3 P = 0.00002* 
Eosinophils abs. 0-800 /µL 287 0-756 264 179 387.5 165.2 0-535 172 0 270.5 P = 0.00049* 
Basophils 0-3 % 0.79 0-4 1 0 1 0.26 0-2 0 0 0 P = 0.00003* 
Basophils abs. 0-300 /µL 72.28 0-564 75 0 99.5 28.03 0-264 0 0 0 P = 0.00014* 
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 Table V-1 continued 
Parameter Ref. range Mean Range Median 1st Qu 3rd Qu Mean Range Median 1st Qu 3rd Qu P* 
 All PCR positive horses (n = 31) All PCR negative horses (n = 87)  
Leucocytes 6.0-12.0 G/L 9.41 5.30-13.80 9.2 7.45 11.1 9.72 3.6-14.3 9.8 7.95 11.25 n. s. 
Erythrocytes 6.0-12.0 T/L 8.39 6.85-10.32 8.37 7.77 8.94 8.93 6.54-13.38 8.87 8.40 9.51 P = 0.00042* 
Haemoglobin 100-180 g/L 124.5 94.0-150.0 124.0 115.5 132.5 129.2 101-212 129 120 137.5 P = 0.08337 
Haematocrit 0.32-0.48 L/L 0.34 0.26-0.41 0.34 0.31 0.36 0.35 0.28-0.52 0.35 0.32 0.37 n. s. 
MCV 34-58 fL 40.15 32.70-49.60 38.8 36.2 43.9 39.15 30.90-50.80 38.1 35.1 42.85 n. s. 
MCH 13-19 pg 14.82 12.40-17.90 14.7 13.6 16.3 14.57 11.70-17.90 14.5 13.15 15.8 n. s. 
MCHC 31-37 g/dL 36.96 35.00-39.00 37.00 36.15 37.80 37.35 32.60-41.00 37.5 36.6 38.15 P = 0.03434* 
Thrombocytes 100-600 G/L 172.5 107.0-286.0 171 134.5 195.5 171 83.0-320.0 162 132 200 n. s. 
Neutrophils 30-75 % 46.09 20.00-66.00 47.00 39.5 54.5 46.32 24-65 49 40.5 53 n. s. 
Neutrophils abs. 3000-6000 /µL 4189 2536-6666 4218 3496 4652 4402 1332-8400 4272 3754 5004 n. s. 
Lymphocytes 25-60 % 46.45 23.00-74.00 44 36.5 52 45.91 28.0-74 43 37.5 53 n. s. 
Lymphocytes abs. 1500-5000 /µL 4546 1792-9408 4171 2768 5797 4584 1736-9870 4346 3058 5528 n. s. 
Monocytes 1-8 % 4.42 0-6 5 3.5 5.5 4.22 0-8 4 4 5 n. s. 
Monocytes abs. 0-100 /µL 403.8 159-732 428 304 472.5 400.6 0-1120 372 289 497.5 n. s. 
Eosinophils 1-10 % 2.42 0-6 3 1 3 2.90 0-7 3 2 4 P = 0.09826 
Eosinophils abs. 0-800 /µL 218.7 0-756 222 73.5 300 268 0-742 258 166 384 P = 0.06017 
Basophils 0-3 % 0.65 0-2 1 0 1 0.66 0-4 1 0 1 n. s. 
Basophils abs. 0-300 /µL 58.1 0-254 53 0 94.5 61.56 0-564 66 0 96.5 n. s. 
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 Table V-1 continued 
Parameter Ref. range Mean Range Median 1st Qu 3rd Qu Mean Range Median 1st Qu 3rd Qu P* 
 PCR positive horses over one year (n = 23) PCR negative horses over one year (n = 64)  
Leucocytes 6.0-12.0 G/L 9.61 5.33-12.70 8.30 7.35 10.75 9.24 3.6-14.1 9.3 7.5 10.9 n. s. 
Erythrocytes 6.0-12.0 T/L 8.46 6.85-10.32 8.42 7.95 8.94 8.8 6.54-13.38 8.81 8.29 9.25 P = 0.09363 
Haemoglobin 100-180 g/L 129.8 115.0-150.0 129.0 124 135.5 133.7 111-212 133 126 140 n. s. 
Haematocrit 0.32-0.48 L/L 0.35 0.31-0.41 0.35 0.34 0.37 0.36 0.30-0.52 0.36 0.34 0.38 n. s. 
MCV 34-58 fL 41.88 35.70-49.60 42.40 37.35 45.85 41.16 33.40-50.8 40.9 37.17 43.95 n. s. 
MCH 13-19 pg 15743 13.50-17.90 15.10 14.15 16.6 15.29 12.9-17.9 15.3 14.2 15.95 n. s. 
MCHC 31-37 g/dL 36.9 35.00-39.00 37.00 36.15 37.8 37.28 32.6-41 37.3 36.4 38.2 P = 0.06836 
Thrombocytes 100-600 G/L 165.1 107.0-272.0 159 129 192.0 156.4 83-242 151 128 180.5 n. s. 
Neutrophils 30-75 % 48.91 26.00-66.00 48.00 44.5 56.5 48.09 24-65 50.5 44 54 n. s. 
Neutrophils abs. 3000-6000 /µL 4276 2773-6666 4232 3694 4652 4337 1332-6825 4218 3778 4780 n. s. 
Lymphocytes 25-60 % 42.96 23.00-70.00 44.00 34.50 47.5 43.66 28-74 41 37 48 n. s. 
Lymphocytes abs. 1500-5000 /µL 4008 1792-7560 3652 2479 4818 4163 1736-9870 3691 2889 4673 n. s. 
Monocytes 1-8 % 4.44 2-6 5 3.5 5 4.19 0-7 4 4 5 n. s. 
Monocytes abs. 0-100 /µL 392 159-714 415 304 491.5 374.1 0-810 353 289.5 431.5 n. s. 
Eosinophils 1-10 % 2.87 0-6 3.0 2 3.5 3.28 0-7 3 2 4 n. s. 
Eosinophils abs. 0-800 /µL 262.3 0-756 238 1485 322.5 295.9 0-742 298.5 184.5 396.2 n. s. 
Basophils 0-3 % 0.83 0-2 1 0 1 0.78 0-4 1 0 1 n. s. 
Basophils abs. 0-300 /µL 75.04 0-254 74 0 107.50 71.28 0-564 75.5 0 98.25 n. s. 
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 Table V-1 continued 
Parameter Ref. range Mean Range Median 1st Qu 3rd Qu Mean Range Median 1st Qu 3rd Qu P* 
 PCR positive horses under one year (n = 8) PCR negative under one year (n = 23)  
Leucocytes 6.0-12.0 G/L 10.54 7.5-13.8 11.25 8.8 11.68 11.03 8.1-14.3 10.8 9.8 12 n. s. 
Erythrocytes 6.0-12.0 T/L 8.19 7.09-9.55 8.11 7.56 8.69 9.29 7.72-10.65 9.31 8.81 9.83 P = 0.00386* 
Haemoglobin 100-180 g/L 109.4 94-120 110.5 106.8 119.8 116.7 101-131 118 111 123 P = 0.03026* 
Haematocrit 0.32-0.48 L/L 0.30 0.26-0.32 0.30 0.29 0.31 0.31 0.28-0.35 0.31 0.30 0.33 P = 0.03568* 
MCV 34-58 fL 35.19 32.7-38.0 34.55 34.17 36.8 33.56 30.9-38.3 33.3 32.55 34.45 P = 0.01595* 
MCH 13-19 pg 13.00 12.4-13.7 13.15 12.9 13.22 12.59 11.7-13.9 12.6 12.3 12.9 P = 0.01181* 
MCHC 31-37 g/dL 37.14 35.8-38.5 37.25 36.15 38.02 37.56 35.7-39.3 37.7 37.05 38.05 n. s. 
Thrombocytes 100-600 G/L 193.9 127-286 177 167.5 233.5 211.7 103.320 220 166.5 249.5 n. s. 
Neutrophils 30-75 % 37.88 20-52 36.5 31.75 46.52 41.39 28-60 42 34.5 46 n. s. 
Neutrophils abs. 3000-6000 /µL 3939 2356-5772 3726 3141 4737 4582 2610-8400 4635 3500 5302 n. s. 
Lymphocytes 25-60 % 56.5 44-74 55 46 66 52.17 32-68 52 45.5 60 n. s. 
Lymphocytes abs. 1500-5000 /µL 6096 3450-9408 5064 4590 7950 5754 3813-8908 5488 4770 6468 n. s. 
Monocytes 1-8 % 4.38 2-6 4.5 3.5 6 4.30 0-8 4 3 6 n. s. 
Monocytes abs. 0-100 /µL 438 230-732 453 402 457 516 0-1120 516 305 595 n. s. 
Eosinophils 1-10 % 1.13 0-4 0 0 2.25 1.83 0-5 2 0 3 n. s. 
Eosinophils abs. 0-800 /µL 93.25 0-368 0 0 169.5 190.2 0-535 196 0 286.5 P = 0.0747 
Basophils 0-3 % 0.13 0-1 0 0 0 0.30 0-2 0 0 0 n. s. 
Basophils abs. 0-300 /µL 9.38 0-75 0 0 0 34.52 0-264 0 0 0 n. s. 
Reference (Ref.) ranges referred to LATIMER & RAKICH (178). MCV = Mean corpuscular volume, MCH = Mean corpuscular haemoglobin, MCHC = Mean corpuscular haemo-
globin concentration, abs. = absolute. Mean, median and quartiles were calculated using R Foundation for Statistical Computing (R version 2.13.0). Blood counts of 156 horses 
were available. Fourteen horses’ ages were unknown, so they were excluded from analyses. Also, 24 re-collected samples from 2009 were excluded. No samples exhibited an ele-
vated number of segmented neutrophils or other cells. Samples were analysed by a one-sided Mann-Whitney U-Test. P-Values ≤ 0.1 are outlined. * significant, if P ≤ 0.05; 
n.s. = not significant. 
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 Figure V-1 
 
P = 0.00042* 
P = 0.08337 
P = 0.09363 P = 0.00386* 
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P = 0.01595* P = 0.01181* 
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 Figure V-1 continued 
 
P = 0.003434* P = 0.06836 
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 Figure V-1 continued 
 
 
P = 0.09826 P = 0.06017 P = 0.0747 
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Figure V-1 Comparison of blood parameters for PCR positive (PCR pos) and PCR negative (PCR 
neg) horses. Blood counts of 156 horses were available. The ages of one PCR positive and thirteen PCR 
negative horses were unknown, and they were thus excluded from analyses. Twenty-four samples from 
2009 that were re-collected one month later were also excluded. Results are shown for all horses 
(n = 118; PCR pos, n = 31; PCR neg, n = 87) and for horses grouped according to their age (PCR pos 
>1 year, n = 23; PCR neg >1 year, n = 64; PCR pos <1 year, n = 8; PCR neg <1 year, n = 23). No samples 
exhibited an elevated number of segmented neutrophils or other cells. Samples were analysed by a one-
sided Mann-Whitney U-Test and boxplots were generated using R Foundation for Statistical Computing 
(R version 2.13.0). Boxes extend from the 25th to the 75th percentile, median is presented as horizontal 
line, and the bars extend to the minimum and maximum value. Dots represent outliers. P-Values ≤ 0.1 are 
outlined. * significant, if P ≤ 0.05. Compare Table V-1 (pp. 46-50). 
V.1.2.3 Differences of blood counts of young and adult horses 
Haematological values for horses younger than one year and older than one year were 
compared by PCR status (Tab. V-1 & Fig. V-1, pp. 46-54). In PCR positive horses less 
than one year-old, the following blood parameter values were significantly lower; De-
creases of RBCC (P = 0.00386), haemoglobin concentration (P = 0.03026), and haema-
tocrit (P = 0.03568) indicated haemolytic anaemia. MCV and MCH were significantly 
elevated in PCR positive horses less than one year-old (P = 0.01595 and P = 0.01181, 
respectively). In contrast to these results, haematocrit was not significantly changed in 
PCR positive horses older than one year, and only slight decreases in RBCC and MCHC 
were found (P = 0.09363 and P = 0.06836, respectively). 
Independent of PCR status, significant differences were found between PCR positive 
horses less than one year-old compared to horses older than one year (Tab. V-1, pp. 46-
50; Fig. V-2, pp. 55-56). 
 
 Figure V-2 
 
P = 0.00014* P = 0.03635* P < 0.00001* P < 0.00001* P < 0.00001* 
P < 0.00001* 
P < 0.00001* P < 0.00001* 
P = 0.00005* P = 0.00004* 
P = 0.0084* P = 0.00002* 
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 Figure V-2 continued 
 
 
Figure V-2 Comparison of blood parameter values of horses older than one year (n = 87) and younger than one year (n = 31) independent of PCR status. Blood counts 
of 156 horses were available. Ages of one PCR positive and thirteen PCR negative horses were unknown, and they were therefore excluded from analyses. Twenty-four sam-
ples from 2009 that were re-collected one month later were also excluded. No samples showed an elevated number of segmented neutrophils or other cells. Samples were ana-
lysed using the one-sided Mann-Whitney U-Test, and boxplots were generated using R Foundation for Statistical Computing (R version 2.13.0). Boxes extend from the 25th to 
the 75th percentile, the median is presented as horizontal line, and the bars extend to the minimum and maximum value. Dots represent outliers. P-Values are outlined if signifi-
cant (P ≤ 0.05). Compare Table V-1 (pp. 46-50). 
P = 0.00049* P = 0.00003* P = 0.00014* 
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V.1.2.4 Cold agglutinins 
In some PCR positive horse blood samples, agglutination induced by antibodies of the 
cold-type was seen. Agglutination repeatably dissolved upon incubation at 37 °C and 
was repeatedly re-induced by incubation at 4 °C. Cold agglutinins can be detected by 
Coombs’ direct antiglobulin testing (353). Since the suspicion of cold agglutinins in 
horse blood was an incidental finding that occurred during sample preparation, the 
Coombs’ testing was not performed immediately after sample collection but three 
months later, and, unfortunately, Coombs’ testing failed. 
 
Figure V-3 Cold Agglutinins. Left: negative horse sample, middle: strong agglutination, right: slight 
agglutination. 
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V.1.3 Microscopic Findings 
V.1.3.1 Light microscopy 
In peripheral blood smears stained with acridine orange and Giemsa, coccoid bacterial 
structures reminiscent of HM species which infect other animals were detected on the 
surface of equine RBCs (Fig. V-4). Also, typical rouleaux formation, and deformation 
and destruction of RBCs were observed. Sometimes, the HM lay in small grooves. 
 
Figure V-4 Giemsa (A, B) and acridine orange (C, D) stained peripheral blood smears of horses in-
fected with haemotrophic mycoplasmas. HMs are indicated by arrowheads. They are attached to RBCs 
and free in the plasma. Rouleaux formation and RBC deformation can be observed. Photographs were 
taken at 1000x magnification. Picture of Panel B was published slightly modified elsewhere (63). 
 
A B 
C D 
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Figure V-5 Scanning electron micrographs of equine red blood cells infected with haemotrophic 
mycoplasmas. Some RBCs are deformed and destructed (D). HMs were detected on the surface of and 
between RBCs (HM). Structures assumed to be attachment (AS) and invagination scars (IS) were obser-
ved as well as structures resembling microcolonies (MC). 
V.1.3.2 Scanning electron microscopy 
In scanning electron microscopy, destruction and deformation of RBCs was directly ob-
served (Fig. V-5 B & D). Sometimes, HM-like particles attached to the surface were 
found (Fig. V-5 B & F). Unfortunately, HMs were frequently found detached from sur-
face of RBCs and were instead detected between RBCs (Fig. V-5 A, D & G). Neverthe-
less, attachment scar-like structures were observed (Fig. V-5 C & D). Also, structures 
similar to M. suis invagination scars (106) were seen (Fig. V-5 E). In some samples, mi-
crocolony structures resembling natural M. suis infections in pigs were detected (DR. 
KATRIN GROEBEL, IVB, pers. comm.; Fig. V-5 A, B & H). In some samples, agglomera-
tion of infected and/or deformed RBCs with WBCs was observed. 
V.1.4 Cultivation 
Cultivation was monitored by visual analysis of agar plates, subcultivation in blind pas-
sages, and 16S rRNA PCR. After failure to cultivate the first horse blood samples col-
lected in February 2008, no further cultivation attempts were made. 
V.1.5 DNA purification 
Blood was lysed by the BEL lysis method and subsequently purified using standard 
methods. Phenol extraction exhibited highest DNA yield, but phenol contamination of 
samples can inhibit PCR and may interfere with SYBR green in real-time PCR. That is 
why, three commercial DNA purification methods (Sigma Gene Elute Bacterial Geno-
mic DNA kit, Qiagen DNeasy blood & tissue kit, Roche MagNA Pure LC system) were 
tested. Efficiency of all three systems was found to be approximately equal, but the Sig-
ma kit exhibited the best price-performance-ratio and was therefore chosen for DNA pu-
rification. 
A selective enrichment of prokaryotic DNA relative to eukaryotic DNA was attempted 
using the Looxster® kit. However, the absolute DNA loss was high and therefore the 
DNA purification efficiency was poor, as HM blood loads were very low. 
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V.1.6 PCR & Sequencing 
V.1.6.1 Conventional 16S PCR 
64 of 103 samples (62.1 %) revealed a positive PCR result using a primer pair targeting 
universal 16S rRNA regions (27F/ 1492R) in a conventional PCR protocol. 57 of 105 
(54.3 %) samples were HM positive as demonstrated by utilisation of a PCR primer pair 
specific for HM (hf1/ h1r). However, 16S rRNA sequencing (hf1/ h1r) was only suc-
cessful in two cases. Comparison to databases using the BLAST tool revealed 97-98 % 
sequence identity with ‘CM haemobovis’ and 93-94 % with M. haemofelis (Tab. V-7, 
p. 82) (62). Sequencing using the universal 16S rRNA primer pair failed to obtain full-
length HM sequences. Instead, amplicons from contaminating bacteria were cloned, or 
no PCR products or clones were obtained. Detailed PCR results are presented in Ta-
ble V-4 (pp. 69-73). 
V.1.6.2 Design of equine HM specific PCR primer pairs 
In two horses, 900 bp of partial 16S rRNA sequences were successfully amplified using 
primer pair hf1 and hr1 (62). These sequences were then used to design equine HM-spe-
cific PCR primer pairs. Oligonucleotides were designed by use of the probe design tool 
in the ARB software package (187), and primer specificity was tested in silico with the 
programme pDRAW (http://www.acaclone.com/ (334)). Possible primer pair sequences 
are outlined in Table IV-3 (p. 39) and their binding specificities in Table V-2 (p. 62). 
Primers were tested in a standard PCR protocol (Ch. IV.6.2, p. 38) at annealing tempe-
ratures of 55 °C and 58 °C. Optimal annealing temperatures were evaluated by gradient 
PCR (Ch. IV.6.3, p. 40). 
Primer combinations amplifying HM from the ‘haemominutum-group’, ‘CM turicen-
sis’, M. haemofelis, or M. haemocanis were discarded. Only three primer combinations 
selectively amplified the 16S rRNA sequence of the novel equine HM isolate and 
‘CM haemobovis’ (F1/R3, F2/R3 and F3/R3). Since these two HM isolates are very 
closely related, it was not possible to find sufficient sequence differences for primer de-
sign exclusively to the equine HM isolate. These three combinations were then tested in 
a SYBR green I real-time PCR assay. The primer pair F3/R3 was subsequently chosen 
for design of the SYBR green I real-time PCR assay specific for the novel equine HM 
isolate, as it exhibited the highest sensitivity compared to the other two combinations, 
and it can be used with an annealing temperature of 58 °C, which enhanced specificity 
of PCR (Tab. V-2, p. 62). 
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Table V-2 Primer pairs tested for specificity for the equine HM isolate 
 F1/R1 F1/R2 F1/R3 F2/R1 F2/R2 F2/R3 F3/R1 F3/R2 F3/R3 
‘haemominutum-group’        
M. ovis - - - - - - - - - 
M. suis - - - - - - - - - 
M. wenyonii - - - - - - - - - 
M. coccoides - - - - - - + + - 
‘haemofelis-group’        
‘CM turicensis’ - - - + + - + + - 
M. haemomuris - - - - - - - - - 
M. haemofelis + + - + + - + + - 
M. haemocanis + + - + + - + + - 
‘CM haemobovis’ + + + + + + + + + 
Plasmid 30/7 + + + + + + + + + 
PCR 55 °C + + + + + + + + + 
PCR 58 °C - + - - + - + + + 
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V.1.6.3 SYBR green I real-time PCR assay 
DIECKMANN et al., 2011 ((63); pp. 140-164) describes the development of the SYBR 
green I real-time PCR assay. In this section, only supplementary material and results 
concerning samples not included in the aforementioned publication are presented. 
Seventy of 211 horse samples (33.2 %) displayed positive SYBR green I real-time PCR 
signals. Table V-4 (pp. 69-73) summarises values of crossing points (CP), melting tem-
peratures (TM), and blood loads of all samples. The mean CP was 31.95 (range: 26.52-
36.38), the mean TM was 80.81 °C (range: 80.04-82.07 °C), and the mean blood load 
was 1.67 x 107 cells/mL blood (range: 1.70 x 102-3.69 x 108 cells/mL blood). Typical 
amplification and melting curves are shown in Figure V-6. High HM loads in blood 
were not associated with disease, anaemia, or abnormalities in blood count (Fig. V-7, 
pp. 64-66). 
 
      
Figure V-6 Amplification and melting curve analysis. A typical example of amplification and melting 
curves comparing one horse sample (no. 72; turquoise; CP = 33.40; TM = 80.93 °C) with a positive con-
trol (1:10 dilution of plasmid 30/7 (62, 63); blue; CP = 8.13; TM = 81.29 °C), and a negative control (wa-
ter; pink). In the negative control, no amplification occurred. The second peak in the horse sample repre-
sents formation of primer dimers. Data analysis was performed using LightCyclerTM software (Roche). 
 
 Figure V-7 
 
P = 0.03706* P = 0.00006* P = 0.00004* P = 0.00045*, 
P = 0.00003*, P = 0.01334* 
UP: rS = -0.53893 
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 Figure V-7 continued 
 
 
P = 0.00353* P = 0.00835* P = 0.0109* 
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Figure V-7 Correlation of bacterial blood loads and haematological values. Bacterial blood loads (log 
copy number per mL of blood) were plotted against haematological values. 156 horses’ blood counts 
were available. Fourteen horses’ ages were unknown, and therefore they were excluded from analyses. 
Twenty-four samples re-collected one month later were also excluded. No samples exhibited an elevated 
number of segmented neutrophils or other cells. MCV = mean corpuscular haemoglobin, MCH = mean 
corpuscular haemoglobin, MCHC = mean corpuscular haemoglobin concentration. Reference ranges 
(178) are indicated by a grey box. • = PCR positive horses older than one year, ο = PCR positive horses 
younger than one year, x = PCR negative horses older than one year, + = PCR negative horse younger 
than one year. Scatterplots were generated using R Foundation for Statistical Computing (R version 
2.13.0). Blood parameters of PCR positive horses older and younger than one year were compared using 
the one-sided Mann-Whitney U-Test. * = P-Values are outlined, if significant (P ≤ 0.05). Correlation was 
analysed by the Spearman rank correlation coefficient (rS). Only coefficients higher than 0.5 and lower 
than -0.5 are indicated. OP = PCR positive older than one year, UP = PCR positive younger than one 
year. 
V.1.7 Comparison of microscopy and PCR results 
Results of the SYBR green I real-time PCR assay were compared to microscopy of acri-
dine orange and Giemsa stained peripheral blood smears (Tab. V-3, p. 67). Acridine 
orange stains were available from 164 samples, while only 158 samples were stained 
with Giemsa. Both stains were available from 118 samples. 211 samples were tested 
with the novel SYBR green I real-time PCR assay. Blood smears stained with either 
acridine orange or Giemsa were available from 204 samples. 102 of 204 samples show-
ed signs of HM (50.0 %). In 37 of 158 Giemsa stained horse blood smears (23.4 %), 
HMs were detected. In acridine orange stained blood smears, HMs were detected in 80 
of 164 samples (48.8 %). In fifteen of 118 samples (12.7 %), HMs were detected in 
Giemsa stained blood smears as well as in acridine orange stained blood smears. 72 of 
118 samples (61.0 %) were negative in both staining techniques. 
48 of 102 samples microscopically diagnosed as HM positive (either Giemsa or acridine 
orange stained) were confirmed positive by PCR (47.1 %). In 72 microscopically HM-
negative samples, six reacted positive in PCR (8.3 %). This corresponds to a rate of 
false-positive microscopic results of 38.8 % and false-negative microscopic results of 
9.2 %. Microscopy of Giemsa stained blood smears revealed in 37 samples HM, of 
which 17 reacted positive in PCR (45.9 %). 42 of 80 samples diagnosed as positive by 
microscopy of acridine orange stained blood smears reacted positive in PCR (52.5 %), 
corresponding to false-positive microscopic rates of 17.4 % in case of Giemsa staining 
and 34.2 % in case of acridine orange. The false-negative rates were 60.5 % (Giemsa) 
and 20.8 % (acridine orange). Overall, Giemsa staining and PCR results agree in 112 
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cases (70.9 %), acridine orange and PCR results yield the same result in 115 cases 
(70.1 %), and all three methods concur in 77 cases (65.2 %). 
Table V-3 Correlation of microscopy and PCR results 
Variable Number of horses 
 Total PCR positive PCR negative 
Microscopy (either Giemsa or acridine orange, n = 204)    
Positive 102 48 54 
Negative 102 17 85 
    
Giemsa (n = 164)    
Positive 37 17 20 
Negative 121 26 95 
    
Acridine orange (n = 158)    
Positive 80 42 38 
Negative 84 11 73 
    
Giemsa and acridine orange (n = 118)    
Positive in both staining techniques 15 11 4 
Negative in both staining techniques 72 6 66 
Positive in Giemsa, negative in acridine orange 2 0 2 
Negative in Giemsa, positive in acridine orange 29 14 15 
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V.1.8 CARD-FISH 
In the first trial, DAPI for nucleus staining was used as counterstain (Fig. V-8 A-C). 
Due to inefficient washing, the background from DAPI staining was very high, and 
even DNA-free RBCs appeared blue. Bacterial 16S rRNA was targeted by an universal 
EUB338 probe (7) labelled with HRP which catalysed the deposition of Cy5-labelled 
fluorescein tyramine. Detected bacteria appeared as red dots (Fig. V-8 C). 
In a second trial, glycophorin A, which is a RBC membrane component, was targeted 
by a FITC-labelled antibody (Fig. V-8 D-F). DAPI staining was still too strong, so it 
was ignored for producing the overlay (Fig. V-8 F). 
In both attempts, coccoid bacteria were detected on the RBC surfaces, as seen in the 
overlays (Fig. V-8 C & F, arrowheads). By hybridisation with a NONEUB probe (352), 
no structures on the RBC surface were detected (data not shown). 
 
Figure V-8 Micrographs of CARD-FISH of horse blood infected with HM. DAPI (blue) was used as 
nucleus counterstain and glycophorin A (FITC, green) as the RBC membrane counterstain. Bacteria 
(white arrowhead) were specifically detected by a HRP-labelled EUB338 probe (red). HRP catalysed the 
deposition of Cy5-labelled fluorescein tyramine. 
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V.1.9 Description of the novel equine HM isolate: ‘Candidatus Mycoplasma 
equi’ 
‘Candidatus Mycoplasma equi’ [Latin: equus, horse] [(Mollicutes) NC; NA; O, wall 
less; NAS (GenBank acc. no. FN421445); S (horse, erythrocyte); DIECKMANN et al. 
Vet. Microbiol. 145: 351-353, 2010]. 
In Giemsa and acridine orange stained blood smears, coccoid bacteria (ca. 0.3 µm) were 
observed on the surface of equine RBCs. Microscopic pictures resembled other HM 
species (e.g. ‘CM turicensis’ (367)). The novel HM species seems to be responsible for 
anaemia in horses, but exact clinical implications have not yet been determined. Analy-
sis of partial 16S rRNA sequences showed that ‘CM equi’ is most closely related to 
‘CM haemobovis’ and M. haemofelis. 
V.1.10 Summary of results 
Table V-4 Summary of results 
Blood count PCR SYBR green Microscopy No. Date of 
sampling Ht Hb RBCC WBCC 16S HM CP TM 
Bact. Load 
GI AO 
18.02.08 / / / / + + Neg / + 001 
16.11.09 0.37 137 8.80 7.2 - - Neg - + 
18.02.08 / / / / + - 30.89 80.57 1.21 x 105 / + 002 
16.11.09 0.38 138 8.28 6.9 - - 33.66 80.59 5.65 x 103 - + 
18.02.08 / / / / - + 30.86 80.83 1.30 x 105 / / 
16.11.09 0.33 115 6.54 7.7 - + Neg + + 003 
09.12.09 0.33 117 6.61 7.3 / / Neg + / 
18.02.08 / / / / + + Neg / + 004 
16.11.09 0.36 133 8.22 10.1 + - 34.05 80.69 2.98 x 103 - + 
18.02.08 / / / / + + Neg / + 005 
16.11.09 0.39 140 8.87 5.8 - - Neg - - 
18.02.08 / / / / - - 32.62 80.18 5.80 x 106 / + 006 
16.11.09 0.40 141 8.91 8.0 + - Neg - - 
18.02.08 / / / / - + 31.02 80.54 8.40 x 104 / + 007 
16.11.09 0.38 139 8.84 7.9 - - Neg - - 
008 18.02.08 / / / / + + 29.65 80.72 4.36 x 107 / - 
009 18.02.08 / / / / - - 31.73 80.69 1.06 x 107 / - 
18.02.08 / / / / + + 28.95 80.90 7.05 x 107 / + 010 
16.11.09 0.32 118 8.29 6.0 - - Neg - + 
18.02.08 / / / / - - Neg / + 011 
16.11.09 0.35 122 7.60 7.0 - - Neg + - 
18.02.08 / / / / + + Neg / - 012 
16.11.09§ 0.33 115 6.85 7.3 + - 32.63 80.86 8.25 x 103 - + 
18.02.08 / / / / + + Neg / + 013 
15.05.08 / / / / + + Neg / + 
18.02.08 / / / / + + 29.79 81.37 1.11 x 106 / + 
15.05.08 / / / / + + Neg / + 014 
16.11.09 0.36 129 7.20 5.3 + - 32.59 80.81 8.85 x 103 - + 
18.02.08 / / / / - + 30.20 80.31 5.55 x 105 / + 
17.11.09 0.35 124 7.38 7.4 + + 32.05 80.46 2.35 x 104 + + 015 
09.12.09 0.33 118 6.98 7.0 / / 31.44 80.35 2.11 x 105 - / 
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Table V-4 continued 
Blood count PCR SYBR green Microscopy No. Date of 
sampling Ht Hb RBCC WBCC 16S HM CP TM 
Bact. Load 
GI AO 
18.02.08 / / / / + + Neg / + 016 
15.05.08 / / / / + + Neg / + 
19.02.08 / / / / + - 32.13 81.06 8.05 x 106 / + 
15.05.08 / / / / + + 36.38 80.31 7.00 x 105 / + 017 
25.07.08 / / / / - - Neg / + 
018 20.02.08 / / / / + + Neg / + 
019 20.02.08 / / / / + + Neg / - 
20.02.08 / / / / + + Neg / + 
18.11.09 0.31 115 7.64 8.3 - - 32.43 80.42 1.19 x 104 + + 020 
09.12.09 0.31 114 7.67 7.1 / / Neg - / 
20.02.08 / / / / + + Neg / / 021 
16.11.09 0.39 143 8.54 11.0 + - Neg - - 
20.02.08 / / / / + + 29.98 80.16 8.25 x 105 / + 
15.05.08 / / / / + + Neg / - 022 
16.11.09 0.37 133 9.00 8.3 - - 33.32 80.16 9.90 x 103 - - 
20.02.08 / / / / + + 29.47 80.35 4.94 x 107 / - 023 
17.11.09 0.37 139 9.22 9.8 + - Neg - + 
20.02.08 / / / / + + Neg / + 
15.05.08 / / / / + + Neg / + 024 
18.11.09 0.33 112 6.56 7.6 - - Neg - - 
20.02.08 / / / / - - Neg / - 025 
16.11.09 0.39 140 9.27 6.8 / / Neg - - 
20.02.08 / / / / + + 26.52 80.23 3.69 x 108 / - 026 
18.11.09 0.36 142 8.39 9.7 / / Neg - - 
027 20.02.08 / / / / + - 29.82 81.06 3.89 x 107 / - 
20.02.08 / / / / + + 29.57 80.21 4.62 x 107 / + 028 
15.05.08 / / / / + + Neg / + 
20.02.08 / / / / + + 27.90 80.60 1.63 x 108 / + 
15.05.08 / / / / + + Neg / + 029 
18.11.09 0.36 129 7.42 8.1 / / Neg - - 
20.02.08 / / / / + + 27.95 80.71 9.50 x 106 / + 
25.07.08 / / / / + - 29.62 80.98 1.41 x 106 / + 030 
18.11.09 0.41 147 8.36 8.3 / / 32.93 81.01 4.86 x 103 - - 
20.02.08 / / / / + + 30.14 80.99 2.00 x 107 / + 031 
17.11.09 0.42 138 8.35 8.0 / / Neg - + 
20.02.08 / / / / + + 28.09# 80.50# 1.05 x 108# / + 032 
15.05.08 / / / / + + Neg / + 
033 20.02.08 / / / / + - 29.30 80.71 4.40 x 107 / / 
034 20.02.08 / / / / + + 28.87 80.04 6.55 x 107 / / 
20.10.08 / / / / + + 30.68 80.62 2.03 x 105 / + 036 
17.11.09§ 0.33 124 8.94 10.8 / / 34.69 80.67 1.05 x 103 - + 
042 20.11.08 / / / / + - Neg / / 
043 08.12.08 / / / / + + Neg / + 
044 08.12.08 / / / / + - 34.98 80.33 2.18 x 105 / / 
045 n/a / / / / + - Neg / + 
046 n/a / / / / / / / / - 
047 n/a / / / / + + 33.63 82.07 7.70 x 105 / + 
048 16.11.09 0.36 132 8.84 8.2 / / Neg - - 
16.11.09 0.39 141 8.54 7.2 + + 31.07 80.94 1.38 x 105 + + 049 
09.12.09 0.39 142 8.62 6.8 / / 35.86 80.74 9.65 x 104 + / 
050 16.11.09 0.39 141 8.37 7.4 / / 32.78 80.30 6.30 x 103 - - 
051 16.11.09§ 0.38 141 8.62 11.5 / / Neg - - 
052 16.11.09 0.37 126 7.25 7.8 / / Neg - - 
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Table V-4 continued 
Blood count PCR SYBR green Microscopy No. Date of 
sampling Ht Hb RBCC WBCC 16S HM CP TM 
Bact. Load 
GI AO 
053 16.11.09§ 0.35 127 7.46 7.5 / / Neg - - 
054 16.11.09 0.38 144 9.12 8.7 / / Neg - - 
055 17.11.09 0.30 110 7.91 9.3 / / Neg - - 
056 17.11.09 0.31 118 9.90 10.3 / / Neg - - 
17.11.09 0.26 94 7.09 11.4 - + 32.03 80.71 2.45 x 104 + + 057 
09.12.09 0.31 112 8.30 15.0 / / Neg + / 
058 17.11.09 0.32 120 9.55 9.8 / / Neg - - 
17.11.09 0.29 109 8.28 11.1 + - 32.17 80.60 1.28 x 103 - + 059 
09.12.09 0.28 105 7.94 16.7 / / 34.04 80.52 3.05 x 103 + / 
17.11.09 0.31 120 9.55 13.8 + + 30.71 80.78 2.65 x 105 + + 060 
09.12.09 0.34 126 10.05 16.3 / / 35.71 80.16 2.00 x 102 - / 
061 17.11.09 0.31 123 9.91 9.8 / / Neg - - 
17.11.09 0.28 100 7.58 7.6 + - 30.79 80.64 2.29 x 105 - + 062 
09.12.09 0.34 126 9.58 12.2 / / Neg - / 
17.11.09 0.31 114 9.53 9.6 - - Neg + + 063 
09.12.09 0.35 130 10.8 13.4 / / Neg - / 
17.11.09 0.30 112 8.86 11.7 / / Neg - + 064 
09.12.09 0.32 117 9.04 17.0 / / Neg - / 
065 17.11.09 0.32 123 10.25 10.3 / / Neg - - 
066 17.11.09 0.30 112 9.04 13.1 / / Neg - - 
17.11.09 0.31 112 9.03 11.5 - + 32.37# 81.49# 6.11 x 104# + + 067 
09.12.09 0.33 120 9.47 12.9 / / 35.81 80.27 1.70 x 102 - / 
068 17.11.09 0.33 122 9.31 10.0 / / Neg - - 
17.11.09 0.30 109 7.93 9.2 + + 33.55 81.42 3.73 x 103 + + 069 
09.12.09 0.32 116 8.45 9.1 / / Neg - / 
17.11.09 0.28 104 7.72 8.6 / - Neg + - 070 
09.12.09 0.35 130 9.84 11.5 / / 34.73 81.58 9.80 x 102 - / 
17.11.09 0.30 111 8.43 8.1 / / Neg - - 071 
09.12.09 0.30 106 8.16 12.6 / / Neg - / 
17.11.09 0.29 111 8.95 14.3 / + Neg - + 072 
09.12.09 0.32 119 9.57 19.5 / / 35.40 80.98 3.31 x 102 + / 
073 17.11.09 0.33 122 8.07 6.6 / / Neg - - 
075 17.11.09 0.37 133 8.50 6.2 / / Neg - + 
076 17.11.09 0.35 128 7.86 7.1 / / Neg - + 
077 17.11.09 0.37 135 8.71 10.6 / / Neg - + 
078 17.11.09 0.38 141 8.42 7.7 / / Neg - - 
079 17.11.09 0.37 143 9.02 8.9 / / Neg - - 
080 17.11.09§ 0.39 137 8.68 10.2 / / Neg - - 
081 17.11.09 0.36 133 8.91 9.3 / / Neg - - 
082 17.11.09 0.32 123 8.92 7.1 / / Neg - - 
083 17.11.09§ 0.34 131 9.22 11.1 / / Neg - - 
084 17.11.09 0.36 132 9.58 12.5 / / Neg - - 
17.11.09 0.35 131 8.93 11.1 + - 30.25 80.85 7.45 x 106 + + 085 
09.12.09 0.33 122 8.27 9.4 / / 34.53# 81.22# 1.18 x 106# - / 
086 17.11.09 0.31 115 7.53 7.2 / / Neg - - 
087 17.11.09 0.33 128 9.28 10.6 / / Neg - - 
088 17.11.09 0.34 132 9.11 12.8 / / Neg - - 
089 17.11.09 0.34 131 9.48 14.1 / / Neg - - 
17.11.09 0.34 125 7.62 8.3 + + 33.07 80.94 8.95 x 103 + + 090 
09.12.09 0.31 111 6.82 6.4 / / Neg - / 
091 17.11.09 0.37 140 8.09 7.5 / / Neg - + 
092 17.11.09 0.31 115 7.50 9.3 / / Neg - - 
093 17.11.09 0.41 152 8.49 10.5 / / Neg - - 
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Table V-4 continued 
Blood count PCR SYBR green Microscopy No. Date of 
sampling Ht Hb RBCC WBCC 16S HM CP TM 
Bact. Load 
GI AO 
094 18.11.09 0.52 212 13.38 3.6 / / Neg - - 
095 18.11.09 0.32 117 8.07 7.7 / / Neg - - 
096 18.11.09 0.34 128 8.89 10.8 / / 30.78 81.01 4.15 x 106 - + 
097 18.11.09 0.38 154 10.26 9.9 / / Neg - - 
18.11.09 0.32 120 7.83 11.1 + + Neg + + 098 
09.12.09 0.36 135 8.99 9.2 / / 33.65 81.97 7.60 x 105 - / 
099 18.11.09 0.34 121 6.87 8.1 / / Neg - - 
100 18.11.09 0.36 137 9.73 10.0 / / Neg - - 
101 18.11.09 0.37 140 9.88 9.6 / / Neg - - 
102 18.11.09 0.33 126 8.98 13.5 / / Neg - - 
18.11.09 0.34 124 7.90 9.2 - + 29.43 81.09 6.70 x 106 + + 103 
09.12.09 0.34 123 7.87 8.7 / / Neg - - 
104 18.11.09 0.39 137 8.80 10.3 / / Neg - - 
105 18.11.09 0.31 116 8.42 10.7 - + 34.54 81.54 6.30 x 104 + + 
106 18.11.09 0.34 121 7.99 5.9 / / 32.49 81.05 6.15 x 105 - - 
107 18.11.09 0.32 123 9.56 11.7 / / Neg - - 
108 18.11.09 0.35 132 9.66 10.7 / / 29.07 80.84 1.27 x 107 - - 
109 18.11.09 0.33 120 8.82 7.4 / / Neg - - 
110 18.11.09 0.32 123 8.54 8.6 / / Neg - - 
111 18.11.09 0.33 127 9.14 6.4 / / 32.32 81.28 3.50 x 104 - - 
112 18.11.09 0.34 127 8.40 8.5 / / Neg - - 
113 18.11.09 0.38 142 9.20 9.3 / / Neg - - 
114 18.11.09 0.40 150 9.27 11.9 / / 33.93 80.96 1.87 x 103 - + 
115 18.11.09 0.36 136 9.99 10.6 / / Neg - - 
116 18.11.09 0.37 141 10.32 9.7 / / 33.73 81.17 2.69 x 103 - + 
117 18.11.09 0.35 133 9.31 11.3 / / Neg - - 
118 18.11.09 0.32 120 8.28 10.3 + + Neg + + 
119 18.11.09 0.35 138 10.11 11.9 / / Neg - - 
120 18.11.09 0.35 136 9.89 10.0 / / Neg - - 
121 18.11.09 0.34 130 8.44 13.0 / / Neg - - 
122 18.11.09 0.37 137 9.24 12.3 / / Neg - + 
123 18.11.09 0.35 131 9.83 10.9 / / Neg - - 
124 18.11.09 0.36 141 10.13 11.4 / / Neg - - 
125 18.11.09 0.35 132 8.87 11.5 / / Neg - - 
126 18.11.09 0.34 130 8.87 12.7 / / 30.28 80.51 1.24 x 106 - + 
127 18.11.09 0.32 120 8.86 12.6 / / 31.78 80.70 9.25 x 104 - + 
128 18.11.09 0.39 154 11.75 13.0 / / Neg - - 
129 18.11.09 0.38 140 8.12 6.6 / / Neg - - 
130 18.11.09 0.36 136 8.55 5.8 / / Neg - - 
19.11.09 0.29 108 8.76 10.9 + + Neg - - 131 
09.12.09 0.32 120 9.64 10.7 / / Neg + / 
19.11.09 0.29 112 8.57 12.2 - + 32.12 81.59 5.05 x 104 - + 132 
09.12.09 0.33 126 9.60 12.7 / / Neg - / 
133 19.11.09 0.33 126 10.64 12.3 / / Neg - - 
134 19.11.09 0.35 131 10.65 11.2 / / Neg - - 
19.11.09§ 0.29 106 8.34 10.8 + + Neg - + 135 
09.12.09 0.30 107 8.25 13.8 / / Neg + / 
19.11.09 0.33 123 9.52 13.2 / / Neg - + 136 
09.12.09 0.34 125 9.49 15.1 / / Neg - / 
137 19.11.09 0.34 129 10.29 11.3 / / Neg - - 
138 19.11.09 0.33 124 9.75 11.5 / / Neg - - 
139 19.11.09 0.32 116 9.02 14.0 / / Neg - + 
140 19.11.09 0.32 119 9.15 7.5 / / 33.60 80.88 6.20 x 103 - + 
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Table V-4 continued 
Blood count PCR SYBR green Microscopy No. Date of 
sampling Ht Hb RBCC WBCC 16S HM CP TM 
Bact. Load 
GI AO 
141 19.11.09 0.31 119 9.15 10.7 / / Neg - - 
142 19.11.09 0.32 121 9.50 8.7 / / Neg - + 
143 06.01.10 0.35 125 7.61 6.1 + + 33.15# 81.21# n.d. + / 
144 06.01.10 0.32 115 6.75 6.6 - - Neg + / 
145 29.12.09 0.15 53 3.00 8.5 - - Neg + / 
146 29.12.09 0.25 91 5.00 5.1 - - Neg + / 
147 16.12.09 0.26 98 6.11 8.5 - - Neg + / 
148 30.12.09 0.28 101 8.62 14.3 - - Neg - / 
149 10.12.09 0.32 114 6.83 13.3 - - Neg + / 
150 28.12.09 0.29 105 6.88 30.4 - - Neg - / 
151 17.12.09 0.29 105 5.80 5.5 - - Neg - / 
152 24.01.10 0.31 115 6.57 2.6 - - Neg - / 
153 19.01.10 0.33 118 7.52 10.2 - - Neg - / 
154 19.01.10 0.40 132 7.84 6.4 - - Neg + / 
155 17.01.10 0.27 94 6.14 6.0 - - Neg + / 
156 21.01.10 0.31 96 5.75 4.6 - - Neg + / 
157 24.01.10 0.20 69 4.90 19.6 - - Neg + / 
158 n/a / / / / - - Neg + / 
159 n/a / / / / + + 35.72 81.38 n.d. + / 
160 n/a / / / / / / 33.04 81.32 n.d. / / 
161 n/a / / / / + + 31.77# 81.30# 2.79 x 107# + / 
No. = sample number; § = horses with a preliminary report of clinical sings characteristic of HM: meagre appearance, shaggy fur, 
and reduced performance; Ht = haematocrit (L/L, reference range: 0.32-0.48), Hb = haemoglobin (g/L, reference range: 100-180), 
RBCC = red blood cell count (1012 cells/L, reference range: 6.0-12.0), WBCC = white blood cell count (109 cells/L, reference range: 
6.0-12.0); CP = crossing point; TM = melting temperature; Neg = negative; Bact. load = bacterial load (per mL of blood); # samples 
were tested twice in SYBR green I real-time PCR and then mean values of CP, TM, and bacterial load were calculated; n.d. = not de-
termined; GI = Giemsa stain; AO = acridine orange stain; - = negative; + = positive; / = not available; n/a = not available. Positive 
PCR and microscopy results are highlighted in red boldface, decreased blood parameters in blue boldface, and increased blood para-
meters in orange boldface. 
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V.2 Phylogenetic analysis of haemotrophic mycoplasmas 
V.2.1 General 
All calculated trees showed similar topologies. A typical tree is presented in Figure V-9 
(p. 77). In concordance with previously published 16S rRNA phylogenies of haemotro-
phic mycoplasmas (155, 220), HM are closely related to the ‘pneumoniae-group’, and 
their closest relatives are members of the ‘fastidiosum-cluster’ (M. fastidiosum, M. cavi-
pharyngis, and M. insons). Within the HM cluster, two subclusters were observed. 
These two subclusters were termed ‘haemofelis-group’ and ‘haemominutum-group’ by 
PETERS et al. (243). This terminology is employed in this thesis as well. The ‘haemofe-
lis-group’ comprises the HM species M. haemofelis, M. haemocanis, M. coccoides, 
M. haemomuris, and the rather novel isolates ‘CM turicensis’ and ‘CM haemobovis’. 
The well-known species M. ovis, M. wenyonii, and M. suis belong to the ‘haemominu-
tum-group’ just like the novel isolates ‘CM erythrocervae’, ‘CM erythrodidelphis’, ‘CM 
kahanei’, ‘CM haemozalophi’, ‘CM haemolamae’, ‘CM haemominutum’, and ‘CM hae-
matoparvum’. Differences of the 16S rRNA sequences of the two subclusters are out-
lined in Table V-5. 
Two-dimensional models of secondary structures of 16S rRNA were created. Within the 
subclusters, the overall architecture of 16S rRNA secondary structure is rather similar 
except for minor base substitutions, deletions, and insertions. However, structures of the 
two HM subclusters differ in four certain aspects. Figures V-10 & 11 (pp. 78-79) show 
the representative structures of the ‘haemofelis’- and ‘haemominutum-group’ (M. hae-
mofelis and M. wenyonii), respectively. The members of the ‘haemofelis-group’ exhibit 
shorter versions of loops eleven and eighteen, whereas loops six and ten are longer. 
Table V-5 Nucleotide positions characteristic for the two haemotrophic Mycoplasma subclusters 
Exceptions Pos Hfg Hmg Fsg Png 
Hfg Hmg 
114 U C U U   
132 A U C A, C, U  Cmk: C 
140 C A, G A U cap, Mhm: A; Mcc: U  
146 G A A, G G  Cme: G 
154 C A C, U U Mhm: U Cmz: U 
167 G U A, G A Mhm: A Cmz: G 
176 U C C, U C   
177 C A, C, U U C, G, U   
188 A, C, U A, G C, T C   
190 A - A U Mhf/ Mhc: U Cmz: U; Cml: A 
191 G - G G cap, Mhm: U Cmz: U; Cmm, Cmp: C 
199 C, G A, G A, G A, G, T   
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Table V-5 continued 
Exceptions Pos Hfg Hmg Fsg Png 
Hfg Hmg 
200 - A, G C, U A, U  Cmo: U, Cmk: C 
201 C, U G C, G C, G Mcc: A  
202 G, U C C C   
222 U G U U Cmt, cap: U  
248 C, U A, G A A, C   
276 G C   cap, Mcc: A Msu: C, U 
284 A G G G   
286 A G A G Cmt: G Cmo: A 
294 U A A G  Cmk, Cmp: G 
297 U G   Cmt, Mhm: A  
303 A U U C, U  Cmp: C 
313 A G A A   
359 A G A A   
360 G A G G   
366 C U U U   
369 C U C U   
403 U C C C  Cmh: U 
444 A, G U A A, G, U   
445 G A G G   
453-481  25 bp trunc.    Cmo: 17 bp trunc. (458-474) 
490 C, U A U A, C, U   
508 A U U A, U   
518 U A U U  Cme, Cmk: C 
544 G A G A, G   
555 T C C C   
576 C G C A, C, G   
582 C U C C   
590 U A, C, G G, U U   
595 A U A A  Cmv: C, Msu: G 
596 A G A A  Msu: U 
597 G A G G   
599 U C C C   
601 U A A, G G   
602 G U G G  Cmk, Cmz: G 
614 G C, U A, G A, G, U   
636 C A, U U U  Msu, Cme: G 
637 C U U U Mhm: A  
644 U C U U  Msu: U 
658 G U A A, G, U Mhm: A  
659 U A C U Mhm: C  
661 G U G A, G   
667 A G A A   
670 U A U U   
671 U C C C, U   
679 A C C C Mhm: G  
683 A G G G Mhm: G  
699 U C C C   
711 U G G G Mhm: C  
735 A G G A, G   
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Table V-5 continued 
Exceptions Pos Hfg Hmg Fsg Png 
Hfg Hmg 
736 A U A A   
739 U C U U   
744 C A C C, U   
770 U C U U   
830 A G U A, G Cmb/ Cmq, Mcc: G Msu: U 
835 G U G G Mhf/ Mhc: A  
851 C G C C Mhf/ Mhc: U  
856 U C A C, U Cmb/ Cmq, Mcc: C Msu: A 
864 U A A A Cmb/Cmq: A  
893 C U C C cap: U  
917 G A G G   
990 U C U C, U   
994 A C, U A A   
995 C A, U C C   
999 C U C C, U   
1000 C, U A, U C U   
1040 G A, U G A Cmb/ Cmq, Cmt: A  
1100 C U C C   
1145 U A U U   
1147 - U - A, G   
1155 A U A A  Msu: A, U 
1164 C U G A, G   
1165 A C C C   
1171 U G G G   
1172 G A C C, U   
1188 A G A A   
1189 U C U U   
1192 C A C C  Cmv: G 
1271 G A G G Mcc: A  
1274 A G A A, G Cmb/ Cmq: G  
1292 C, U C C C, U   
1293 C, U U A G   
1327 U A U U Mhf/ Mhc: C  
1354 C U C C  Msu: C, U 
1368 G A G G   
1377 A, G A A A Mhf/ Mhc: C Cme, Cmh: G 
1424 G U G U Mhm: A Cml: A 
1425 G A U A   
1426 G C A A  Mov/ Cmo: U 
1429 U A, G U C, U   
1436 A C C A, C   
Numbering of positions (pos) correspond to the numbering of the 16S rRNA sequence of E. coli. Only 
positions, in which the consensus sequence of ‘haemofelis’ (Hfg)- and ‘haemominutum’ (Hmg)-group 
differs, were taken into consideration; Fsg = ‘fastidiosum-group', Png = ‘pneumoniae’-group; 
Mhm = M. haemomuris, Cmt = ‘CM turicensis’, Msu = M. suis, Cmm = ‘CM haemominutum’, 
Cmp = ‘CM haematoparvum’, Cmk = ‘CM kahanei’, cap = novel HM isolates from capybara, 
Mhf = M. haemofelis, Mhc = M. haemocanis, Cme = ‘CM erythrodidelphis’, Mcc = M. coccoides, 
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Cmz = ‘CM haemozalophi’, Cml = ‘CM haemolamae’, Cmb = ‘CM haemobovis’, Cmq = ‘CM equi’, 
Mwe = M. wenyonii, Cmo = ‘CM haemovis’, cer = novel HM isolates from cervids, Cmv: 
‘CM erythrocervae’, Mov = M. ovis; trunc. = truncation; A = adenine, C = cytosine, G = guanine, 
U = uracil, - = gap. 
 
Figure V-9 Phylogenetic tree of haemotrophic mycoplasmas based on 16S rRNA sequences. A tree 
calculated by the maximum likelihood method in combination with a similarity filter of 25 % is shown. 
The tree was re-sampled 1000 times. Bootstrap percentage values are given as numbers at the nodes. Only 
values higher than 45 % are shown. The scale bar indicates the estimated evolutionary distance. Species 
and GenBank acc. no. are given at axes of single isolates. Clusters including more than two species were 
grouped. The triangle size indicates homology within the clusters, and the number inside of the triangle 
indicates the number of group members. Clostridium perfringens served as outgroup for tree rooting. The 
alignment of one member of each species can be found in the appendix on pp. 194-201. 
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Figure V-10 Two dimensional model of 16S rRNA 
secondary structure of M. haemofelis (NC_014970, 
1429 bp). Structure was created using the ARB 
software package (187) and processed with Xfig 
(http://www.xfig.org/). Colour code: blue = helix pai-
ring, red = non-helix pairing, green = loop. Black num-
bers indicate base positions according to E. coli num-
bering, and orange numbers indicate helix numbers. 
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Figure V-2 Two dimensional model of 16S rRNA 
secondary structure of M. wenyonii (AY946266, 
1471 bp). Structure was created using the ARB 
software package (187) and processed with Xfig 
(http://www.xfig.org/). Colour code: blue = helix pai-
ring, red = non-helix pairing, green = loop. Black num-
bers indicate base positions according to E. coli num-
bering, and orange numbers indicate helix numbers. 
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In all 16S rRNA trees calculated in this study, M. ovis and ‘CM haemovis’ could not be 
separated into two distinct clusters (Fig. V-12 A). ‘CM haemovis’ was described in 
2009 (140) and differs from M. ovis only by a 17 bp truncation in loop 18 (Fig. V-12 B 
& C) and some minor base substitutions (Tab. V-6). 
  
Figure V-12 Part of the 16S rRNA tree showing the position of M. ovis and ‘CM haemovis’ and part 
of the 16S rRNA secondary structures. Part of a tree calculated with the maximum likelihood method 
and a 25 % similarity filter is shown in panel A. To see the whole tree, refer to Figure V-10, p. 77. Panel 
B shows part of the 16S rRNA secondary structure of M. ovis (GU230144), and panel C describes part of 
the 16S rRNA secondary structure of ‘CM haemovis’ (EU165512). The overall structures of both species 
resemble the structure of M. wenyonii (Fig. V-11, p. 79). 
Table V-6 Nucleotide positions characteristic for the ovine Mycoplasma isolates M. ovis (Mov) and 
‘CM haemovis’ (Cmo) 
Pos Cmo Mov Hmg Hfg Fsg Png 
200 U G A, G - C, U A, U 
286 A G G A, G A G 
354 A G G G G G 
458-475 17 bp trunc.      
Numbering of positions (pos) correspond to E. coli; Hmg = ‘haemominutum’-group, Hfg = ‘haemofelis’-
group, Fsg = ‘fastidiosum-group’, Png = ‘pneumoniae’-group; trunc. = truncation; A = adenine, C = cyto-
sine, G = guanine, U = uracil, - = gap. 
A B 
C 
18 
18 
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V.2.2 Phylogeny of novel HM isolates in cattle 
In anaemic cattle in Northern Germany, two distinct HM isolates were found (Fig. V-
13). One isolate was clearly identified as the well-known species, M. wenyonii (2, 219), 
and the other isolate was identified as the rather new species ‘Candidatus M. haemo-
bovis’ (139, 314). These results were published ((130); pp. 137-139). 
 
Figure V-3 Phylogenetic analysis of 16S rRNA gene sequences illustrating the position of the bovine 
isolates among the HM group. The tree was constructed using the maximum likelihood method and a 
minimum similarity filter of 25 %. Bootstrap values are given in percent at the tree nodes (1000 
bootstraps). Species names and the corresponding acc. no. are given at each axis. The scale bar represents 
the estimated evolutionary distance. Bacillus subtilis served as an outgroup for tree rooting. The tree was 
reprinted from HOELZLE et al., 2011 ((130), pp. 137-139). The corresponding alignment can be found in 
the appendix on pp. 202-206. 
V.2.3 Phylogeny of Mycoplasma suis in wild boars 
Occurrence of M. suis in wild boars was reported for the first time in Germany. A pre-
valence of 10.03 % was found. Characterisation of eighteen randomly chosen isolates 
revealed two M. suis-subclusters: the ‘Guangdong’- and the ‘Illinois’-cluster (Fig. V-
14). These results were published ((128); pp. 129-133). 
V.2.4 Phylogeny of the novel equine HM isolate 
A novel equine HM isolate was found in Northern German horses. Partial 16S rRNA 
sequences (880 to 916 bp; acc. no. FN421443, FN421444, FN421445) showed the 
greatest sequence identity (97-98 %) with the bovine HM species ‘CM haemobovis’ 
(Tab. V-7, p. 82; Fig. V-15, p. 83). Refer to DIECKMANN et al., 2010 ((62); pp. 134-136) 
for more details. 
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Figure V-4 Phylogenetic tree based on 16S rRNA sequences showing the position of the wild boar 
isolates among HMs. The tree was constructed using the neighbour-joining method in combination with 
the Felsenstein correction model and a 25 % similarity filter. Species assignation and accession numbers 
are given at each axis. Bacillus subtilis served as an outgroup. Bootstrap values are given at the nodes of 
the tree (1000 bootstraps). The scale bar indicates estimated evolutionary distance. The wild boar isolates 
are highlighted in bold face. They form two groups, group A showing highest similarity to M. suis ‘Illi-
nois’ (U88565) and group B to M. suis ‘Guangdong’ (AY492086). Tree was reprinted from HOELZLE et 
al., 2010 ((128), pp. 129-133). The corresponding alignment can be found in the appendix on pp. 210-
218. 
Table V-7 Similarity matrix of the novel equine HM isolates to selected HM species 
  Species 1 2 3 4 5 6 7 8 9 10 
1 equine HM isolate 30/7 (FN421445)  97 98 94 94 90 87 83 83 82 
2 equine HM isolate 32/2 (FN421443) 97  97 93 93 90 87 83 83 82 
3 CM haemobovis' (EF460765) 98 97  94 94 88 86 80 82 79 
4 M. haemocanis (AF197337) 94 93 94  99 88 86 80 79 80 
5 M. haemofelis (U95297) 94 93 94 99  88 86 80 79 81 
6 CM turicensis' (DQ825450) 90 90 88 88 88  90 82 82 83 
7 M. haemomuris (U82963) 87 87 86 86 86 90  82 78 79 
8 M. wenyonii (AY769937) 83 83 80 80 80 82 82  90 95 
9 M. suis (AF029394) 83 83 82 79 79 82 78 90  90 
10 M. ovis (AF338268) 82 82 79 80 81 83 79 95 90  
Similarity values were obtained from BLAST and are given in percent. 
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Figure V-5 Comparative sequence analysis using 16S rRNA sequences showing the position of the 
equine isolates among the HMs. Equine HM isolates are highlighted in bold-face. Size of sequences of 
isolate no. 30/7, 30/14 and 32/3 are between 880 and 916 bp, while sequences of isolate no. 90, 111, and 
127 represent 117 bp-amplicons of the equine HM specific SYBR green I real-time PCR assay. The tree 
shown was produced by applying the maximum likelihood method in combination with a 25 % similarity 
filter. The numbers at the nodes indicate bootstrap values in percent (1000 bootstraps). Only values higher 
than 45 % are presented here. The scale bar represents the estimated evolutionary distance. Clostridium 
perfringens served as an outgroup for tree rooting. Clusters including more than two species were group-
ed. Size of triangle indicates homology within the clusters and the number inside of the triangle indicates 
the number of group members. An alignment comprising all equine HM and ‘CM haemobovis’ isolates 
can be found in the appendix on pp. 207-209. 
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VI. DISCUSSION 
VI.1 Haemotrophic mycoplasmas in horses 
In contrast to the well-known HM species in cattle, pigs, small ruminants, dogs, and 
cats (136, 210, 364), almost nothing was known about HM infections in horses with the 
exception of a 1978 case report based on cytology (101). The emerging significance of 
HM in domestic and free-ranging animals is evidenced by the rising number of newly 
described HM isolates and species in recent years (199, 263, 309, 314, 350, 351, 355, 
360). Recently, putative HM infection in horses was discussed in online fora (e.g. 
www.reitforum.de, www.hufreheforum.de) and German journals (‘Pferdespiegel’, ‘Pfer-
deheilkunde’ (93, 231)). NIEMENDAL analysed 108 blood smears for evidence of HM in 
his doctoral thesis and found a prevalence of 19.4-75.9 % (230, 231). 
In the equine practice BEEKENHOF (Luneburg Heath, Northern Germany), a long history 
of purported HM infection in horses exists (DR. M. DIECKMANN, pers. comm.). Horses 
were reported to be meagre, do not develop well, showing a ruff haircoat, apathy, and 
reduced performance. Thorough clinical investigation and haematological analysis have 
revealed no abnormalities besides slight transient anaemia and, in some cases, a sele-
nium deficiency. In peripheral blood smears stained with Giemsa, HM-like particles 
were observed (DR. M. WINKLER, synlab.vet, pers. comm.). Agents responsible for 
anaemia such as equine infectious anaemia virus, Theileria sp., Babesia sp., and Ehrli-
chia sp. were excluded. 
Based on these reports, the present study was performed to evaluate the real clinical sig-
nificance of equine HM infections. At the beginning, several DNA purification methods 
were tested for suitability of isolation of HM in horse blood. Since blood loads were 
very low in the affected horses examined by this study, bacterial DNA purification was 
a crucial step in sample processing. Unfortunately, every purification method results in 
partial loss of bacterial DNA, but most commercial kits are able to remove most PCR-
inhibitory factors. However, successful detection of purified bacterial DNA with com-
mercial kits requires at least 103 cells/mL blood (113, 379). Many of this study’s horse 
blood samples had a HM blood load near the minimum required cell concentration. Ef-
ficiency of the phenol-chloroform extraction was higher, but the remaining phenol mo-
lecules interfered in both SYBR green I real-time PCR and conventional PCR approa-
ches. Repeated EtOH precipitation removed phenol but led to DNA loss. 
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Although bacterial DNA was detected in 57 of 105 samples by conventional 16S rRNA 
PCR (primer pair hf1/ h1r), cloning and sequencing were only successful in three cases. 
Strangely, PCR results with different primer pairs did not match in all cases (Tab. V-4, 
pp. 69-73). These discrepancies may be explained by interference between non-specific 
DNA sequences and the desired bacterial DNA sequence at low bacterial blood loads in 
broad-spectrum PCR (379). ZUCOL et al. showed that detection of bloodstream infec-
tions necessitates a higher bacterial load than for detection of bacterial DNA in pure cul-
tures (379). AKANE et al. demonstrated that haem in blood may inhibit amplification of 
DNA by PCR (4). Finally, remaining eukaryotic DNA of equine blood components may 
have interfered during PCR, inhibiting correct binding of oligonucleotides and Taq 
DNA polymerase to bacterial DNA. Thus, conventional PCR may not be the appro-
priate tool for detection of low-level HM infections, and conventional PCR results with-
out confirmation by sequencing should be interpreted with caution. 
Nevertheless, this Ph.D. thesis exhibits the first molecular proof that HM infections do 
occur in horses ((62); pp. 134-136). 
 
After successful molecular proof of the existence of equine HM, a SYBR green I real-
time PCR assay was developed and published ((63); pp. 141-165). This tool allows 
more sensitive, equine HM-specific detection in larger sample sizes compared to con-
ventional PCR approaches. Recently, real-time PCR methods were developed for HM 
detection, leading to an increasing number of detection of novel HM isolates. These no-
vel PCR methods have displaced hitherto used diagnostic tools based on microscopy; 
microscopy is too insensitive for detection of HM in animals with a subclinical course 
of disease or with low bacterial blood loads (16, 215, 269, 336). With the newly deve-
loped SYBR green I real-time PCR assay, an unambiguous and sensitive detection of 
HM in blood of affected horses is now possible. Equine HM prevalence was 33.2 % (70 
of 211 samples exhibited a positive SYBR green I real-time PCR result; Tab. V-4, 
pp. 69-73). This value is high in comparison to the prevalence of HM in other animals: 
feline (0.5 to 8.5 % (361)) and canine HM in Switzerland (1.2 % (358)), Africa (6.0 % 
(11)), and Spain (0.6-14.3 % (271)), and M. suis in pigs in Germany (13.9 % (269)). Si-
milarly high prevalences were observed for ‘CM haemobovis’ in cattle in Japan (22.3 % 
(315)), ‘CM haemominutum’ in cats in Australia and South Africa (24.0-38.0 % (362)), 
feline HM in Northern Italy (18.9 % (95)), and ‘CM haemolamae’ in Switzerland 
(18.6 % (161)). 
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However, the HM prevalence in this study may represent an overestimate, as (i) most 
samples of this study were derived from a single breeding farm in Northern Germany, 
(ii) suspicious HM cases were previously reported at this farm (DR. M. DIECKMANN & 
DR. M. WINKLER, pers. comm.), and (iii) the sample number was rather low. In order to 
determine if the high HM infection prevalence is a regional phenomenon or a single-
herd, sporadic event, the study should be repeated with a higher sampling number, and 
with samples originating from other locations, both in Germany and abroad. For exam-
ple, M. suis was shown to occur throughout Germany (269), and feline HM cases have 
been reported from around the world (365). Varying prevalence data may reflect regio-
nal differences and occurrence of possible vectors. 
 
Despite the development of highly sensitive real-time PCR assays, microscopy of peri-
pheral blood smears stained with Giemsa or acridine orange is still the method of choice 
for detection of HM in many laboratories. Therefore, microscopic and PCR results were 
compared concerning sensitivity and specificity. PCR and microscopic results of Giem-
sa and acridine orange stained peripheral blood smears did not correlate well (Tab. V-3, 
p. 67). To a large extent, microscopically positive animals reacted negatively in PCR 
(9.2 % false-negative) and vice versa (38.8 % false-positive). False-negative microsco-
pic detection may have resulted from low bacterial loads or inapparent infections with 
bacteria absent from blood. Blood loads of 4.4 x 106 ‘CM turicensis’ copies/mL were 
reported to correspond to only one bacterium per 1000 to 10000 RBCs (215). This ex-
plains why a definitive microscopic detection of this feline HM species in blood has not 
met with success in the past few years (361, 367), even though, the 16S rRNA sequence 
of this agent was determined in 2005 (360). RITZMANN et al. reported that at least 
106 M. suis cells/mL blood must be present for an unambiguous microscopic detection 
(269). Bacterial loads in the affected horses from this study were in the same low range 
(at an average of 1.67 x 107 cells/mL blood, range: 1.70 x 102 to 3.69 x 108 cells/mL), 
hindering the unambiguous identification of HM on the RBC surface using microscopy 
and conventional PCR methods. False-positive microscopic results may be due to con-
fusion of HM with Howell-Jolly bodies, background debris, and staining artefacts (164, 
198, 220, 314). Problems with false-positive and false-negative microscopic results are 
a well-known phenomenon in HM diagnostics (16, 118, 122, 269, 359). Evaluation of 
microscopic results depends on the observer’s subjective impression, and there are no 
reference values, leading to difficulties when estimating the bacterial load in blood. 
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M. haemofelis can exhibit intense parasitaemia in the acute stage of infection, but bacte-
ria may be rapidly cleared from blood, leading to negative cytological findings (5, 114). 
Because of this cyclic nature of parasitaemia, absence of bacteria from examined blood 
smears does not necessarily exclude an HM infection. 
The false-positive and false-negative detection rates differed depending on whether 
Giemsa and acridine orange staining was used. Acridine orange staining is purportedly 
more sensitive than Giemsa staining (28). This study corroborated this earlier finding; 
the false-negative detection rate was lower for acridine orange stained blood smears 
(20.8 % and 60.5 %, respectively). However, the false-positive detection rate for acri-
dine orange (34.2 %) was twice as high as samples stained with Giemsa (17.4 %). One 
possible explanation is that fluorescence staining may be more apt to form artefacts and 
staining precipitates, which may be later confused with bacteria. 
Therefore, real-time PCR approaches should be used as routine diagnostic tools for HM 
detection since they are more sensitive than microscopy. 
The probability of false-positive or false-negative SYBR green I real-time PCR results 
was low since specificity and sensitivity were checked by triplicate runs of serial dilu-
tions of pCR30/7 plasmid DNA and testing of several mycoplasmal and non-mycoplas-
mal DNA (63). Due to the closed-tube system, the risk of carry-over contamination was 
low. However, it remains difficult to establish a novel diagnostic tool when a good refe-
rence method is missing. Longer storage of blood samples or DNA may have led to 
DNA degradation, and therefore, samples with a long history of storage may have ap-
peared PCR negative by mistake. This may explain why several samples from 2008 re-
acted negative in the SYBR green I real-time PCR (performed in 2009/2010) even 
though, the samples were positive in 2008, as determined by microscopy and conven-
tional PCR. DNA and blood had been stored at -20 °C, but DNA can degrade due to re-
peated freezing and thawing. Blood samples, which were sent by synlab.vet, had a long 
‘travel history’; they were shipped from the veterinarian to the lab, where they were fur-
ther processed before being sent to Zurich. Taking this into account, the calculated 
blood loads in the samples with a longer storage or shipment history may have been too 
low or possibly PCR may have reacted negative in error. 
 
In order to evaluate the clinical significance of the Winter 2009/2010 samples (no. 001-
007, 010-012, 014, 015, 020-026, 029-031, 036, 048-142; n = 156; Tab. VIII-1, pp. 165-
175), complete blood counts were prepared, and correlation of HM infection status and 
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haematological values was analysed. Blood counts of 24 horses, which were re-sampled 
one month later, and blood counts of horses without age information (n = 14) were ex-
cluded from this analysis. In 27 of 156 samples (17.3 %), for which a complete blood 
count was available, a normocytic, normochromic anaemia was observed. In twelve ca-
ses (7.7 %), a microcytic, hypochromic anaemia was found. In cattle infected with 
M. wenyonii and in sheep infected with M. ovis, both macrocytic, normochromic (172, 
251) and normocytic, normochromic anaemia (307) were reported, while in cattle infec-
ted with ‘CM haemobovis’, a hyperchromic, macrocytic anaemia was observed (315). 
However, equine HM infection was neither significantly associated with anaemia nor 
did bacterial blood loads correlate with haematological parameters (Fig. V-1, pp. 51-54; 
Fig. V-8, pp. 64-66). Absence of correlation between anaemia and HM infection was al-
so reported for ‘CM haemolamae’ (336) as well as for feline (16, 95, 361) and canine 
(236) HM, whereas M. suis infection in pigs is mostly accompanied by severe anaemia 
(normochromic, normocytic) along with strong correlation of haematocrit, haemoglo-
bin, and RBCC (136, 269). In contrast, GUIMARAES et al. found no correlation for 
M. suis (107), and MUSEUX et al. reported a correlation between RBCC, haematocrit, 
and haemoglobin with blood loads of ‘CM turicensis’ (215). 
In all PCR positive animals independent of age, only RBCC and MCHC were signifi-
cantly lowered. Also, a tendency of decreased eosinophil numbers was observed. Inte-
restingly, in infected animals younger than one year-old, parameters indicative of anae-
mia (haematocrit, haemoglobin, and RBCC) were significantly lowered, but not in older 
infected horses. In the young animals, MCV and MCH were significantly increased 
(Fig. V-1, pp. 51-54). Thus, one can hypothesise that this type of infection runs a more 
severe course in younger horses, as it does in llamas (199, 263) and sea lions (351). 
M. suis- and M. haemofelis- parasitized RBCs may be sequestrated in the spleen. This 
may lead to the removal of the organisms by reticular cells without destroying the host 
cells (193, 194, 252). Similar removal mechanisms were reported for Plasmodium falci-
parum in malaria infected patients (277). Perhaps, similar effects are present in horses, 
hindering the detection of HM on the RBC surface. 
In general, significant differences between the blood counts of horses younger than one 
year and horses older than one year were detected, independent of PCR status. Earlier 
reports showed that blood counts of young horses generally differ from older horses 
(47, 115, 341), but no distinct reference ranges for younger horses are given. Reference 
ranges can slightly vary from country to country and from race to race (especially for 
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drafting horses, thoroughbreds, and ponies (80, 115, 178, 341)). The horse’s physical 
condition may also have an impact on haematological values (80).  
 
In horses, HM infection seems to have a subclinical and asymptomatic course of di-
sease, showing only low to moderate bacterial blood loads and low morbidity. For this 
reason, HM detection in horse blood and assignment of distinct clinical signs is compli-
cated. Frequently, horses in this study only displayed unspecific clinical signs such as 
slimming, shaggy fur, apathy, and a poor performance. Therefore, bacterial loads near 
the detection limit do not seem to play an important clinical role. Similar clinical signs 
were reported for HM infection in llamas, where the infection has been called “failure to 
thrive syndrome” (263). In combination with “equine chronic fatigue syndrome”, TA-
RELLO found roundish particles on the RBC surface. The exact nature of these particles, 
however, was not analysed (318). In the review of RAZIN, also a connection of myco-
plasmas and chronic fatigue syndrome was picked up (261). 
Pathogenicity of HM species differ. M. haemofelis causes severe haemolytic anaemia in 
cats, while ‘CM haemominutum’ and ‘CM turicensis’ seem to be of lower morbidity 
(85, 359, 361). M. haemofelis may develop overt clinical signs in combination with se-
vere anaemia in acutely infected cats, but chronically infected animals may not show 
clinical signs despite high HM blood loads (361). The bovine HM species M. wenyonii 
and ‘CM haemobovis’ also differ in morbidity; HMs were detectable and blood count 
was changed without apparent or specific clinical signs in cattle (314, 315). NISHIZAWA 
et al. described low-level infections with poor PCR intensity in cattle showing no speci-
fic clinical signs (233). Even isolates of a single HM species may result in different pa-
thogenicity, as shown by the novel M. suis isolate, which is able to invade RBCs. This 
new isolate leads to a fatal course of disease in pigs (106) while the classical isolate re-
mains attached to the RBC surface. Infection with M. haemocanis is clinically inappa-
rent, especially in the absence of immunocompromising conditions like splenectomy or 
coexistent infections (164, 236). 
A subclinical course of infection may result in severe anaemia when the animal gets 
stressed or otherwise immunocompromised. Two cases of horses showing these unspe-
cific clinical signs in combination with a progressive haemolytic anaemia (haematocrit 
of 0.26 L/L, decreasing to 0.13 L/L) were reported (DR. M. DIECKMANN, pers. comm.). 
HM-like particles could be detected in Giemsa stained blood smears (DR. M. WINKLER, 
pers. comm.). Disease in these horses had a fatal outcome, but, unfortunately, these ca-
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ses happened before this study, and thus, the cases were not documented properly. More 
investigations in the field of clinical characterisation of this novel infection in horses 
must be done in future to establish a clear clinical picture and to examine the pathogenic 
potential of HM infection in horses. Presumably, affected horses’ immune defence is re-
duced, and therefore the horse is more receptive for further infections. Furthermore, the 
impact of clinical manifestations and subclinical courses on breeding and sporting 
achievement of affected horses should be examined. In sows, for example, reduced fer-
tility was reported (136). In the case of mild chronic courses of the disease, the owner 
has to count on a temporary reduction of use in sporting and breeding, and should ex-
pect retarded development in younger horses. In a more severe course of disease, even 
death may occur. 
 
In some cases, two or three samples from one horse were collected over a time spanning 
from Spring 2008 to Winter 2009 (Tab. VIII-1, pp. 165-175). Seven of these horses ex-
hibited a positive SYBR green I real-time PCR result in the samples from both years 
(Tab. V-4, pp. 69-73). Either they were infected again or they remained chronically in-
fected. Chronic infection states, in which HM were only detected periodically and in 
low numbers in the blood, were also described for feline (361, 364) and canine HM (18, 
164), M. suis in pigs (136), and ‘CM haemolamae’ in alpacas (336). In horse no. 36, a 
“failure to thrive syndrome” was reported since birth (DR. M. DIECKMANN, pers. 
comm.). She was always a little bit smaller than her contemporaries and had a low nutri-
tional condition of 3-4 of 10 (AAEP; 3 = thin, 4 = moderately thin). Accordingly, HMs 
were detected in blood smears in 2008 for the first time. HM infection was confirmed 
by SYBR green I real-time PCR in both samples from 2008 and 2009 (2.03 x 105 and 
1.05 x 103 cells/mL blood). Ill-thrift and a “failure to thrive syndrome” were already re-
ported for lambs (36, 53) and llamas (263). However, twelve horses that tested positive 
in the 2008 samples reacted negatively in the 2009 samples, and three horses that tested 
negative in the 2008 samples reacted positively in the 2009 samples. In the first case, 
the horses may have eliminated the infective agent from blood. In the second case, ei-
ther the horses became infected during the months between the first and the second 
sampling, or the first sample was false-negative due to DNA degradation resulting from 
long storage. 
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In some blood samples, agglutination was observed. Agglutination was able to be re-
solved at 37 °C and re-induced at 4 °C. This incidental finding led to the hypothesis of 
occurrence of cold-reactive auto-antibodies. Unfortunately, Coomb’s testing failed, 
since the test was not carried out immediately after sampling and RBCs started to lyse 
after some time of storage. Further studies should perform Coomb’s testing directly 
after sampling for verification of the existence of cold agglutinins. However, rouleaux 
formation of equine RBCs and auto-agglutination may be mixed up (213), interfering 
with Coomb’s testing. Thus, Coombs’ testing may not work at all, and results should be 
interpreted cautiously. Cold agglutinins in conjunction with HM infection were obser-
ved in mice (48), cats (192, 328, 380), and dogs (17, 35). In M. suis-infected pigs, cold-
reactive antibodies are a well-known phenomenon and contribute to clinical signs like 
acrocyanosis (136, 138). M. pneumoniae is capable of inducing cold agglutinins in 
humans (220). However, the pathogenic role of possible cold agglutinins in horses is 
unknown. 
 
HM blood loads can be reduced by application of tetracyclines, as shown for several 
animals (e.g. pigs (136), cats (321), and llamas (336)). Tetracycline therapy in horses 
may be problematic, since they may be allergic to tetracycline drugs. Therefore, this 
kind of therapy should be reserved for the most severe courses of disease. In most cases, 
horses recovered by themselves after three to six months, helped by a vitamin-rich diet. 
In some cases, horses exhibited selenium deficiency, so food was supplemented with se-
lenium (DR. M. DIECKMANN, pers. comm.). However, selenium concentration in serum 
was not serially analysed and a correlation of HM and selenium concentration is just 
speculation. It was shown that sheep with access to high quality food and/or trace ele-
ment supplements can lessen the severity of anaemia (36, 110, 210). 
 
Horses were analysed for risk factors for HM infection, like age, gender, or pregnancy, 
but no significant differences between PCR positive and PCR negative horses were 
found. This may be due to the small sample number, and therefore, the study should be 
repeated with a higher number of samples. For canine HM infections, housing in ken-
nels, young age, crossbreeding, and mange infections are reported risk factors (164, 
236). Increased susceptibility of kennel dogs may be due to infestations with R. sangui-
neus, “the kennel tick” (55), which is a known vector for M. haemocanis (283). Male 
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gender, old age, and feline leukaemia virus and feline immunodeficiency virus infec-
tions are risk factors for feline HM infections (16, 105, 322, 361, 362). 
Immunosuppression and stress seem to play a role in the development of clinical signs. 
In winter, when horses are coming back from grazing land, the herds are often regroup-
ed. Thus, horses may have stress due to conflicts of hierarchy and acclimatisation to a 
new environment. In this situation, the owners often report about horses which do not 
develop well, becoming meagre and apathetic. Development of overt ‘haemobartonello-
sis’ in llama is associated with stress conditions like shipping, relocation, parturition, 
and concurrent illness (199, 336). Most samples in this study were taken during this 
time period of regrouping the horses.  
 
Since the infection often occurs in autumn after grazing season, transmission of HM is 
assumed to occur by vectors like ticks or horse flies. The grazing lands in the Weser 
marsh are highly infested with ticks (Ixodes sp.; DR. RAINER OEHME, Landesgesund-
heitsamt Baden-Württemberg Ref. 93, Allgemeine Hygiene und Infektionsschutz, Stutt-
gart, Deutschland, pers. comm.). Seasonal correlation of HM infection in cats (95) and 
pigs (173) supported the assumption of transmission via blood-sucking vectors. The 
seasonal aspect is also known for further tick-borne diseases (181, 200), which is in 
accordance with seasonal differences in tick abundance (280). Transmission via blood-
sucking arthropods was shown for several HM species including ticks, lice, flies, and 
mosquitoes (22, 139, 177, 283, 284). In contrast, canine or feline HM was not detected 
in unfed ticks (Ixodes sp.) in Switzerland (363), which may offer an explanation for the 
low prevalences of canine and feline HM in Switzerland. Perhaps, relevant vector in-
sects are not indigenous in Central Europe (3) but rather in southern countries (37, 61, 
196, 267, 335). In southern regions of Europe, where R. sanguineus is indigenous (23, 
96), higher prevalences of canine HM were observed (11, 164, 165, 236, 271). Higher 
prevalences of feline HM were found in South and West Switzerland, which are known 
for higher mean annual temperatures, and where potential vectors R. sanguineus and 
D. reticulatus are indigenous (3, 23, 361). Furthermore, vector transmission was sub-
stantiated by NASH & BOBADE, who found a higher prevalence of M. haemofelis in cats 
infested with fleas (216). ROURA et al. reported that dogs infected with vector-borne in-
fections (e.g. Leishmania infantum, Ehrlichia canis, Anaplasma platys, Babesia canis) 
showed a higher prevalence of HM (271). 
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The idea of transmission of equine HM via ticks can be supported on several grounds: 
(i) horses were often infested with high numbers of ticks (DR. MICHAEL DIECKMANN, 
pers. comm.), and (ii) in the region of Weser marsh (grazing lands in summer), Ixodes 
sp. are widely distributed (280). I. ricinus as well as D. reticulatus and D. marginatus 
are known to transmit vector-borne pathogens like Babesia sp., Theileria sp., Ehrlichia 
sp., Borrelia burgdorferi, and feline HM (15, 180, 273, 280, 319, 363). Due to climate 
change (humid summers and mild winters), ticks have become more widely distributed 
in increasing numbers in northern regions (181, 200), leading to higher prevalences of 
previously rare diseases (e.g. babesiosis, anaplasmosis, ehrlichiosis) (56, 117). While 
I. ricinus is widely distributed in Germany (200), D. reticulates, D. marginatus, and 
Haemaphysalis sp. were only found sporadically (14, 15, 180). These species were pre-
viously restricted to Southern or Eastern Germany (180, 203), but are now starting to 
appear in Northern Germany (117). One has to assume that Dermacentor sp. will be on 
the rise (DR. RAINER OEHME, pers. comm.), especially in meadow- and marshlands 
(117). Ixodes sp. and Dermacentor sp. are known to feed on small and large mammalian 
animals; Ixodes sp. prefer rodents (280), and Dermacentor sp. infest mainly horses and 
dogs (117). Wild animals like deer and boar may be highly infested (117, 280). There-
fore, a systematic study of tick distribution in Northern Germany should be performed, 
and unfed ticks and ticks collected from animals should be tested for HM. The SYBR 
green I real-time PCR assay developed in this thesis work would provide a useful in-
strument for performing these studies. The prevalence of tick-borne diseases (equine ba-
besiosis, equine theileriosis) is significantly lower in Germany and Switzerland than in 
France, Spain, and Portugal (286). However, infection rates and number of ticks har-
bouring bacteria and viruses are increasing (117, 181, 200). 
In utero transmission was shown for a four day-old cria and an one day-old llama (6, 
81). Also, transplacental infection of M. haemocanis in dogs (171) and M. haemomuris 
in rodents may occur (240). Interestingly, two mares (no. 49 and 15) and their corres-
ponding offsprings (no. 67, born in 2009, and no. 85, born in 2007) were PCR positive. 
Unfortunately, no data was available on the health status of the foals before blood samp-
ling in November 2009. Thus, transplacental transmission could occur in horses as well 
and should be taken into account in future studies. 
 
Researchers assume that only a small fraction of bacteria is known thus far; especially 
uncultivable bacteria are hard to detect. Design of fluorescently labelled nucleic acid 
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probes based on comparative sequence analysis provides a powerful tool for identifica-
tion of novel, uncultivable bacterial species (8, 59, 303). Due to the integration of a sig-
nal amplification step, sensitivity of CARD-FISH (catalysed reporter deposition fluores-
cence in situ hybridisation) is ten to twenty times higher than the conventional FISH ap-
proach. CARD-FISH also allows detection of cells with low numbers of ribosomes and 
individuals against highly auto-fluorescent backgrounds (8). Since at least 103 cells/cm2 
should be present, which corresponds to approximately 105 cells/mL blood (8), detec-
tion of low-level HM infections may be difficult. However, HM detection was possible 
in one horse sample with a blood load of 7.70 x 105 cells/mL blood using an universal 
bacterial probe targeting rRNA (EUB338; Fig. V-8, p. 68). Development of a probe 
specific to the novel equine isolate would allow accurate and sensitive detection of HM 
in blood. However, this specific CARD-FISH assay remains to be established. To the 
author’s knowledge, the only report of HM detection via FISH was very recently pub-
lished for feline HM (244): M. haemofelis was detected by FISH in blood and tissues of 
a cat exhibiting high blood loads, but detection of ‘CM turicensis’ and ‘CM haemomi-
nutum’ in tissues failed – presumably because of low blood loads (244). 
 
To further characterise the novel equine HM isolate, scanning electron microscopy was 
performed (Fig. V-5, p. 59). Rarely, round particles of about 300 nm in diameter were 
found on the RBC surface, but more frequently in between RBCs. The size of this novel 
infective agent was near the 250 nm detection limit in light microscopy, giving rise to 
another possible explanation for the low sensitivity of light microscopic detection meth-
ods. The observed morphology and cell size were in accordance with those found in 
other HM species, e.g. M. haemomuris (300-750 nm (316)), M. haemofelis (500 nm (60, 
152, 367)), M. ovis (0.5-1 µm (223)), M. suis (up to 1 µm (106)), ‘CM haemolamae’ 
(400-600 nm (263)), ‘CM haemominutum’ (300 nm (86, 367)), and ‘CM turicensis’ 
(300 nm (367)). This substantiates the suspicion that the herein reported eperythrocytic 
structures indeed represent HM in equine blood. However, pleomorphic forms (e.g. 
ring- or rod-shaped cells, and cell chains) as described for other HM species (376), were 
not detected. Bacteria were often detected lying in small grooves. Appearance of inva-
ginations and indentations was also described for M. wenyonii (31), M. ovis (109), and 
M. suis (376). 
Mostly, blood was anti-coagulated by EDTA, for which a detachment effect was re-
ported (5, 265). Later, SEM samples were anti-coagulated with citrate. Unfortunately, 
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detachment effects still appeared. This may be due to long delays between sampling and 
fixation or other unknown causes in sample preparation. 
‘Haemobartonella’-like species are only rarely found free in the plasma, in contrast to 
the more freely detected ‘Eperythrozoon’-like species (220). For M. coccoides, a loose 
contact between parasite and host cell, where the parasite did not lie in an indentations 
alongside free cells in the plasma, was observed (316). M. coccoides was reported to 
have low pathogenicity; the novel equine HM species also seem to be of low pathogeni-
city. M. wenyonii – a bovine HM of low pathogenicity (172, 315) – does not induce sig-
nificant membrane alterations and forms only slight depressions (163). M. suis (106, 
376) and M. haemofelis (152), on the other hand, form deep indentations in the RBC 
membrane and cause severe disease in pigs (136) and cats (210). Thus one may postu-
late that the intensity of adherence and membrane alterations influences the pathogenici-
ty of HM. Structures resembling attachment and invagination scars (106) were detected 
on the surface of equine RBCs. Possible attachment scars were also found for feline 
RBCs infected with ‘CM turicensis’ (367) or M. haemofelis (152). These lesions may 
hypothetically result in increased osmotic RBC fragility (191, 374); increased osmotic 
RBC fragility was shown for feline HM (151, 360) and was also detected in equine 
RBCs in this study. ZACHARY & BASGALL found that membrane alterations of porcine 
RBCs retained, although M. suis cells were cleared from blood, implicating a participa-
tion of RBC-own cytoskeleton structures in irreversible RBC deformation (376). This 
hypothesis was supported by findings of our institute; M. suis binds to RBCs’ actin (78). 
In contrast, llama RBCs seem to be more resistant against membrane deformations; 
RBC deformations in HM infected llamas were not found (166, 263). Membrane defor-
mations and indentations are a common feature of other blood-borne infections, such as 
Bartonella bacilliformis in humans (19). B. bacilliformis secrets a protein that causes 
membrane deformation and aids in binding and invading the RBCs (204). Mycoplasma 
infections may actively induce eryptosis in the cases of M. hyorhinis (241) and M. suis 
(79). 
More often than single HM, microcolonies were detected on the surface of RBCs and in 
between RBCs, ‘sticking’ them together. At first glance, these structures looked like 
‘dirt’. For pigs naturally infected with M. suis, similar structures were observed (DR. 
KATRIN GROEBEL, IVB, pers. comm.). Microcolonies were also detected in M. suis in 
vitro cultures established by SABRINA SCHREINER (Ph.D. Thesis, IVB), and SEM of 
M. pneumoniae have revealed similar cauliflower-shaped microcolonies on human 
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RBCs (257). Unfortunately, due to preparation instability, it was not possible to take a 
closer look on microcolony structures in equine samples. Confirmation by immunogold 
staining methods should be done in future. Results from experimental infection studies 
are often obtained from splenectomised or otherwise immunocompromised animals, and 
data from experimentally infected animals cannot be mapped one-to-one to the naturally 
infected animals presented in this study. Experimental infection studies leave out impor-
tant interactions between the bacteria and the host immune system. Further studies on 
natural HM infections in animals have to show the implications of possible microcolo-
nies in blood of affected animals. To the best of the author’s knowledge, microcolonies 
have not yet been detected in experimentally infected animals, and these structures are 
only known from naturally infected animals. Perhaps, the ability to ‘hide’ behind fibril 
structures in microcolonies helps the bacteria to evade the host immune system. 
In order to analyse the fine structure of the novel equine HM species and to further exa-
mine possible intracellularity, transmission electron micrographs have to be prepared in 
future investigations. Intracellularity may preclude detection of HM by light microscopy 
and SEM in late stages of infection. In experimentally M. suis-infected pigs on day ele-
ven post infection, for example, bacteria were not or only rarely detected on the RBC 
surface despite the high blood loads of 1010 to 1011 cells/mL blood (106). M. suis was 
the first HM species to be found inside of RBCs. Other blood-borne pathogens that were 
previously considered to be purely epicellular were also recently found inside RBCs 
(e.g. Bartonella henselae (170)). 
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VI.2 Phylogenetic analysis of novel HM isolates 
The Mycoplasma phylogeny published in this thesis is in good agreement with pre-
viously published studies (155, 208, 219, 220, 265): The haemotrophic mycoplasmas 
clearly belong to the large group of Mollicutes, formed a separate cluster within in the 
group of mycoplasmas, and they are closest related to members of the ‘pneumoniae-
group’ (Fig. V-9, p. 77). Within the HM group, two distinct subclusters are present. 
Analysis of secondary structure of 16S rRNA substantiated these findings of two sepa-
rate clusters. Four different structural features were found (Fig. V-10 & Fig. V-11, 
pp. 78-79). The variability of certain loops was reported by WOESE (369). PETERS et al. 
introduced the designations ‘haemominutum-group’ and ‘haemofelis-group’ (243) for 
the two HM subclusters. JOHANSSON et al. (155), NEIMARK et al. (220), and MESSICK et 
al. (208) reported a characteristic truncation (E. coli numbering: 453-481), which is 
present in the ‘haemofelis-group’ but absent in the ‘haemominutum-group’ (Tab. V-5, 
pp. 74-76). The well-established species M. suis, M. wenyonii, and M. ovis (formerly 
known as Eperythrozoon sp.) belong to the ‘haemominutum-group’, while the ‘haemo-
felis-group’ comprises the long-known species M. haemofelis, M. haemocanis, and 
M. haemomuris (formerly classified as Haemobartonella sp.). The two genera Epery-
throzoon and Haemobartonella were previously separated due to morphological differ-
ences (220). Due to phylogenetic analyses presenting two distinct clusters, one may sus-
pect that this differentiation of the pre-sequencing era was justified. The only exception 
to this finding is M. coccoides, which belongs to the ‘haemofelis-group’, but was for-
merly known as E. coccoides. 
All calculated trees exhibited similar global tree topologies. However, low bootstrap va-
lues indicated unstable local branching orders. Branching order within the clusters va-
ried between neighbour joining and maximum likelihood trees. When interpreting trees, 
one must be aware that “any phylogenetic tree represents only a possible model of the 
process and results of evolution” (188), since “different treeing methods are based on 
different models of evolution” (186), and that “trees are not stable structures but dyna-
mically change in response to acquisition and inclusion of new data” (188). Neverthe-
less, assignment of the HM species to the two subclusters was in accordance in all tree-
ing methods. Within the ‘haemominutum’-group, close relationships between cervid 
HM species and M. wenyonii, as well as closest relationship between ‘CM haemozalo-
phi’ and ‘CM haemolamae’ were displayed in all treeing methods, as reflected by high 
bootstrap values. Also, ‘CM haemominutum’ and ‘CM haematoparvum’ exhibited close 
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relationships in all calculated trees. However, branching order of ‘CM erythrodidelphis’ 
and ‘CM kahanei’ varied. Within the ‘haemofelis-group’, the close relationship between 
M. haemofelis, M. haemocanis, ‘CM haemobovis’, and the novel equine HM isolate was 
confirmed in all calculated 16S rRNA trees by high bootstrap values. On the other hand, 
branching order within the subcluster comprising M. haemomuris, M. coccoides, and 
‘CM turicensis’ was unstable using different treeing methods in combination with dif-
ferent similarity filters. 
Some species are closely related, displaying only minor differences in the 16S rRNA se-
quence. M. haemofelis and M. haemocanis show 97-98 % 16S rRNA sequence identity 
but differ more in rnpB sequences (26, 243). Infection studies revealed no cross-infecti-
vity (84), and therefore, designation as separate species seems to be justified. Thus, 16S 
rRNA sequences may not be the sole appropriate tool for delineation of closely related 
HM species. Species definition is somewhat arbitrary in bacteriology, and the concept 
of genospecies was introduced to define members of one species as having “70 % or 
greater DNA-DNA-relatedness with 5 °C or less ∆TM” (8, 349, 356). This corresponds 
to an approximate 16S rRNA identity of 97-98 %. Although the elaborate and time-con-
suming DNA-DNA hybridisation technique is regarded as the “gold standard” for spe-
cies delineation (356), 16S rRNA sequence analysis is widely used for classification and 
phylogenetic purposes (302). However, in cases of closely related organisms, 16S 
rRNA’s resolution is not sufficient (88, 302). As was stated previously, 16S rRNA may 
not be the appropriate tool for phylogenetic classification of mycoplasmas, since they 
“tend to lack a higher than normal fraction of the highly conserved oligonucleotide se-
quences found in almost all 16S rRNA catalogues from normal eubacteria” (368), po-
tentially resulting in “inexact or incorrect phylogenetic placement” (368). Housekeeping 
genes like RNase P RNA subunit (rnpB), elongation factor Tu (EF-Tu), or the β-subunit 
of RNA polymerase (rpoB) may provide more appropriate molecules to differentiate 
mycoplasmas (26, 159, 168, 243), as was shown for other closely related bacteria (e.g. 
Chlamydia sp. (123), Streptococcus sp. (71, 317), Staphylococcus sp. (70), and Entero-
bacteriaceae (211)). Some Bacillus strains share more than 99 % 16S rRNA sequence 
identity but show less than 70 % DNA-DNA-hybridisation relatedness (88, 349). 
In the case of M. ovis and ‘CM haemovis’, differentiation between these two species 
based on 16S rRNA sequencing is not justified in the author’s opinion, as they both in-
fect sheep and differ only in 17 bp (Fig. V-12, Tab. V-6, p. 80). Accordingly, no distinct 
branching order of these isolates was observed. Thus, these two isolates may represent 
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strain variations of the same species. However, this has to be confirmed by further 
phylogenetic analyses. 
Phylogenetic analysis of the novel equine HM was complicated by the low bacterial 
blood loads which inhibited conventional PCR approaches. This is a well-known pheno-
menon in bloodstream infections (329). In three cases, sequencing of approx. 900 bp 
was successful (acc. no. FN421443, FN421444, FN421445). However, definite phylo-
genetic classification is hampered, when only part of the 16S rRNA gene is known 
(302, 349), especially if the more variable 5’-region is missing (186). The complete 
16S rRNA gene has a size of about 1400 bp (M. suis: 1469 bp (238), M. haemofelis: 
1429 bp (12)). Rhizobium galegae’s phylogenetic position differs based on use of partial 
or complete 16S rRNA sequences (349). For definite classification of the novel equine 
HM isolate, at least the complete 16S rRNA sequence is required. Ideally, additional 
phylogenetic marker genes should be analysed, and DNA-DNA hybridisation experi-
ments should be performed. 
Interestingly, infections of cattle herds with ‘CM haemobovis’ were reported in the 
same region (130) as the novel equine HM isolate. Since these two isolates showed mi-
nor differences in 16S rRNA sequences (97-98 % sequence identity), their relationship 
situation seems to be quite similar to that of M. haemofelis and M. haemocanis. Further 
phylogenetic and cross-infectivity analyses are necessary to determine if the novel 
equine HM isolate is in fact a separate species. Therefore, the designation ‘Candidatus 
Mycoplasma equi’ would be proposed, as the ‘Candidatus’ designation is reserved to 
describe the provisional status of new, incompletely described taxa (214, 220). Unfortu-
nately, amplification of the complete 16S rRNA gene as well as of the rnpB gene of 
equine HM isolates failed, since the low bacterial blood loads complicate conventional 
PCR approaches and cloning. Additionally, since the agent was not cultivable, it was 
not possible to extract the high amounts of bacterial DNA required for DNA-DNA hy-
bridisation experiments. 
There are, however, examples of closely related Mycoplasma species which only exhibit 
slight differences in 16S rRNA sequences; species delineation via DNA-DNA hybridi-
sation and serological data confirms their classification of different species (248). If fur-
ther analyses reveal no distinct species delineation of the novel equine HM isolate, then 
‘CM haemobovis’ can probably cross-infect cattle and horses. Mycoplasma host specifi-
city has been questioned recently (249). M. ovis, for example, can infect a broader host 
range, including sheep, goat and deer (51, 52, 220). In that case, a pathovar or subspe-
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cies designation in mycoplasmology should be considered. For historical reasons, HM 
species were named after the animal species they were isolated from, as clear phyloge-
netic analyses were not possible in the past. This convention in nomenclature may lead 
to classification of the same organisms as different species. 
‘CM turicensis’ clustered together with rodent HM species (M. haemomuris and M. coc-
coides). Thus, the corresponding HM species may have been developed in co-evolution 
with their hosts, or HM may have been transmitted from prey to predator or vice versa 
and later adapted to the new host. However, rodents probably do not play an important 
role as reservoir (363). 
VI.3 Conclusion 
In this thesis work, the first molecular proof of the existence of a HM infection in horses 
was presented, and a SYBR green I real-time PCR assay specific to the novel equine 
HM isolate was established. Furthermore, the significance of equine HM infections was 
analysed; this kind of infection seems to have a more severe course of disease in young 
animals. In the last decade, new HM species were regularly discovered. Advanced dia-
gnostic techniques, such as PCR, real-time PCR, and FISH, simplified the detection of 
uncultivable bacteria and contributed to an increasing number of new discoveries. New 
sequencing technologies facilitated their recognition and classification. The herein pub-
lished Mycoplasma phylogeny was in good accordance with previous publications. Due 
to climate change, possible vectors have opened up new methods of distribution, and 
therefore, vector-borne infections are on the rise. With the emergence of immunocom-
promising diseases, organ transplants, and cancer therapies, HM’s zoonotic potential de-
serves careful future study, as HMs were recently isolated from immunocompromised 
humans (67, 72). 
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Abstract 
Hemotrophic mycoplasmas (HM) are small, cell wall-less bacteria and infections are 
known for a wide range of animals. First indications of HM in Nigerian horses due to 
microscopy were given in 1978. However the first molecular proof of HM in horses was 
not reported until 2010, when a fragment of about 900 bp of the 16S rRNA of the 
equine HM was obtained. This sequence was used for development of a SYBR green I 
real-time PCR assay specific for equine HM. The lower detection limit of the PCR was 
10 genome equivalents per ml of blood. The newly designed assay was successfully ap-
plied for the detection and quantification of HM in horses in Germany. A high sample 
prevalence of 26.5 % (95 %CI: 18.8-35.5 %) was found (31 out of 117 horses). The 
mean bacterial load was 1.10 x 106 cells/ ml blood (range: minimum 1.05 x 103, maxi-
mum 1.27 x 107). Equine HM were also detected by microscopy (Giemsa and acridine 
orange stained blood smears), but results do not correlate very well with PCR results, as 
microscopy proved rather unspecific and not sensitive. In horses younger than one year 
a significant correlation between PCR positive status and anemia was found. No corre-
lation was found in PCR positive animals older than one year. Therefore we assume that 
HM infection has a higher clinical relevance in young animals. 
Introduction 
Hemotrophic mycoplasmas (HM) are cell wall-less specialized bacteria which are uni-
quely adapted to cause eperythrocytic or intraerythrocytic infections in their hosts resul-
ting in deformity and damage of red blood cells (RBCs) (11, 14, 24). Formerly classi-
fied as Haemobartonella and Eperythrozoon species within the order Rickettsiales, HM 
are now classified within the genus Mycoplasma based on phylogenetic analysis of the 
16S rRNA and RNase P genes (6, 22, 29-33). Infections with HM in pigs, cattle and 
cats are well-characterized and clinically marked by an overt life-threatening hemolytic 
anemia or a subtle chronic anemia, ill-thrift, infertility, lethargy, depression, weight 
loss, growth retardation in young animals and immune suppression. Thereby HM are 
host-specific and one HM species can only infect a narrow range of animal hosts or 
even only one animal host species. To date no in vitro cultivation system has been es-
tablished and diagnosis relies mainly upon microscopic evaluation of peripheral blood 
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smears and PCR techniques (14, 24). In the last years quantitative real-time PCR assays 
for the specific detection of several HM species have been established. These assays de-
monstrate an increased sensitivity of diagnostics compared to microscopic detection and 
conventional PCR techniques (16, 44, 46, 56). 
Recently we found the first molecular proof of a novel HM isolate infecting horses. 
16S rRNA of this novel equine HM isolate shows identity of 97-98 % to the bovine spe-
cies ‘Candidatus M. haemobovis’ (8). The current knowledge about HM infections in 
horses is rather restricted, in contrast to the long known HM infections in pigs (14), cat-
tle (24) and cats (54). The only aforementioned report about equine HM was published 
in 1978, in which ‘haemobartonellosis’ of horses in Nigeria was microscopically dia-
gnosed (10). 
Further studies are necessary to investigate the prevalence and significance of HM in-
fections in horses using specific and sensitive detection methods. Based on the expe-
rience with HM infecting other animal species the application of a quantitative real-time 
PCR assay would be most suitable. Using specific oligonucleotide primers in combina-
tion with a SYBR green I real-time PCR assay including a melting curve analysis would 
provide such a sensitive and specific diagnostic tool and would allow the quantification 
of the infective agent in blood of affected horses. Due to its possibility for standardiza-
tion and automation, its reproducibility and its minimal contamination risk (no amplifi-
cation carry-over), it would provide an inexpensive and reliable diagnostic technique, 
which could be used in routine diagnostics. 
Aims of this study were the determination of occurrence of HM infections in horses, 
and evaluation of its clinical importance with regard to the induction of anemia. There-
fore an equine HM specific quantitative SYBR green I real-time PCR assay for detec-
tion of equine HM in horse blood samples was developed. 
Material & Methods 
Samples 
For establishment of the SYBR green I real-time PCR assay, DNA from two HM posi-
tive horses (8) and 66 HM negative horses collected from horses presented at the Clinic 
for Horses (Vetsuisse Faculty, University of Zurich) for unrelated purposes were inclu-
ded. These 66 animals had been analyzed for the presence of HM by a HM-specific uni-
versal SYBR green I real-time PCR assay (56). 
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For screening for equine HM infections, EDTA-anti-coagulated blood samples of 117 
horses originating from one breeding farm in Northern Germany with known HM histo-
ry (8) were collected. This farm takes care of about 120 horses of different ages and 
breeds. Young horses (9 months to 2 years) were grouped according to their gender and 
age. During summer young horses are grazed in the marshlands of the river Weser. 
From October to April young horses are kept at the farm in barns with daily turn-out on 
pasture. Riding hoses and brood mares stay at the farm throughout the year. Blood sam-
ples were collected from 117 horses, thereof were: 70 mares (59.8 %; 19 of them were 
pregnant (27.1 %)), 17 geldings (14.5 %) and 30 stallions (25.6 %). Horses were of the 
age of 9 months to 26 years, mean age of horses was 4.3 years. 112 of the horses were 
warm blood breeds (95.7 %); also there were two German riding ponies (1.7 %), one 
tinker (0.9 %), one thoroughbred (0.9 %) and one pinto (0.9 %) included into the study. 
Seven horses (6.0 %) were reported with the following clinical preliminary report: poor 
nutritional condition, shaggy fur, poor performance. 
Laboratory examination of horse blood samples 
Hematological parameters, i.e. hematocrit (Ht), hemoglobin (Hb), red blood cell count 
(RBCC) and white blood cell count (WBCC), were determined (synlab.vet, Geesthacht, 
Germany) within 24 hours after sampling. Hematocrit was used as parameter of anemia 
(Ht < 0.32 l/l indicates anemia, reference range: 0.32-0.48 l/l). Giemsa and acridine 
orange stained peripheral blood smears were prepared. 
DNA preparation 
Genomic DNA was extracted from 800 µl EDTA-anti-coagulated blood by a direct lysis 
method (15). Pellets were then used to extract genomic DNA with the GenEluteTM Bac-
terial Genomic DNA Kit (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). Geno-
mic DNA was eluted in 200 µl elution buffer and stored at -20 °C until use. To monitor 
cross-contamination extraction controls consisting of PBS were performed accordingly 
within each batch of 12 samples. 
Standard DNA 
Plasmid DNA containing the partial 16S rRNA sequence of the equine HM isolate 30/7, 
(accession number FN421445, (8)) was used as standard DNA for determination of sen-
sitivity of the assay and for quantification of HM. Cloning was performed using the TO-
PO TA pCR2.1 cloning kit (Invitrogen, Basel, Switzerland), and the 30/7 plasmid DNA 
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was purified using the GenEluteTM Plasmid Miniprep Kit (Sigma-Aldrich) according to 
the manufacturer’s instructions. Purity and concentration of the plasmid were checked 
by agarose gel electrophoresis and optical density measurements (Biophotometer, Vau-
daux-Eppendorf). Plasmid size of pCR30/7 of 4.8 kb was used to calculate the concen-
trations in plasmid copies per micro liter corresponding to genome equivalents (GE) of 
the equine HM isolate. Dilutions of 106, 105, 104 GE per reaction of the purified plasmid 
DNA were included as standard controls for HM quantification in each SYBR green I 
PCR run. Quantitative interpretation of the PCR results was obtained by the LightCyc-
lerTM software (Roche Diagnostics, Rotkreuz, Switzerland). The number of bacterial 
cells in horse blood samples was calculated as follows: cells per ml blood = average GE 
(determined by LC software) x 50 (16). 
SYBR green I real-time PCR assay 
Primers were designed for amplification of a 107 bp product of a 16S rRNA region spe-
cific for the equine HM isolate (8) using the ARB probe design tool (21). Therefore 
16S rRNA sequences of hemotrophic mycoplasmas, non-hemotrophic mycoplasmas and 
non-mycoplasmal organisms were integrated into an ARB database, aligned using the 
ClustalW tool and the alignment was refined manually. Accession numbers, primer se-
quences and part of the alignment are shown in Table 1. Primer binding specificities 
were tested using pDRAW32 (www.acaclone.com; (47)) and primer sequences were 
searched for sequence homologies using the BLAST tool 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi; (2)). Primers were purchased from Eurofins 
MWG Operon (Ebersberg, Germany). 
The LightCyclerTM 2.0 System (Roche) was used in combination with the LightCycler® 
FastStart DNA MasterPLUS SYBR green I master mix kit (Roche). Each glass capillary 
contained 15 µl of master mix (10 µl water, 1 µl primer mix (0.25 µM each), 4 µl pre-
mixed master mix (5x)) and 5 µl of extracted template DNA. Cycling conditions were 
as follows: preincubation (15 min at 95 °C) and 45 cycles of amplification (10 sec 
95 °C, 5 sec 55 °C, 20 sec 72°C). A melting curve was generated using the following 
settings: heating from 65 °C to 95 °C with a ramp rate of 0.1 °C per sec. A no template 
control (water) was included in each run to check for contamination. 
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Determination of specificity and sensitivity of the new designed SYBR green I real-time 
PCR assay 
Specificity of assay was tested using DNA from equine HM isolates (8) and HM nega-
tive horse samples (n = 66). Other bacterial DNA samples used for specificity testing 
are listed in Table 2. 
The analytical lower limit of detection (LOD) of the SYBR green I PCR assay was de-
termined. Therefore pCR30/7 plasmid DNA was spectrophotometrically quantified and 
DNA concentrations were adjusted to 53 pg representing 107 GE. Ten-fold serial dilu-
tions were analyzed in triplicates. The pCR30/7 plasmid DNA was calculated as 5.3 ag 
per copy (genome weight = genomic length (bp) x 665 Da/bp x 1.67 x 10-24 g/Da (16), 
size of pCR30/7 plasmid = 4.8 kb). 
Determination of intra- and inter-assay variations 
Evaluation of the reproducibility of the crossing point (CP) values and melting tempera-
tures (TM) were performed by analysis of the coefficient of variation (CV). For testing 
the intra-assay variation three standard series of pCR30/7 plasmid DNA (107 to 101 GE) 
were tested within one run. Inter-assay variations were determined by performing three 
standard curves of pCR30/7 plasmid DNA (107 to 101 GE) on different days. 
Gel electrophoresis, DNA sequencing and sequence analysis 
To verify the size of amplicons the SYBR green I real-time PCR were completely ap-
plied on a 2 % agarose gel. PCR products were excised from the gel, purified using the 
QIAquick Gel Extraction Kit (Qiagen AG, Hombrechtikon, Switzerland), cloned (TO-
PO TA Cloning Kit, Invitrogen) according to the manufacturer’s instructions and se-
quenced (Eurofins MWG Operon). Sequences were searched for homologies using the 
BLAST tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi; (2)). 
Statistical analysis 
Data were compiled and analyzed using Excel (Microsoft, Wallisellen, Switzerland) and 
R Foundation for Statistical Computing (R version 2.11.1; Vienna, Austria). For observ-
ed prevalence 95 % confidence intervals (CI) were calculated. Categorical values (gen-
der, anemia, clinical status, pregnancy, type of housing) were analyzed by Fisher’s exact 
test and continuous variables (age, hematological parameter) by the Mann-Whitney U-
test. Correlation of hematocrit and blood loads was assessed by the spearman rank cor-
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relation coefficient (rs). Differences were considered statistically as significant, if 
P ≤ 0.05. 
Nucleotide sequence accession numbers 
The nucleotide sequences have been deposited at GenBank with accession number 
FR668084, FR998085 and FR668086. 
Results 
SYBR green I real-time PCR assay: Primer design and assay setup 
Equine HM specific primer sequences are presented in Table 1. The primer design was 
based on published 16S rRNA gene sequences of HM, selected non-HM, and selected 
other horse-associated bacteria. At least two mismatches in the forward or reverse pri-
mer sequence were found when aligned with the 16S rRNA of nearly all HM species 
and other bacteria. However, no mismatches were found with the 16S rRNA of the bo-
vine species ‘Candidatus M. haemobovis’, as it is nearly identical to the 16S rRNA of 
the equine HM. 
The assay was evaluated as positive, if two criteria were fulfilled: first, an exponential 
increase in fluorescence acquisition during the first 32 cycles of PCR (CP < 32). Sam-
ples with crossing points of 32 to 35 cycles were repeated to verify results. If the CP 
values were consistently lower than 35 cycles, the sample would be regarded as posi-
tive. Second, the melting temperature (TM) curve showed a distinct peak at 
TM = 81 ± 1°C. If the curve was not distinct and/ or a certain TM determination was not 
possible, the samples were repeated to verify results. If no amplification occurred, the 
CP values were > 35 cycles or no distinct TM curve could be obtained, the PCR reaction 
was assigned as negative. In all runs the positive controls (pCR30/7 pCR plasmid DNA) 
were positive and the no template controls (water) were negative. Only PCR runs fulfil-
ling these criteria were taken into consideration. 
Evaluation of the SYBR green I real-time PCR assay  
The SYBR green I real-time PCR assay reacted positive with DNA from equine HM 
isolated from horse blood. Also cross-reaction with ‘Candidatus M. haemobovis’ was 
observed as expected. Neither other HM, nor non-HM species, nor non-mycoplasmal 
organisms gave a positive signal (Tab. 2). Additionally, all universal HM PCR (56) ne-
gative horses (n = 66) reacted negative in the novel SYBR green I real-time PCR assay. 
Presence or absence and size of amplified DNA (107 bp) derived by the SYBR green I 
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real-time PCR assay was confirmed by agarose gel electrophoresis (Figure 1) and am-
plicon specificity of the positive control was verified by sequencing showing an overall 
identity of 100 % with the primer spanned region. Sequencing of three selected PCR 
products revealed sequences of 105-106 bp showing an identity of 99-100 % to Myco-
plasma sp. horse isolate 30/7 (Acc. no. FN421445) and 96-98 % identity to ‘Candidatus 
M. haemobovis’ (Acc. no. EF460765).  
For analysis of sensitivity ten-fold serial dilutions of pCR30/7 plasmid DNA ranging 
from 5.3 ag to 53 pg (corresponding to 100 to 107 GE) per reaction were tested in the 
SYBR green I real-time PCR assay. PCR reacted positive if at least 10 GE/ ml blood 
were present. 
Intra- and inter-assay variations were measured to determine the reproducibility of the 
SYBR green I real-time PCR assay. For the intra-assay variation the coefficients of va-
riation (CV) of CP and TM values were in the range of 0.435 to 9.151 % and 0.019 to 
0.070 %, respectively. For the inter-assay variation the CV of CP values varied from 
0.143 to 9.873 % and CV of TM values from 0.031 to 0.418 % (Table 3). 
Evaluation of significance of HM infection in horses by SYBR green I real-time PCR  
To evaluate significance of HM infection in horses, 117 blood samples of anemic and 
non-anemic horses were tested. Thirty-one horse blood samples (26.5 %; 95 %CI: 18.8-
35.5 %) revealed a positive SYBR green I real-time PCR result showing a mean cros-
sing point of CP = 32.28 ± 1.44 (range: minimum 29.43, maximum 34.69) and a mean 
melting temperature of TM = 80.88 ± 0.37 °C (range: minimum 80.16, maximum 81.78). 
Nine horses showing an anemia (Ht < 0.32; 9/23, 39.1 %), ten horses with a low level 
hematocrit (Ht = 0.32-0.34; 10/38, 26.3 %) and twelve non-anemic horses (Ht > 0.34; 
12/56, 21.4 %) exhibited positive PCR results. 
All equine blood samples that tested positive by the newly designed SYBR green I real-
time PCR assay were further analyzed for HM quantification. The overall mean bac-
terial load was 1.10 x 106 cells/ ml blood (range: minimum 1.05 x 103, maximum 
1.27 x 107). In anemic and PCR positive horses a mean bacterial load of 1.10 x 106 
cells/ ml blood (range: minimum 1.28 x 103, maximum 4.15 x 106) was observed and in 
non-anemic and PCR positive horses a mean bacterial load of 1.42 x105 cells/ ml blood 
(range: minimum 1.05 x 103, maximum 1.27 x 107) was detected. In the group of horses 
(n = 7) with the preliminary report of showing a reduced performance condition, having 
a shaggy fur and being meager, two horses showed a positive PCR signal (28.6 %; 
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95 %CI: 3.7-71.0 %) with a mean bacterial load of 4.65 x 103 cells/ ml blood (range: 
minimum 1.05 x 103, maximum 8.25 x 103). 
Hematological findings 
Ht, Hb, RBCC and WBCC were analyzed and compared to reference values (7). Twen-
ty-three of 117 horses (28.2 %) were anemic, whereas 38 more horses (32.5 %) showed 
a low level Ht within the reference range (0.32-0.34 l/l). Mean Ht was 0.34 l/l (range: 
minimum 0.26, maximum 0.52). Mainly young horses (< 1 year) were affected from 
low Ht values (n = 30, mean Ht = 0.31 l/l, range: minimum 0.26, maximum 0.35). They 
mostly showed a low level Hb concentration (n = 30; mean Hb = 115.3 g/l; range: mini-
mum 94, maximum 129; reference range: 100-180 g/l) and a low level RBCC (n = 30; 
mean RBCC = 9.1 x 1012 cells/l; range: minimum 7.09 x 1012, maximum 10.64 x 1012; 
reference range: 6.0-12.0 x 1012 cells/l), too. Mean Hb of all animals (n = 117) was 
128 g/l (range: minimum 94, maximum 212) and mean RBCC was 8.80 x 1012 cells/l 
(range: minimum 6.54 x109, maximum 13.38 x 109). Some horses exhibited a leucocy-
tosis (n = 16, 13.7 %; mean WBCC = 13.1 x 109 cells/l; reference range: 6.0-12.0 x 109 
cells/l). The overall (n = 117) mean WBCC was 9.6 x 109 cells/l (range: minimum 
3.6 x 109, maximum 14.3 x 109). 
No evidence for infections with other anemia-associated agents, e.g. Theileria equi or 
Babesia caballi, was found in Giemsa stained blood smears. Infections with equine ane-
mia virus could be excluded, too, due to clinical and laboratory findings. 
Characteristics of HM PCR positive horses 
Looking at the complete population investigated, PCR positive horses had significantly 
lower RBCC than PCR negative horses (P = 0.001; Figure 3, Table 4). In addition, Ht 
and Hb tended to be lower in PCR positive horses compared with PCR negative animals 
(Figure 3, Table 4). No significant difference was found in WBCC. However, in horses 
< 1 year, Ht, Hb, and RBCC were significantly lower in PCR positive compared with 
PCR negative horses (P = 0.023, P = 0.021, P = 0.013, respectively; Figure 3, Table 4). 
In contrast, in PCR positive animals > 1 year all measured blood parameters were not 
significantly different compared with PCR negative horses. PCR positive horses 
< 1 year showed significantly lower Ht and Hb values than PCR positive horses 
> 1 year (P < 0.0001) and a significantly higher WBCC (P = 0.04), but no significantly 
changed RBCC (Figure 4). No significant correlations between bacterial blood loads 
and blood parameters could be found (assessed by the spearman rank correlation coeffi-
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cient rs, Table 4). PCR positive status of the overall population independent from age 
was not significantly associated with anemia. However, in horses < 1 year anemia was 
associated with infection. In general, PCR positive and PCR negative horses showed no 
significant differences in age, gender, pregnancy and clinical status.  
Comparison of SYBR green I real-time PCR results to microscopic detection methods 
Results of SYBR green I real-time PCR assay were compared to results of microscopy 
of Giemsa and acridine orange stained peripheral blood smears (Figure 2). Forty-six of 
117 samples (39.3 %) revealed HM in peripheral blood smears stained with either 
Giemsa or acridine orange. In 17 Giemsa (14.5 %) and in 44 acridine orange (37.6 %) 
stained horse blood smears HM were detected as coccoid structures of approx. 0.3-
0.4 µm in size closely attached to the surface of RBCs. In fifteen samples (12.8 %) HM 
could be detected in both staining techniques and 71 samples (60.7 %) were negative in 
both staining techniques. 
Twenty-five of 46 samples microscopically diagnosed as HM positive (either Giemsa or 
acridine orange stained) were confirmed as positive by PCR (54.3 %). In 71 microsco-
pically HM-negative samples, six reacted positive in PCR (8.5 %). This corresponds to 
a rate of false-positive microscopic results of 23.3 % and false-negative microscopic 
results of 19.4 %.  
Discussion 
Although first evidence of equine HM infections have been described a long time ago 
by microscopy (10) our knowledge of HM in horses is rather limited. Recently the mo-
lecular confirmation of HM in horses was published for the first time (8). 
In this study we describe the development of the first SYBR green I real-time PCR as-
say for the sensitive and specific detection of HM in the blood of horses and the appli-
cation of the assay for the detection of HM in a horse population in Germany and analy-
sis of its clinical importance. Formerly the diagnosis of HM infections was based on the 
microscopic detection in chemically stained blood smears – a method which is not spe-
cific and sensitive enough to detect animals with low bacterial blood loads (4, 37, 48). 
For other HM species, e.g. M. haemofelis, M. suis, M. haemocanis and ‘Candidatus 
M. turicensis’, the establishment of specific and sensitive real-time PCR methods has 
delivered valuable insights into the significance of HM infections in cats, dogs and pigs 
(3, 16, 44, 53). Accordingly the reliable quantitative detection of HM infections in hor-
ses is the crucial step for the evaluation of the actual significance of equine HM. Our 
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newly developed SYBR green I real-time PCR assay demonstrated a sensitivity of 
10 GE/ ml blood. The analytical specificity of the SYBR green I real-time PCR was 
confirmed by testing DNA from different bacteria (mycoplasmas and other bacteria 
with clinical relatedness). As predicted in silico only cross reactivity was found with the 
‘Candidatus M. haemobovis’ DNA. 
Comparison of the PCR and microscopic results revealed a poor correlation. To some 
extent microscopically positive tested animals reacted negative in PCR and vice versa. 
False-negative microscopic detection may result from low bacterial loads or inapparent 
infections with bacteria being absent from blood, whereas false-positive microscopic re-
sults are because of confusion of HM with Howell-Jolly or Heinz bodies, background 
debris and staining artifacts (19, 22, 42). It was reported earlier that blood loads of 
4.4 x 106 ‘Candidatus M. turicensis’ copies/ ml blood correspond to only one bacterium 
per 103 to 104 RBCs (26). Bacterial blood loads of affected horses in this study were in 
the same range hindering the unambiguous identification of HM on the surface of RBCs 
by microscopy. Using the newly designed SYBR green I real-time PCR assay an unam-
biguous and sensitive detection of HM in blood of affected horses was possible. The 
possibility of false-positive or false-negative SYBR green I real-time PCR results is 
negligible due to its high specificity and sensitivity. However, it remains difficult to 
establish a novel diagnostics tool, when a good reference method is missing. 
The HM prevalence in the horse population investigated in this study was 26.5 % (95 % 
CI: 18.8-35.5 %). Analogically high HM prevalences of 22.3 % and 18.6 %, respective-
ly, were found in cattle without apparent clinical signs in Japan (‘Candidatus M. hae-
mobovis’, (43)) and in alpacas in Switzerland (18). In comparison, prevalences of feline 
(0.5 to 8.5 %) (52) and canine HM in Switzerland (1.2 %) (51) are considerably lower. 
Since our study includes horses of only one farm the general prevalence and pathogenic 
potential of equine HM cannot be assessed on the basis of the present data. Further stu-
dies are necessary to determine the actual prevalence and to analyze, whether the found 
HM infections may be a regional phenomenon or a single-herd, sporadic event. 
Younger horses seem to be more affected by an equine HM infection. Though red blood 
cell count (RBCC) was significantly lowered in all PCR positive animals, hematocrit 
(Ht) and hemoglobin (Hb) were also significantly lowered in infected animals < 1 year, 
but not in infected horses > 1 year (Figure 3 and Figure 4). Therefore, this found corre-
lation in horses < 1 year should be investigated in future, if an equine HM infection has 
a more severe course of disease in young horses, as it was described for HM infection in 
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llamas (23, 35) and sea lions (49). Overall looking at the entire population independent 
of age, equine HM infection was not associated with anemia and blood loads do not cor-
relate with Ht values. Absence of correlation of anemia and HM infection was also re-
ported for feline HM (52), whereas M. suis infection in pigs is often accompanied by se-
vere anemia and strong correlation of Ht, Hb and RBCC (14,37).  
In horses, HM infection most often seems to have a subclinical or asymptomatic course 
of disease showing only low bacterial loads in blood. For this reason detection of HM in 
horse blood as well as assignment of a distinct clinical manifestation is complicated. 
Mostly, horses only show unspecific clinical signs like slimming, shaggy fur, apathy 
and a bad general performance.  
HM were detected by SYBR green I real-time PCR in healthy horses without any clini-
cal signs and without showing abnormalities in the blood count. A similar situation was 
reported for ‘Candidatus M. haemolamae’ and M. haemocanis. Disease and anemia 
seem to be developed only by stressed, immunocompromised or co-infected animals 
(19, 24, 48). For M. wenyonii it was described that clinical signs were more present in 
combination with concurrent infections with Anaplasma marginale (17). An undulating 
course of infection alternating between pronounced clinical signs and an asymptomatic 
stage was described for feline HM and M. suis (14, 54). Therefore it can be assumed 
that bacterial loads near the detection limit do not play an important clinical role. Never-
theless the balance of bacteria and host immune system may be disturbed by stress or 
concurrent infections and an asymptomatic infection may turn into a clinical manifesta-
tion of disease with more or less pronounced clinical signs. 
Interestingly, infections of cattle herds with a rather similar HM species (‘Candidatus 
M. haemobovis’) were reported in the same region (13). Both, equine and bovine HM 
isolate, exhibits high 16S rRNA sequence identity (97-98 %). According to the cut-off 
values (9) this sequence difference may be not enough for designation of a novel spe-
cies. Therefore it could be speculated that the equine HM isolate and ‘Candidatus 
M. haemobovis’ could be one species cross-infecting cattle and horses. Host specificity 
of mycoplasmas was recently questioned (34). In respect of historical reasons HM spe-
cies were named after the animal species they were isolated from. A similar situation as 
in horse and cattle is given with M. haemofelis (cat) and M. haemocanis (dog), which 
shows a 16S rRNA sequence identity of 99.3-99.7 %, but only 94.3-95.5 % sequence 
identity of the RNase P (rnpB) gene (33, 41). Further phylogenetic analyses (e.g. se-
quencing of the rnpB gene) and cross-infectivity studies are necessary to evaluate, if the 
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novel equine HM isolate is an own species with the proposed designation ‘Candidatus 
Mycoplasma equi’. Unfortunately amplification and sequencing of the full length 
16S rRNA and the rnpB gene failed during this study as well as in our previous study 
(8). 
In conclusion we confirmed HM infections in Northern Germany using our newly de-
signed SYBR green I real-time PCR assay. The clinical significance of equine HM in-
fections still remains difficult to interpret and only in horses younger than one year 
equine HM infection was associated with anemia. More investigations in the field of cli-
nical characterization of this novel infection in horses have to be done in future to esta-
blish a clear clinical picture and to examine the pathogenic potential of HM infection in 
horses. The herein developed SYBR green I real-time PCR assay provides an important 
prerequisite for doing so. 
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 Tables 
Table 1 Alignment of primer sequences with target and non target species 16S rRNA sequences of closely related organisms. 
Species Forward primer 5‘-3‘ Reverse primer 5‘-3‘ Acc. No. Reference 
Primer sequence CAGGCGGATGTGTAAGTTC CGCCTCCGGTGTTCTTAAAC   
Novel equine HM isolate 30/7 ------------------- -------------------- FN421445 (8) 
‘Candidatus Mycoplasma haemobovis’ ------------------- -------------------- EU367965 (42) 
Mycoplasma haemofelis ------------------- ------T-----------G- AY150984 (45) 
‘Candidatus Mycoplasma haemominutum’ T-------CAAA–TGA-CT A-----T-------C–C--T DQ157149 (52) 
‘Candidatus Mycoplasma turicensis’ ----------AA------- ------T------------T DQ825450 (55) 
Mycoplasma haemomuris ---------TG-------- ------T---------G--T U82963 (36) 
Mycoplasma coccoides ----------AAC------ ------T------------T AY171918 (32) 
Mycoplasma suis T----T–-A----GTA-C- A-----T-------C–C--T U88565 (36) 
Mycoplasma wenyonii T------GGAG--TGA-C- A-----T-------C–C--T AF016546 (31) 
Mycoplasma ovis T------GGAG-CTGA-C- A-----T-------C–C--T AF338268 (28) 
‘Candidatus Mycoplasma haematoparvum’ T-------CAA--TGA-GT A-----T-------C-CCA- AY532390 (20) 
‘Candidatus Mycoplasma haemodidelphis’ T-------CAGTCTGA-C- -----TT-------C–C--T AF178676 (25) 
‘Candidatus Mycoplasma kahanei’ T-------GAGT–TGA-CT A-----T-------C–C--T AF338269 (27) 
‘Candidatus Mycoplasma haemolamae’ T---T---G–A--TGA-C- A-----T-------C–C--T AF306346 (25) 
Mycoplasma pneumoniae ---------TGAA----CT ----A-T-------C–TC-T NC_000912 (12) 
Mycoplasma arginini T----T–T-TAT-----CT -----TT---------CC-T M24579 (50) 
Mycoplasma penetrans ---------T-AC----CT ------T---------CC-T NC_004432 (39) 
Escherichia coli -------T-TGT-----CA ----A-----A---C–CC-G U18997 d.s. 
Bacillus cereus ----T--T-TCT-----CT ----A-T-------C-CC-T AY138272 (38) 
Bacillus subtilis -------T-TCT-----CT ----A-T-------C-CC-T AB042061 d.s. 
Salmonella enterica -------T-TGT-----CA ----A-----A---C–CC-G U92197 d.s. 
Bartonella quintana T--------ATT-----CA ----A-T-------C-CCGA BX897700 (1) 
Streptococcus equi -------T-TGA-----CT ----A---------C–CC-T DQ303186 (5) 
Clostridium perfringens T---------AT-----GG ----A-T---------CCTA AB045286 (40) 
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 Table 2 Bacterial strains used for evaluation of specificity of the newly designed SYBR green I real-time PCR assay 
Species Origin Result 
Hemotrophic mycoplasmas   
Horse isolate No. 30/7 Field straina Positive 
Horse isolates Field samples, n = 117 31 positive 
Horse blood controls Field samplesb, n = 66 Negative 
‘Candidatus Mycoplasma haemobovis’ Field strainsc, n = 6 Positive 
Mycoplasma haemofelis d Negative 
Mycoplasma haemominutum d Negative 
‘Candidatus Mycoplasma turicensis’ d Negative 
Mycoplasma wenyonii Field strainsc, n = 4  Negative 
Mycoplasma suis Strain 3808e Negative 
Mycoplasma suis Strain 3806e Negative 
Mycoplasma suis Strain 146e Negative 
‘Candidatus Mycoplasma haemolamae’ Field strainsf, n = 5 Negative 
   
Non-hemotrophic mycoplasmas 
  
Mycoplasma arginini g Negative 
Mycoplasma penetrans g Negative 
Mycoplasma pneumoniae Sebastian Schmidlh Negative 
   
Non-mycoplasma organisms 
  
Bacillus cereus isolated from horseg Negative 
Bartonella bacilliformis Christoph Dehioi Negative 
Bartonella henselae Christoph Dehioi Negative 
Bartonella quintana ‘Fuller’ Christoph Dehioi Negative 
Bartonella quintana ‘Toulouse’ Christoph Dehioi Negative 
Bartonella tribocorum Christoph Dehioi Negative 
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 Clostridium perfringens Type A isolated from horseg Negative 
Escherichia coli isolated from horseg Negative 
Salmonella sp. isolated from horseg Negative 
Streptococcus equi isolated from horseg Negative 
a
 Field strain isolated from an anemic horse (8), used as positive control for the SYBR green I real-time PCR assay (see material and methods); b DNA of horse blood samples 
collected from horses presented at the Clinic for Horses, Equine Department, Vetsuisse Faculty, University of Zurich, for unrelated purposes; negative for any HM infection 
(SYBR green I real-time PCR assay covering any HM species (56)); c Field strains isolated from anemic cattle (13); d DNA of three feline HM isolates from anemic cats (53, 55, 
57); e Blood from splenectomized pigs experimentally infected with M. suis (Institute of Veterinary Bacteriology, University of Zurich); f Field strains isolated from anemic alpa-
cas (Hoelzle et al., manuscript in preparation); g Strain collection of Institute of Veterinary Bacteriology; h provided by Sebastian Schmidl (Department of General Microbiology, 
Georg-August-University of Göttingen); i DNA provided by Christoph Dehio (Infection Biology, Biozentrum, University of Basel) 
Table 3 Inter-assay and intra-assay reproducibility of the newly designed SYBR green I real-time PCR assay 
 Inter-assay variation Intra-assay variation 
Copy numbera Mean CP (± SD)b CV (%)c Mean TM (± SD)b CV (%) Mean CP (± SD)b CV (%) Mean TM (± SD)b CV (%) 
107 GEd 22.46 ± 0.032 0.143 81.19 ± 0.092 0.126 22.34 ± 0.097 0.435 81.32 ± 0.031 0.038 
106 GE 26.32 ± 0.233 0.885 81.17 ± 0.076 0.093 26.21 ± 0.010 0.038 81.26 ± 0.030 0.037 
105 GE 28.89 ± 0.586 2.029 81.19± 0.025 0.031 29.10 ± 0.127 0.435 81.18 ± 0.025 0.031 
104 GE 26.57 ± 0.385 1.449 81.17 ± 0.040 0.050 26.36 ± 0.537 2.036 81.20 ± 0.015 0.019 
103 GE 32.78 ± 2.874 8.766 81.26 ± 0.096 0.119 34.28 ± 0.212 0.619 81.30 ± 0.057 0.070 
102 GE 28.24 ± 2.517 8.914 81.20 ± 0.121 0.150 28.02 ± 2.564 9.151 81.38 ± 0.038 0.047 
101 GE 31.37 ± 3.097e 9.873 81.22 ± 0.339e 0.418 33.56f n.d.g 81.46f n.d. 
a
 Copy number were calculated from spectrophotometrically quantified DNA as described in the material and methods section; b Mean crossing point (CP), mean melting tempe-
rature (TM) and standard deviations (SD) were calculated from triplicates of each concentration; c coefficient of variation; d genome equivalents; e only 2/3 reactions were posi-
tive; f only 1/3 reactions were positive; g not determined 
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 Table 4 Hematological values of PCR positive and PCR negative horses 
Variable PCR negative (n = 86) PCR positive (n = 31)   
 Median 95 % CIa Median 95 % CI Reference rangeb P 
Htc 0.35 0.32-0.37 0.34 0.31-0.36 0.32-0.48 l/l 0.133 
Hbd 129.50 120.25-137.75 124.00 115.50-132.50 100-180 g/l 0.069 
RBCCe 8.89 8.39-9.52 8.42 7.92-8.97 6.0-12.0 x 1012 cells/l 0.001* 
WBCCf 9.80 7.93-11.18 9.20 7.45-11.10 6.0-12.0 x 109 cells/l 0.700 
     
 PCR negative, > 1 year (n = 64) PCR positive, > 1 year (n = 23)   
 Median 95 % CI Median 95 % CI Reference range P 
Ht 0.36 0.34-0.38 0.35 0.34-0.37 0.32-0.48 l/l 0.196 
Hb 133.00 126.00-140.00 129.00 124.00-135.50 100-180 g/l 0.105 
RBCC 8.81 8.29-9.25 8.42 7.95-8.94 6.0-12.0 x 1012 cells/l 0.094 
WBCC 9.30 7.58-10.93 8.30 7.35-10.75 6.0-12.0 x 109 cells/l 0.652 
 
    
 PCR negative, < 1 year (n = 22) PCR positive, < 1 year (n = 8)   
 Median 95 % CI Median 95 % CI Reference range P 
Ht 0.31 0.30-0.33 0.30 0.29-0.31 0.32-0.48 l/l 0.023* 
Hb 118.50 111.25-123.00 110.50 106.75-113.75 100-180 g/l 0.021* 
RBCC 9.41 8.82-9.86 8.43 7.84-9.06 6.0-12.0 x 1012 cells/l 0.013* 
WBCC 10.75 9.80-11.65 11.25 8.80-11.68 6.0-12.0 x 109 cells/l 0.593 
Results of hematological analysis are shown for all horses and for horses grouped according to their age (> 1 year; < 1 year); a confidence interval; b Reference range according to 
(7);c hematocrit; d hemoglobin; e red blood cell count, f white blood cell count; * significant if p ≤ 0.05 
 
V
III
.
 A
PPEN
D
IX
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 161
 
VIII. APPENDIX 162 
Figures 
 
Figure 1 SYBR green I real-time PCR assay of 10 samples applied on an 2% agarose gel. An amplicon of 
the corresponding size of 107 bp was obtained in PCR positive horses (lane 3 = no. 90; 4 = no. 103; 
5 = no. 108; 6 = no. 111; 7 = no. 114; 9 = no. 126; 10 = no. 127) and amplification was absent in no tem-
plate control (lane no. 1) and PCR negative horses (lane 2 = no.86; lane 8 = no. 117). 100 bp ladder (lane 
11; New England Biolabs, Bioconcept, Allschwil, Switzerland) was used for accession of amplicon sizes. 
 
 
Figure 2 Micrographs of Giemsa (A) and acridine orange (B) stained peripheral blood smears (magnifi-
cation 1000x) of a horse infected with hemotrophic mycoplasmas. Roundish particles of approx. 0.3-
0.4 µm in size are detected on the surface of red blood cells in both staining techniques. In Giemsa stain-
ed blood smear it can be seen, that some hemotrophic mycoplasmas are laying in small grooves on the 
surface of the erythrocytes. 
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Figure 3 Blood parame-
ters ((A) hemoglobin, (B) 
hematocrit, (C) red blood 
cell count, (D) white 
blood cell count) of PCR 
positive (PCR pos) and 
PCR negative (PCR neg) 
horses are presented as 
box plots. Results are 
shown for all horses and 
for horses grouped accor-
ding to their age (< 1 
year, > 1 year). Boxes ex-
tend from the 25th to the 
75th percentile, median is 
presented as horizontal 
line and the bars extend 
to the minimum and ma-
ximum value. Dots repre-
sent outliers. Values from 
PCR positive and PCR 
negative horses were ana-
lyzed for significant dif-
ferences using the Mann-
Whitney U-test. P-values 
are listed in Table 4. 
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Figure 4 Comparison of corre-
lation between blood parame-
ters ((A) hemoglobin, (B) he-
matocrit, (C) red blood cell 
count, (D) white blood cell 
count) and bacterial load in 
PCR positive horses > 1 year 
(n = 23) and PCR positive hor-
ses < 1 year (n = 8)). Grey bo-
xes indicate the corresponding 
reference ranges according to 
Cowell &Tyler (7). Differen-
ces are significant, if P ≤ 0.05. 
 VIII.2 Detailed presentation of samples 
Table VIII-1 Detailed presentation of blood samples collected during this study 
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n/a 18.02.08 MD AL + - - - HM+, 15.01.08 001 Dacana 2003 M 
yes 
H 
16.11.09 MD EDTA + + - +  
n/a 18.02.08 MD EDTA + - - -  002 Shirley 1997 M 
no 
H 
16.11.09 MD EDTA + + - +  
n/a 18.02.08 MD EDTA - - - -  
no 16.11.09 MD EDTA + + - +  003 Bretagne 1992 M 
no 
H 
09.12.09 MD Citrate - + + +  
n/a 18.02.08 MD EDTA + - - -  004 Weltfee 1999 M 
yes 
H 
16.11.09 MD EDTA + + - +  
n/a 18.02.08 MD EDTA + - - -  005 Emelie 2002 M 
yes 
H 
16.11.09 MD EDTA + + - +  
n/a 18.02.08 MD EDTA + - - -  006 Leca 2002 M 
yes 
H 
16.11.09 MD EDTA + + - +  
n/a 18.02.08 MD EDTA + - - -  007 Royal Star 2003 M 
yes 
H 
16.11.09 MD EDTA + + - +  
008 Pussy Cat 1987 M n/a H 18.02.08 MD EDTA + - - -  
009 Lawenna 1989 M n/a H 18.02.08 MD EDTA + - - -  
n/a 18.02.08 MD AL + - - - HM+, 14.11.07 
010 Dipsy 2004 M 
no 
H 16.11.09 MD EDTA + + - +  
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 Table VIII-1 continued 
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n/a 18.02.08 MD EDTA + - - - HM+, 15.01.08 011 Kaja 2002 M 
no 
T 
16.11.09 MD EDTA + + - +  
18.02.08 MD EDTA + - - -  012 Darcy 2003 G / H 
16.11.09 MD EDTA + + - + NC 4, lazy, shaggy 
18.02.08 MD EDTA + - - -  013 Dante 2005 G / H 
15.05.08 MD EDTA + - + -  
n/a 18.02.08 MD EDTA + - - -  
n/a 15.05.08 MD EDTA + - +   014 Kassiopeia 1992 M 
no 
T 
16.11.09 MD EDTA + + - +  
n/a 18.02.08 MD EDTA + - - -  
17.11.09 MD EDTA + + - +  015 Wolkenfee 1998 M 
no 
H 
09.12.09 MD Citrate - + + +  
no 18.02.08 MD EDTA + - - - HM+, 09.02.08 016 Pagina 1987 M 
no 
T 
15.05.08 MD EDTA + - + -  
19.02.08 MD EDTA + - - - HM+, 18.02.08 
15.05.08 MD EDTA + - + -  017 Lucky 1998 G / H 
25.07.08 MD EDTA + - + -  
018 Don Giovanni 2005 S / O 20.02.08 MD EDTA + - - -  
019 Don Fidelio 2005 S / H 20.02.08 MD EDTA + - - -  
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 Table VIII-1 continued 
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S / 20.02.08 MD EDTA + - - -  
18.11.09 MD EDTA + + - +  020 Escot 2006 G / 
H 
09.12.09 MD Citrate - + + +  
n/a 20.02.08 MD EDTA - - - -  021 Lilli 2004 M 
yes 
H 
16.11.09 MD EDTA + + - +  
n/a 20.02.08 MD EDTA + - - -  
n/a 15.05.08 MD EDTA + - +   022 Dondra 2005 M 
yes 
H 
16.11.09 MD EDTA + + - +  
n/a 20.02.08 MD EDTA + - - -  023 Dorit 2006 M 
yes 
H 
17.11.09 MD EDTA + + - +  
20.02.08 MD EDTA + - - -  
15.05.08 MD EDTA + - +   024 Tristan 1998 G / F 
18.11.09 MD EDTA + + - +  
n/a 20.02.08 MD EDTA + - - -  025 Caray 1995 M 
no 
H 
16.11.09 MD EDTA + + - +  
n/a 20.02.08 MD EDTA + - - -  026 Rubina 2000 M 
no 
H 
18.11.09 MD EDTA + + - +  
027 Watzlaff 1988 G / H 20.02.08 MD EDTA + - - -  
20.02.08 MD EDTA + - - -  
028 Kensington 2004 G / H 15.05.08 MD EDTA + - +   
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 Table VIII-1 continued 
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n/a 20.02.08 MD EDTA + - - -  
n/a 15.05.08 MD EDTA + - + -  029 Freia 1987 M 
yes 
H 
18.11.09 MD EDTA + + - +  
n/a 20.02.08 MD EDTA + - - -  
n/a 25.07.08 MD EDTA + - + +  030 Robina 1990 M 
yes 
H 
18.11.09 MD EDTA + + - +  
n/a 20.02.08 MD EDTA + - - -  031 Exotic Lady 1989 M 
yes 
O 
17.11.09 MD EDTA + + - +  
 n/a 20.02.08 MD EDTA + - - -  032 Lady Graciana 1997 M 
n/a 
H 
15.05.08 MD EDTA + - + -  
033 Gybsy 1993 M n/a n/a 20.02.08 MD EDTA - - - - HM+*, 21.01.08 
034 Lady 1988 M n/a n/a 20.02.08 MD EDTA - - - - HM+*, 29.11.07 
no 20.10.08 MD EDTA + - + - suspected HM infection 036 Peggy 2007 M 
no 
H 
17.11.09 MD EDTA + + - + NC 3, poor development 
042 DeeDee Dakota n/a M n/a T 20.11.08 MD EDTA - - + - suspected HM infection 
043 Grace n/a n/a n/a n/a 08.12.08 MD EDTA + - + - suspected HM infection 
044 n/a n/a n/a n/a n/a 08.12.08 MD EDTA - - + - suspected HM infection 
045 Quite Vanitas n/a n/a n/a n/a n/a MD EDTA + - + - suspected HM infection 
046 Reagan n/a n/a n/a n/a n/a MD - + - - - suspected HM infection 
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 Table VIII-1 continued 
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047 n/a n/a n/a n/a n/a n/a MD EDTA + - + - suspected HM infection 
048 Romina S 1997 M yes H 16.11.09 MD EDTA + + - +  
16.11.09 MD EDTA + + - +  049 Gesche 1996 M yes D 
09.12.09 MD Citrate - + + +  
050 Acordia 1995 M yes O 16.11.09 MD EDTA + + - +  
051 Belle de Jour 2005 M no H 16.11.09 MD EDTA + + - + shaggy, NC 3-4 
052 Piccoline 2001 M yes W 16.11.09 MD EDTA + + - +  
053 Friemo 2001 G / H 16.11.09 MD EDTA + + - + lazy, nerveless 
054 Luise 2004 M yes H 16.11.09 MD EDTA + + - +  
055 Dali 2009 S / H 17.11.09 MD EDTA + + - +  
056 Findus 2009 S / H 17.11.09 MD EDTA + + - +  
17.11.09 MD EDTA + + - +  057 Quebec 2009 S / H 
09.12.09 MD Citrate - + + +  
058 Sam 2009 S / H 17.11.09 MD EDTA + + - +  
17.11.09 MD EDTA + + - +  059 Lorenz 2009 S / H 
09.12.09 MD Citrate - + + +  
17.11.09 MD EDTA + + - +  060 Fabian 2009 S / H 
09.12.09 MD Citrate - + + +  
061 Seppi 2009 S / H 17.11.09 MD EDTA + + - +  
17.11.09 MD EDTA + + - +  
062 Benetton B 2009 S / H 09.12.09 MD Citrate - + + +  
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 Table VIII-1 continued 
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17.11.09 MD EDTA + + - +  063 Franz-Josef 2009 S / H 
09.12.09 MD Citrate - + + +  
17.11.09 MD EDTA + + - + 064 So What 2009 S / H 
09.12.09 MD Citrate - + + + 
AB, infected with Rh. equi 
065 Catnap 2009 S / H 17.11.09 MD EDTA + + - +  
066 Sandman 2009 S / H 17.11.09 MD EDTA + + - +  
17.11.09 MD EDTA + + - +  067 Montano 2009 S / D 
09.12.09 MD Citrate - + + +  
068 Schneider 2009 S / O 17.11.09 MD EDTA + + - +  
17.11.09 MD EDTA + + - +  069 Rocky 2009 S / H 
09.12.09 MD Citrate - + + +  
17.11.09 MD EDTA + + - +  070 Cosimo 2009 S / H 
09.12.09 MD Citrate - + + +  
17.11.09 MD EDTA + + - +  071 Squirl 2009 S / H 
09.12.09 MD Citrate - + + +  
17.11.09 MD EDTA + + - +  072 Quiddith 2009 S / BW 
09.12.09 MD Citrate - + + +  
073 Dolly 1995 M no TH 17.11.09 MD EDTA + + - +  
075 Churchill 1996 G / B 17.11.09 MD EDTA + + - +  
076 Karamé 1995 M no T 17.11.09 MD EDTA + + - +  
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 Table VIII-1 continued 
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077 Kara 2006 M yes T 17.11.09 MD EDTA + + - +  
078 Absolutely 2003 M yes H 17.11.09 MD EDTA + + - +  
079 Conny 2006 M no H 17.11.09 MD EDTA + + - +  
080 Tabora 2006 M yes T 17.11.09 MD EDTA + + - + NC recovered 
081 Sia 2006 M no H 17.11.09 MD EDTA + + - +  
082 Donella 2007 M no H 17.11.09 MD EDTA + + - +  
083 Vitesse 2008 M no H 17.11.09 MD EDTA + + - + NC recovered 
084 Sahara 2007 M no H 17.11.09 MD EDTA + + - +  
17.11.09 MD EDTA + + - +  085 Delight 2007 M no H 
09.12.09 MD Citrate - + + +  
086 Argentina 2003 M no H 17.11.09 MD EDTA + + - +  
087 Contina 2007 M no H 17.11.09 MD EDTA + + - +  
088 Pintia 2007 M no H 17.11.09 MD EDTA + + - +  
089 Clara 2007 M no H 17.11.09 MD EDTA + + - +  
17.11.09 MD EDTA + + - +  090 Coralie 2006 M no HO 
09.12.09 MD Citrate - + + +  
091 Bretagna 1995 M no H 17.11.09 MD EDTA + + - +  
092 Gweenie 2006 M no H 17.11.09 MD EDTA + + - +  
093 Cheyenne  M no PI 17.11.09 MD EDTA + + - +  
094 Lennert 2007 G / H 18.11.09 MD EDTA + + - +  
095 Robby 2007 G / H 18.11.09 MD EDTA + + - +  
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 Table VIII-1 continued 
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096 Paul 2007 G / H 18.11.09 MD EDTA + + - +  
097 Spock 2007 G / H 18.11.09 MD EDTA + + - +  
18.11.09 MD EDTA + + - +  098 Robert 2007 G / H 
09.12.09 MD Citrate - + + +  
099 Winnetou 1998 G / TI 18.11.09 MD EDTA + + - +  
100 Sita 2008 M no H 18.11.09 MD EDTA + + - +  
101 Valerie 2008 M no H 18.11.09 MD EDTA + + - +  
102 Dira 2007 M no H 18.11.09 MD EDTA + + - +  
18.11.09 MD EDTA + + - +  103 Dieter 2007 G / H 
09.12.09 MD Citrate - + + +  
104 Keanu 2007 G / T 18.11.09 MD EDTA + + - +  
105 Mondega 2007 M no H 18.11.09 MD EDTA + + - +  
106 Lecado 2004 G / H 18.11.09 MD EDTA + + - +  
107 Vacita 2008 M no H 18.11.09 MD EDTA + + - +  
108 Cica Trice 2008 M no H 18.11.09 MD EDTA + + - +  
109 Vicky 2008 M no H 18.11.09 MD EDTA + + - +  
110 Sentosa 2008 M no H 18.11.09 MD EDTA + + - +  
111 Katana 2008 M no T 18.11.09 MD EDTA + + - +  
112 Quirina 2008 M no H 18.11.09 MD EDTA + + - +  
113 Vita 2007 M no H 18.11.09 MD EDTA + + - +  
114 Royalty 2007 M no H 18.11.09 MD EDTA + + - +  
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 Table VIII-1 continued 
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115 Ballimo 2008 S / H 18.11.09 MD EDTA + + - +  
116 Don Absolut 2008 S / H 18.11.09 MD EDTA + + - +  
117 Basti 2008 S / H 18.11.09 MD EDTA + + - +  
118 Roberto 2008 S / H 18.11.09 MD EDTA + + - +  
119 Stanley 2008 S / H 18.11.09 MD EDTA + + - +  
120 Cicero 2008 S / H 18.11.09 MD EDTA + + - +  
121 Faro 2008 S / H 18.11.09 MD EDTA + + - +  
122 Lexo 2008 S / H 18.11.09 MD EDTA + + - +  
123 Carl-Otto 2008 S / H 18.11.09 MD EDTA + + - +  
124 Sky Jumper 2007 G / H 18.11.09 MD EDTA + + - +  
125 Escolit 2007 G / H 18.11.09 MD EDTA + + - +  
126 Dickens 2008 S / H 18.11.09 MD EDTA + + - +  
127 Anuk 2008 S / H 18.11.09 MD EDTA + + - +  
128 Willibald 2008 S / H 18.11.09 MD EDTA + + - +  
129 Viktor 1983 G / T 18.11.09 MD EDTA + + - +  
130 Honey Heart 2001 M no WU 18.11.09 MD EDTA + + - +  
19.11.09 MD EDTA + + - +  131 Valeca 2009 M no H 
09.12.09 MD Citrate - + + +  
19.11.09 MD EDTA + + - +  132 Feline 2009 M no H 
09.12.09 MD Citrate - + + +  
133 Elbany 2009 M no H 19.11.09 MD EDTA + + - +  
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 Table VIII-1 continued 
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134 Selda 2009 M no H 19.11.09 MD EDTA + + - +  
19.11.09 MD EDTA + + - + 135 Vally 2009 M no H 
09.12.09 MD Citrate - + + + 
AB because of a lung disease 
19.11.09 MD EDTA + + - +  136 Sissi 2009 M no H 
09.12.09 MD Citrate + + + +  
137 Chiara 2009 M no H 19.11.09 MD EDTA + + - +  
138 Di 2009 M no H 19.11.09 MD EDTA + + - +  
139 Verena 2009 M no H 19.11.09 MD EDTA + + - +  
140 Celestine 2009 M no H 19.11.09 MD EDTA + + - +  
141 Chandra 2009 M no T 19.11.09 MD EDTA + + - +  
142 Celina 2009 M no H 19.11.09 MD EDTA + + - +  
143 Sambucco n/a n/a n/a n/a 06.01.10 SY EDTA - + - + HM+ 
144 Quirin n/a S n/a n/a 06.01.10 SY EDTA - + - + HM+ 
145 La Bamboula 1994 M n/a n/a 29.12.09 SY EDTA - + - + HM+ 
146 Loretta n/a n/a n/a n/a 29.12.09 SY EDTA - + - + HM+ 
147 Notje 2004 n/a n/a n/a 16.12.09 SY EDTA - + - + HM+ 
148 Kanif 2009 S / A 30.12.09 SY EDTA - + - + HM+ 
149 Giuliani 1994 G / n/a 10.12.09 SY EDTA - + - + HM+ 
150 Aragon 2006 G / n/a 28.12.09 SY EDTA - + - + HM+ 
151 Ronja 2003 M n/a n/a 17.12.09 SY EDTA - + - + HM+ 
152 Merlin n/a n/a n/a n/a 24.01.10 SY EDTA - + - + HM+ 
V
III
.
 A
PPEN
D
IX
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 174
 
 Table VIII-1 continued 
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153 Kalle 2005 G / SH 19.01.10 SY EDTA - + - + HM+ 
154 Rebana n/a n/a n/a n/a 19.01.10 SY EDTA - + - + HM+ 
155 Cockney n/a S / n/a 17.01.10 SY EDTA - + - + HM+ 
156 Silmoor n/a G / n/a 21.01.10 SY EDTA - + - + HM+ 
157 Lyn’s Halast n/a n/a n/a n/a 24.01.10 SY EDTA - + - + HM+ 
158 n/a n/a n/a n/a n/a n/a SY EDTA - + - - HM+ 
159 n/a n/a n/a n/a n/a n/a SY EDTA - + - - HM+ 
160 Fury n/a n/a n/a n/a n/a SP EDTA - - - -  
161 n/a n/a n/a n/a n/a n/a SY EDTA - + - -  
Blood was anti-coagulated with EDTA, Citrate (Vacuette Greiner Bio-One, St. Gallen, CH) or Alsever’s Solution (AL); AO = Acridine Orange Staining; GI = Giemsa Staining; 
SEM = Scanning Electron Microscopy; M = Mare, G = Gelding, S = Stallion; H = Hanoverian, T = Trakehner, F = Friesian, O = Oldenburg, D = German Riding Pony, 
W = Westphalian, BW = Belgian Warmblood, TH = Thoroughbred, B = Brandenburger, HO = Holsteiner, PI = Pinto, TI = Tinker, WU = Wuerttemberger, A = Arabian, 
SH = Shetland Pony; MD = Dr. Michael Dieckmann (Equine Practice Beekenhof, GER); SY = samples were sent by synlab.vet (Geesthacht, GER); SP = Sarah Prohaska (IVB, 
UZH); HM+ means horses were conspicuous in condition and therefore a complete blood count and chemistry was made by the attending veterinarian, HM like particles could be 
detected in a Giemsa stained peripheral blood smears by synlab.vet (Geesthacht, GER); n/a = not available; NC = nutritional condition (according to the guidelines of the Ameri-
can Association of Equine Practitioners (AAEP): 1 = poor, 2 = very thin, 3 = thin, 4 = moderately thin, 5 = moderate (optimal condition), 6 = moderate to fleshy, 7 = fleshy, 
8 = fat, 9 = extremely fat); AB = treated with antibiotics; Rh. equi = Rhodococcus equi. 
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 Table VIII-2 Negative horse blood samples collected during this study. 
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035 Rivano n/a G / n/a 31.07.08 LF EDTA + - + -  
037 Joya 1998 M n/a Q 10.11.08 CH EDTA + - + -  
038 Fiona 2002 M n/a FR 10.11.08 CH EDTA + - + -  
039 Vivaldi 1999 n/a / n/a 10.11.08 CH EDTA + - + -  
040 Casper 2002 n/a / n/a 10.11.08 CH EDTA + - + -  
041 Da Vinci VI 1996 n/a / n/a 10.11.08 CH EDTA + - + -  
164 Falun 1997 G/S n/a W 15.07.09 RH EDTA - - - + negative for any HM (305)* 
165 n/a n/a n/a n/a I n/a RH EDTA - - - + negative for any HM (305)* 
166 Schiwago 1988 G/S / P 27.07.09 RH EDTA - - - + negative for any HM (305)* 
167 Charmeuse 1981 M n/a FR 30.07.09 RH EDTA - - - + negative for any HM (305)* 
168 Igor 1990 G/S / DU 05.08.09 RH EDTA - - - + negative for any HM (305)* 
169 Bavaria 2009 M n/a SW 06.08.09 RH EDTA - - - + negative for any HM (305)* 
170 Fjallar 1994 G/S / I 08.08.09 RH EDTA - - - + negative for any HM (305)* 
171 Taktur 1991 G/S / I 10.08.09 RH EDTA - - - + negative for any HM (305)* 
172 Raziella 2004 M n/a SW 10.08.09 RH EDTA - - - + negative for any HM (305)* 
173 n/a 2009 S / WC 10.08.09 RH EDTA - - - + negative for any HM (305)* 
174 Carla 2000 M n/a n/a 10.08.09 RH EDTA - - - + negative for any HM (305)* 
175 Jimy 2002 G/S / MA 11.08.09 RH EDTA - - - + negative for any HM (305)* 
176 Adino II 1994 G/S / SW 12.08.09 RH EDTA - - - + negative for any HM (305)* 
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 Table VIII-2 continued 
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177 Magic Merlin 2004 M n/a IR 12.08.09 RH EDTA - - - + negative for any HM (305)* 
178 Gustur 2009 S / I 18.08.09 RH EDTA - - - + negative for any HM (305)* 
179 Kivien Crown 1998 G/S / ST 17.08.09 RH EDTA - - - + negative for any HM (305)* 
180 Cupido 2000 G/S / SH 20.08.09 RH EDTA - - - + negative for any HM (305)* 
181 Lona 1970 M n/a P 20.08.09 RH EDTA - - - + negative for any HM (305)* 
182 Wisky 2001 G/S / TI 07.09.09 RH EDTA - - - + negative for any HM (305)* 
183 Svipa 2009 M n/a I 08.09.09 RH EDTA - - - + negative for any HM (305)* 
184 Terry 1986 M n/a SN 16.09.09 RH EDTA - - - + negative for any HM (305)* 
185 Carmien 1990 M n/a SF 22.09.09 RH EDTA - - - + negative for any HM (305)* 
186 Picolo 1990 G/S / SH 23.09.09 RH EDTA - - - + negative for any HM (305)* 
187 Ecki 2006 G/S / SX 05.10.09 RH EDTA - - - + negative for any HM (305)* 
188 Nikita 2001 M n/a ST 08.10.09 RH EDTA - - - + negative for any HM (305)* 
189 Fabio 2004 G/S / WC 09.10.09 RH EDTA - - - + negative for any HM (305)* 
190 Falina 2004 M n/a TH 12.10.09 RH EDTA - - - + negative for any HM (305)* 
191 Andaluz 2000 G/S / n/a 12.10.09 RH EDTA - - - + negative for any HM (305)* 
192 Targa 2001 M n/a Q 12.10.09 RH EDTA - - - + negative for any HM (305)* 
193 Ramzes B 1999 G/S / SW 13.10.09 RH EDTA - - - + negative for any HM (305)* 
194 Hamilton Darcy 1988 G/S / IR 13.10.09 RH EDTA - - - + negative for any HM (305)* 
195 Gitan 1985 G/S / SH 13.10.09 RH EDTA - - - + negative for any HM (305)* 
196 Snake River 2007 M n/a TH 13.10.09 RH EDTA - - - + negative for any HM (305)* 
197 Tigre 1984 G/S / DP 14.10.09 RH EDTA - - - + negative for any HM (305)* 
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 Table VIII-2 continued 
P
e
r
i
p
h
e
r
a
l
 
b
l
o
o
d
 
s
m
e
a
r
 
N
o
.
 
H
o
r
s
e
 
A
g
e
 
G
e
n
d
e
r
 
P
r
e
g
n
a
n
c
y
 
B
r
e
e
d
 
S
a
m
p
l
i
n
g
 
D
a
t
e
 
S
a
m
p
l
e
d
 
b
y
 
B
l
o
o
d
 
AO GI 
S
E
M
 
p
r
e
p
a
r
a
t
i
o
n
 
C
o
m
p
l
e
t
e
 
b
l
o
o
d
 
c
o
u
n
t
 
P
r
e
l
i
m
i
n
a
r
y
 
r
e
p
o
r
t
 
198 Lazar 1996 G/S / B 14.10.09 RH EDTA - - - + negative for any HM (305)* 
199 Stjarni 1989 G/S / I 15.10.09 RH EDTA - - - + negative for any HM (305)* 
200 Amadeus 1998 G/S / IR 15.10.09 RH EDTA - - - + negative for any HM (305)* 
201 Nevada 1993 M n/a DU 16.10.09 RH EDTA - - - + negative for any HM (305)* 
202 Baroness Senta 1993 M n/a HA 16.10.09 RH EDTA - - - + negative for any HM (305)* 
203 Maisi 1989 M n/a IT 16.10.09 RH EDTA - - - + negative for any HM (305)* 
204 Montan 2001 G/S / ME 20.10.09 RH EDTA - - - + negative for any HM (305)* 
205 Una 2002 M n/a FR 20.10.09 RH EDTA - - - + negative for any HM (305)* 
206 Bolestro 1988 G/S / H 20.10.09 RH EDTA - - - + negative for any HM (305)* 
207 Carmencita 1999 M n/a Q 20.10.09 RH EDTA - - - + negative for any HM (305)* 
208 Pantau 2002 G/S / P 21.10.09 RH EDTA - - - + negative for any HM (305)* 
209 Baxte 2002 G/S / CZ 21.10.09 RH EDTA - - - + negative for any HM (305)* 
210 Isar 1990 G/S / SW 22.10.09 RH EDTA - - - + negative for any HM (305)* 
211 Danceur 1990 G/S / PE 22.10.09 RH EDTA - - - + negative for any HM (305)* 
212 Heya 2004 M n/a FR 22.10.09 RH EDTA - - - + negative for any HM (305)* 
213 Ricky 2004 G/S / Q 23.10.09 RH EDTA - - - + negative for any HM (305)* 
214 Jonny-Boy 1984 G/S / I 24.10.09 RH EDTA - - - + negative for any HM (305)* 
215 Queen 1991 M n/a TH 26.10.09 RH EDTA - - - + negative for any HM (305)* 
216 Angel Bea Doc 1984 M n/a Q 26.10.09 RH EDTA - - - + negative for any HM (305)* 
217 Romeo 1999 G/S / HU 26.10.09 RH EDTA - - - + negative for any HM (305)* 
218 Branca 1993 M n/a N 26.10.09 RH EDTA - - - + negative for any HM (305)* 
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 Table VIII-2 continued 
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219 Patches 2002 M n/a PH 27.10.09 RH EDTA - - - + negative for any HM (305)* 
220 Granissa 1997 M n/a O 27.10.09 RH EDTA - - - + negative for any HM (305)* 
221 Nando 1996 G/S / T 28.10.09 RH EDTA - - - + negative for any HM (305)* 
222 Lagano 1993 G/S / HO 29.10.09 RH EDTA - - - + negative for any HM (305)* 
223 Pablo 2003 G/S / SH 31.10.09 RH EDTA - - - + negative for any HM (305)* 
224 Lorenzo 2006 G/S / SC 02.11.09 RH EDTA - - - + negative for any HM (305)* 
225 Agogo 2005 M n/a SW 03.11.09 RH EDTA - - - + negative for any HM (305)* 
226 Odin 2003 G/S / I 03.11.09 RH EDTA - - - + negative for any HM (305)* 
227 Nico 1995 G/S / HA 03.11.09 RH EDTA - - - + negative for any HM (305)* 
228 Corentilla 2006 M n/a SW 03.11.09 RH EDTA - - - + negative for any HM (305)* 
229 Hero 1991 G/S / BW 04.11.09 RH EDTA - - - + negative for any HM (305)* 
Legend see Table VII-1; G/S = desexed status unknown; Q = Quarter Horse, FR = Freiberger, I = Icelandic Horse, P = Pony, DU = Dutch Warmblood, SW = Swiss Warmblood, 
WC = Welsh Cob Pony, MA = Macedonian Warmblood, IR = Irish Sport Horse, ST = Standardbred, SN = Spanish Warmblood, SF = Selle Francaise, SX = Saxon Warmblood, 
DP = Dutch Pony, HA = Haflinger, IT = Sella Italiano, ME = Mecklenburger, CZ = Czech Warmblood, PE = Percheron, HU = Hungarian Warmblood, N = Noriker, PH = Paint 
Horse; SC = Swedish Warmblood, LF = Larissa Fuchs (IVB, UZH), CH = Chirurgical department, Vetclinics, UZH, RH = blood samples were provided by Regina Hofmann-
Lehmann, Vetclinics, UZH; * samples were checked by a SYBR green I PCR assay comprising all known HM (366). 
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 VIII.3 Summary of complete blood counts 
Table VIII-3 Complete blood counts of samples collected in Autumn/ Winter 2009/ 2010. Abnormal values are highlighted in colour. Repeated sampling of 24 samples in 
December 2009 is highlighted in yellow (compare Table VIII-1, pp. 165-175). Blood counts were produced by synlab.vet (Geesthacht, GER). 
    Complete blood count Differential haemogram 
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Reference range 6.0-12.0 G/l 
6.0-12.0 
T/l 
100-180 
g/l 
0.32-0.48 
l/l 
34-58 
fl 
13-19 
pg 
31-37 
g/dl 
100-600 
G/l 
30-75 
% 
3000-6000 
/µl 
0-1 
% 
0-100 
/µl 
25-60 
% 
1500-5000 
/µl 1-8 % 0-100 /µl 1-10 % 
0-800 
/µl 0-3 % 
0-300 
/µl 0 % /µl 
001 Dacana 7.2 8.80 137 0.37 41.7 15.6 37.3 113 54 3888 0 0 37 2664 5 360 3 216 1 72 0 0 
002 Shirley 6.9 8.28 138 0.38 46.3 16.7 36.0 188 58 4002 0 0 35 2415 5 345 2 138 0 0 0 0 
003 Bretagne 7.7 6.54 115 0.33 50.0 17.6 35.2 232 58 4466 0 0 34 2618 4 308 3 231 1 77 0 0 
003 Bretagne 7.3 6.61 117 0.33 49.8 17.7 35.6 182 61 4453 0 0 31 2263 4 292 3 219 1 73 0 0 
004 Weltfee 10.1 8.22 133 0.36 43.6 16.2 37.2 208 66 6666 0 0 23 2323 5 505 6 606 0 0 0 0 
005 Emelie 5.8 8.87 140 0.39 43.6 15.8 36.2 120 53 3074 0 0 37 2146 5 290 4 232 1 58 0 0 
006 Leca 8.0 8.91 141 0.40 44.4 15.8 35.6 222 49 3920 0 0 41 3280 4 320 5 400 1 80 0 0 
007 Royal Star 7.9 8.84 139 0.38 43.2 15.7 36.4 162 48 3792 0 0 42 3318 4 316 5 395 1 79 0 0 
010 Dipsy 6.0 8.29 118 0.32 38.1 14.2 37.3 159 54 3240 0 0 35 2100 6 360 3 180 2 120 0 0 
011 Kaja 7.0 7.60 122 0.35 45.7 16.1 35.2 169 56 3920 0 0 36 2520 5 350 2 140 1 70 0 0 
012 Darcy 7.3 6.85 115 0.33 48.0 16.8 35.0 212 63 4599 0 0 28 2044 6 438 1 73 2 146 0 0 
014 Kassiopeia 5.3 7.20 129 0.36 49.6 17.9 36.1 108 56 2968 0 0 37 1961 3 159 3 159 1 53 0 0 
015 Wolkenfee 7.4 7.38 124 0.35 47.2 16.8 35.6 196 60 4440 0 0 34 2516 5 370 1 74 0 0 0 0 
015 Wolkenfee 7.0 6.98 118 0.33 47.3 16.9 35.8 201 58 4060 0 0 37 2590 4 280 1 70 0 0 0 0 
020 Escot 8.3 7.64 115 0.31 41.1 15.1 36.6 121 43 3569 0 0 49 4067 4 332 3 249 1 83 0 0 
020 Escot 7.1 7.67 114 0.31 40.7 14.9 36.5 111 46 3266 0 0 48 3408 4 284 2 142 0 0 0 0 
021 Lilli 11.0 8.54 143 0.39 46.0 16.7 36.4 157 26 2860 0 0 70 7700 0 0 4 440 0 0 0 0 
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Reference range 6.0-12.0 G/l 
6.0-12.0 
T/l 
100-180 
g/l 
0.32-0.48 
l/l 
34-58 
fl 
13-19 
pg 
31-37 
g/dl 
100-600 
G/l 
30-75 
% 
3000-6000 
/µl 
0-1 
% 
0-100 
/µl 
25-60 
% 
1500-5000 
/µl 1-8 % 0-100 /µl 1-10 % 
0-800 
/µl 0-3 % 
0-300 
/µl 0 % /µl 
022 Dondra 8.3 9.00 133 0.37 40.7 14.8 36.3 125 53 4399 0 0 36 2988 6 498 4 332 1 83 0 0 
023 Dorit 9.8 9.22 139 0.37 39.6 15.1 38.1 153 54 5292 0 0 38 3724 5 490 2 196 1 98 0 0 
024 Tristan 7.6 6.56 112 0.33 49.8 17.1 34.3 196 51 3876 0 0 40 3040 5 380 3 228 1 76 0 0 
025 Caray 6.8 9.27 140 0.39 41.6 15.1 36.3 164 53 3604 0 0 38 2584 5 340 4 272 0 0 0 0 
026 Rubina 9.7 8.39 142 0.36 43.4 16.9 39.0 122 50 4850 0 0 38 3686 4 388 7 679 1 97 0 0 
029 Freia 8.1 7.42 129 0.36 48.8 17.4 35.6 146 55 4455 0 0 36 2916 3 243 6 486 0 0 0 0 
030 Robina 8.3 8.36 147 0.41 49.3 17.6 35.7 107 56 4648 0 0 34 2822 5 415 5 415 0 0 0 0 
031 Exotic Lady 8.0 8.35 138 0.42 50.7 16.5 32.6 149 52 4160 0 0 43 3440 3 240 2 160 0 0 0 0 
036 Peggy 10.8 8.94 124 0.33 36.7 13.9 37.8 140 47 5076 0 0 44 4752 5 540 3 324 1 108 0 0 
048 Romina S 8.2 8.84 132 0.36 40.3 14.9 37.1 165 59 4838 0 0 30 2460 4 328 6 492 1 82 0 0 
049 Gesche 7.2 8.54 141 0.39 45.4 16.5 36.3 189 47 3384 0 0 45 3240 4 288 3 216 1 72 0 0 
049 Gesche 6.8 8.62 142 0.39 45.7 16.5 36.0 170 42 2856 0 0 50 3400 5 340 2 136 1 68 0 0 
050 Acordia 7.4 8.37 141 0.39 46.5 16.8 36.2 180 57 4218 0 0 33 2442 6 444 3 222 1 74 0 0 
051 Belle de Jour 11.5 8.62 141 0.38 43.6 16.4 37.5 134 35 4025 0 0 61 7015 3 345 1 115 0 0 0 0 
052 Piccoline 7.8 7.25 126 0.37 50.8 17.4 34.2 149 54 4212 0 0 36 2808 4 312 5 390 1 78 0 0 
053 Friemo 7.5 7.46 127 0.35 46.8 17.0 36.4 104 46 3450 0 0 45 3375 3 225 3 225 3 225 0 0 
054 Luise 8.7 9.12 144 0.38 41.9 15.8 37.7 176 44 3828 0 0 49 4263 4 348 2 174 1 87 0 0 
055 Dali 9.3 7.91 110 0.30 38.3 13.9 36.3 196 50 4650 0 0 41 3813 6 558 3 279 0 0 0 0 
056 Findus 10.3 9.90 118 0.31 30.9 11.9 38.6 301 45 4635 0 0 48 4944 6 618 1 103 0 0 0 0 
057 Quebec 11.4 7.09 94 0.26 36.8 13.3 36.0 234 50 5700 0 0 46 5244 4 456 0 0 0 0 0 0 
057 Quebec 15.0 8.30 112 0.31 37.7 13.5 35.8 126 38 5700 0 0 56 8400 2 300 4 600 0 0 0 0 
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Reference range 6.0-12.0 G/l 
6.0-12.0 
T/l 
100-180 
g/l 
0.32-0.48 
l/l 
34-58 
fl 
13-19 
pg 
31-37 
g/dl 
100-600 
G/l 
30-75 
% 
3000-6000 
/µl 
0-1 
% 
0-100 
/µl 
25-60 
% 
1500-5000 
/µl 1-8 % 0-100 /µl 1-10 % 
0-800 
/µl 0-3 % 
0-300 
/µl 0 % /µl 
058 Sam 9.8 9.55 120 0.32 33.4 12.6 37.6 220 34 3332 0 0 63 6174 0 0 3 294 0 0 0 0 
059 Lorenz 11.1 8.28 109 0.29 34.7 13.2 38.0 183 52 5772 0 0 44 4884 4 444 0 0 0 0 0 0 
059 Lorenz 16.7 7.94 105 0.28 35.1 13.2 37.6 174 62 10354 0 0 38 6346 0 0 0 0 0 0 0 0 
060 Fabian 13.8 9.55 120 0.31 32.7 12.6 38.5 220 32 4416 0 0 66 9108 2 276 0 0 0 0 0 0 
060 Fabian 16.3 10.05 126 0.34 33.4 12.5 37.5 243 54 8802 0 0 46 7498 0 0 0 0 0 0 0 0 
061 Seppi 9.8 9.91 123 0.31 31.6 12.4 39.3 145 42 4116 0 0 56 5488 0 0 2 196 0 0 0 0 
062 Benetton B 7.6 7.58 100 0.28 36.8 13.2 35.8 170 31 2356 0 0 60 4560 6 456 3 228 0 0 0 0 
062 Benetton B 12.2 9.58 126 0.34 35.9 13.2 36.6 198 36 4392 0 0 60 7320 4 488 0 0 0 0 0 0 
063 Franz-Josef 9.6 9.53 114 0.31 32.0 12.0 37.4 250 34 3264 0 0 60 5760 2 192 4 384 0 0 0 0 
063 Franz-Josef 13.4 10.85 130 0.35 31.8 12.0 37.7 280 48 6432 0 0 52 6968 0 0 0 0 0 0 0 0 
064 So What 11.7 8.86 112 0.30 33.4 12.6 37.8 245 42 4914 0 0 54 6318 2 234 0 0 2 234 0 0 
064 So What 17.0 9.04 117 0.32 35.1 12.9 36.9 236 60 10200 0 0 40 6800 0 0 0 0 0 0 0 0 
065 Catnap 10.3 10.25 123 0.32 31.6 12.0 38.0 288 45 4635 0 0 46 4738 6 618 3 309 0 0 0 0 
066 Sandman 13.1 9.04 112 0.30 32.9 12.4 37.7 103 28 3668 0 0 68 8908 2 262 2 262 0 0 0 0 
067 Montano 11.5 9.03 112 0.31 33.8 12.4 36.7 286 32 3680 0 0 66 7590 2 230 0 0 0 0 0 0 
067 Montano 12.9 9.47 120 0.33 34.3 12.7 36.9 246 32 4128 0 0 68 8772 0 0 0 0 0 0 0 0 
068 Schneider 10.0 9.31 122 0.33 35.3 13.1 37.1 249 52 5200 0 0 44 4400 4 400 0 0 0 0 0 0 
069 Rocky 9.2 7.93 109 0.30 38.0 13.7 36.2 171 41 3772 0 0 50 4600 5 460 4 368 0 0 0 0 
069 Rocky 9.1 8.45 116 0.32 38.2 13.7 35.9 123 32 2912 0 0 68 6188 0 0 0 0 0 0 0 0 
070 Cosimo 8.6 7.72 104 0.28 36.7 13.5 36.7 184 35 3010 0 0 57 4902 6 516 2 172 0 0 0 0 
070 Cosimo 11.5 9.84 130 0.35 35.7 13.2 37.0 206 26 2990 0 0 74 8510 0 0 0 0 0 0 0 0 
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Reference range 6.0-12.0 G/l 
6.0-12.0 
T/l 
100-180 
g/l 
0.32-0.48 
l/l 
34-58 
fl 
13-19 
pg 
31-37 
g/dl 
100-600 
G/l 
30-75 
% 
3000-6000 
/µl 
0-1 
% 
0-100 
/µl 
25-60 
% 
1500-5000 
/µl 1-8 % 0-100 /µl 1-10 % 
0-800 
/µl 0-3 % 
0-300 
/µl 0 % /µl 
071 Squirl 8.1 8.43 111 0.30 35.9 13.2 36.6 118 41 3321 0 0 48 3888 7 567 3 243 1 81 0 0 
071 Squirl 12.6 8.16 106 0.30 36.4 13.0 35.7 174 58 7308 0 0 37 4662 4 504 1 126 0 0 0 0 
072 Quiddith 14.3 8.95 111 0.29 32.8 12.4 37.8 171 40 5720 0 0 56 8008 4 572 0 0 0 0 0 0 
072 Quiddith 19.5 9.57 119 0.32 33.2 12.4 37.4 149 28 5460 0 0 70 13650 2 390 0 0 0 0 0 0 
073 Dolly 6.6 8.07 122 0.33 40.9 15.1 37.0 172 49 3234 0 0 42 2772 5 330 3 198 1 66 0 0 
075 Churchill 6.2 8.50 133 0.37 43.1 15.6 36.3 104 63 3906 0 0 28 1736 5 310 3 186 1 62 0 0 
076 Karamé 7.1 7.86 128 0.35 45.0 16.3 36.2 149 60 4260 0 0 31 2201 4 284 5 355 0 0 0 0 
077 Kara 10.6 8.71 135 0.37 42.6 15.5 36.4 100 50 5300 0 0 43 4558 4 424 3 318 0 0 0 0 
078 Absolutely 7.7 8.42 141 0.38 45.5 16.7 36.8 234 60 4620 0 0 30 2310 4 308 5 385 1 77 0 0 
079 Conny 8.9 9.02 143 0.37 41.0 15.9 38.6 144 48 4272 0 0 44 3916 4 356 2 178 2 178 0 0 
080 Tabora 10.2 8.68 137 0.39 44.4 15.8 35.6 136 46 4692 0 0 47 4794 3 306 3 306 1 102 0 0 
081 Sia 9.3 8.91 133 0.36 40.6 14.9 36.7 110 46 4278 0 0 49 4557 4 372 1 93 0 0 0 0 
082 Donella 7.1 8.92 123 0.32 36.2 13.8 38.1 171 53 3763 0 0 37 2627 4 284 5 355 1 71 0 0 
083 Vitesse 11.1 9.22 131 0.34 37.0 14.2 38.4 136 30 3330 0 0 66 7326 4 444 0 0 0 0 0 0 
084 Sahara 12.5 9.58 132 0.36 37.1 13.8 37.2 91 51 6375 0 0 46 5750 0 0 2 250 1 125 0 0 
085 Delight 11.1 8.93 131 0.35 39.6 14.7 37.0 272 50 5550 0 0 44 4884 3 333 2 222 1 111 0 0 
085 Delight 9.4 8.27 122 0.33 39.9 14.8 37.0 177 45 4230 0 0 47 4418 4 376 3 282 1 94 0 0 
086 Argentina 7.2 7.53 115 0.31 41.7 15.3 36.6 165 52 3744 0 0 41 2952 4 288 2 144 1 72 0 0 
087 Contina 10.6 9.28 128 0.33 35.8 13.8 38.6 144 43 4558 0 0 45 4770 4 424 7 742 1 106 0 0 
088 Pintia 12.8 9.11 132 0.34 37.2 14.5 38.9 214 39 4992 0 0 57 7296 1 128 3 384 0 0 0 0 
089 Clara 14.1 9.48 131 0.34 36.0 13.8 38.4 221 24 3384 0 0 70 9870 2 282 0 0 4 564 0 0 
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Reference range 6.0-12.0 G/l 
6.0-12.0 
T/l 
100-180 
g/l 
0.32-0.48 
l/l 
34-58 
fl 
13-19 
pg 
31-37 
g/dl 
100-600 
G/l 
30-75 
% 
3000-6000 
/µl 
0-1 
% 
0-100 
/µl 
25-60 
% 
1500-5000 
/µl 1-8 % 0-100 /µl 1-10 % 
0-800 
/µl 0-3 % 
0-300 
/µl 0 % /µl 
090 Coralie 8.3 7.62 125 0.34 44.2 16.4 37.1 140 46 3818 0 0 44 3652 5 415 3 249 2 166 0 0 
090 Coralie 6.4 6.82 111 0.31 45.0 16.3 36.2 148 41 2624 0 0 50 3200 7 448 1 64 1 64 0 0 
091 Bretagna 7.5 8.09 140 0.37 45.6 17.3 37.9 119 52 3900 0 0 41 3075 4 300 2 150 1 75 0 0 
092 Gweenie 9.3 7.50 115 0.31 41.9 15.3 36.6 128 47 4371 0 0 46 4278 4 372 2 186 1 93 0 0 
093 Cheyenne 10.5 8.49 152 0.41 48.5 17.9 36.9 121 65 6825 0 0 28 2940 4 420 3 315 0 0 0 0 
094 Lennert 3.6 13.38 212 0.52 38.7 15.8 40.9 83 37 1332 0 0 54 1944 6 216 2 72 1 36 0 0 
095 Robby 7.7 8.07 117 0.32 39.0 14.5 37.1 154 40 3080 0 0 48 3696 7 539 4 308 1 77 0 0 
096 Paul 10.8 8.89 128 0.34 37.9 14.4 38.0 118 26 2808 0 0 70 7560 2 216 0 0 2 216 0 0 
097 Spock 9.9 10.26 154 0.38 36.6 15.0 41.0 189 55 5445 0 0 36 3564 5 495 3 297 1 99 0 0 
098 Robert 11.1 7.83 120 0.32 41.3 15.3 37.2 135 57 6327 0 0 32 3552 6 666 4 444 1 111 0 0 
098 Robert 9.2 8.99 135 0.36 40.3 15.0 37.3 150 54 4968 0 0 33 3036 8 736 3 276 2 184 0 0 
099 Winnetou 8.1 6.87 121 0.34 49.8 17.6 35.4 143 50 4050 0 0 38 3078 6 486 6 486 0 0 0 0 
100 Sita 10.0 9.73 137 0.36 36.9 14.1 38.2 201 42 4200 0 0 50 5000 5 500 3 300 0 0 0 0 
101 Valerie 9.6 9.88 140 0.37 36.9 14.2 38.4 221 44 4224 0 0 47 4512 4 384 4 384 1 96 0 0 
102 Dira 13.5 8.98 126 0.33 36.5 14.0 38.4 199 28 3780 0 0 62 8370 6 810 4 540 0 0 0 0 
103 Dieter 9.2 7.90 124 0.34 42.4 15.7 37.0 159 46 4232 0 0 44 4048 6 552 3 276 1 92 0 0 
103 Dieter 8.7 7.87 123 0.34 43.3 15.6 36.1 123 42 3654 0 0 42 3654 10 870 5 435 1 87 0 0 
104 Keanu 10.3 8.80 137 0.39 43.8 15.6 35.6 113 49 5047 0 0 42 4326 4 412 4 412 1 103 0 0 
105 Mondega 10.7 8.42 116 0.31 36.8 13.8 37.4 174 48 5136 0 0 43 4601 5 535 3 321 1 107 0 0 
106 Lecado 5.9 7.99 121 0.34 42.4 15.1 35.7 175 47 2773 0 0 46 2714 3 177 4 236 0 0 0 0 
107 Vacita 11.7 9.56 123 0.32 33.7 12.9 38.2 185 38 4446 0 0 58 6786 4 468 0 0 0 0 0 0 
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31-37 
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G/l 
30-75 
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3000-6000 
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0-1 
% 
0-100 
/µl 
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% 
1500-5000 
/µl 1-8 % 0-100 /µl 1-10 % 
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/µl 0-3 % 
0-300 
/µl 0 % /µl 
108 Cica Trice 10.7 9.66 132 0.35 36.0 13.7 37.9 129 32 3424 0 0 64 6848 4 428 0 0 0 0 0 0 
109 Vicky 7.4 8.82 120 0.33 37.5 13.6 36.3 195 51 3774 0 0 41 3034 5 370 2 148 1 74 0 0 
110 Sentosa 8.6 8.54 123 0.32 37.9 14.4 38.0 165 51 4386 0 0 40 3440 5 430 3 258 1 86 0 0 
111 Katana 6.4 9.14 127 0.33 35.7 13.9 39.0 152 64 4096 0 0 28 1792 5 320 2 128 1 64 0 0 
112 Quirina 8.5 8.40 127 0.34 40.1 15.1 37.7 166 56 4760 0 0 35 2975 5 425 3 255 1 85 0 0 
113 Vita 9.3 9.20 142 0.38 40.9 15.4 37.8 130 42 3906 0 0 49 4557 4 372 4 372 1 93 0 0 
114 Royalty 11.9 9.27 150 0.40 42.7 16.2 37.9 129 38 4522 0 0 54 6426 6 714 2 238 0 0 0 0 
115 Ballimo 10.6 9.99 136 0.36 36.3 13.6 37.5 154 53 5618 0 0 37 3922 6 636 3 318 1 106 0 0 
116 Don Absolut 9.7 10.32 141 0.37 36.1 13.7 37.8 236 48 4656 0 0 43 4171 5 485 3 291 1 97 0 0 
117 Basti 11.3 9.31 133 0.35 37.8 14.3 37.8 123 57 6441 0 0 33 3729 6 678 3 339 1 113 0 0 
118 Roberto 10.3 8.28 120 0.32 38.0 14.5 38.1 190 46 4738 0 0 42 4326 7 721 4 412 1 103 0 0 
118 Roberto 11.3 8.10 117 0.30 37.4 14.4 38.6 226 50 5650 0 0 40 4520 6 678 4 452 0 0 0 0 
119 Stanley 11.9 10.11 138 0.35 34.5 13.6 39.5 225 52 6188 0 0 39 4641 5 595 4 476 0 0 0 0 
120 Cicero 10.0 9.89 136 0.35 35.7 13.8 38.5 149 45 4500 0 0 43 4300 5 500 6 600 1 100 0 0 
121 Faro 13.0 8.44 130 0.34 40.4 15.4 38.1 128 24 3120 0 0 68 8840 2 260 4 520 2 260 0 0 
122 Lexo 12.3 9.24 137 0.37 39.9 14.8 37.1 146 24 2952 0 0 74 9102 2 246 0 0 0 0 0 0 
123 Carl-Otto 10.9 9.83 131 0.35 35.2 13.3 37.9 185 52 5668 0 0 41 4469 4 436 3 327 0 0 0 0 
124 Sky Jumper 11.4 10.13 141 0.36 35.3 13.9 39.4 179 50 5700 0 0 48 5472 2 228 0 0 0 0 0 0 
125 Escolit 11.5 8.87 132 0.35 39.3 14.9 37.8 121 38 4370 0 0 56 6440 2 230 4 460 0 0 0 0 
126 Dickens 12.7 8.87 130 0.34 38.8 14.7 37.8 195 42 5334 0 0 50 6350 2 254 4 508 2 254 0 0 
127 Anuk 12.6 8.86 120 0.32 36.3 13.5 37.3 144 32 4032 0 0 60 7560 2 252 6 756 0 0 0 0 
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/µl 0 % /µl 
128 Willibald 13.0 11.75 154 0.39 33.4 13.1 39.3 242 52 6760 0 0 38 4940 5 650 4 520 1 130 0 0 
129 Viktor 6.6 8.12 140 0.38 46.9 17.2 36.7 129 63 4158 0 0 29 1914 4 264 4 264 0 0 0 0 
130 Honey Heart 5.8 8.55 136 0.36 41.6 15.9 38.2 109 53 3074 0 0 37 2146 6 348 4 232 0 0 0 0 
131 Valeca 10.9 8.76 108 0.29 33.3 12.3 37.0 162 34 3706 0 0 60 6540 4 436 2 218 0 0 0 0 
131 Valeca 10.7 9.64 120 0.32 32.8 12.4 38.0 190 28 2996 0 0 72 7704 0 0 0 0 0 0 0 0 
132 Feline 12.2 8.57 112 0.29 34.3 13.1 38.1 160 20 2440 0 0 74 9028 6 732 0 0 0 0 0 0 
132 Feline 12.7 9.60 126 0.33 34.2 13.1 38.4 117 38 4826 0 0 62 7874 0 0 0 0 0 0 0 0 
133 Elbany 12.3 10.64 126 0.33 31.1 11.8 38.1 121 44 5412 0 0 52 6396 4 492 0 0 0 0 0 0 
134 Selda 11.2 10.65 131 0.35 32.5 12.3 37.9 201 28 3136 0 0 66 7392 4 448 2 224 0 0 0 0 
135 Vally 10.8 8.34 106 0.29 34.3 12.7 37.1 183 54 5832 0 0 37 3996 7 756 1 108 1 108 0 0 
135 Vally 13.8 8.25 107 0.30 35.8 13.0 36.3 188 68 9384 0 0 30 4140 2 276 0 0 0 0 0 0 
136 Sissi 13.2 9.52 123 0.33 34.6 12.9 37.4 320 38 5016 0 0 52 6864 4 528 4 528 2 264 0 0 
136 Sissi 15.1 9.49 125 0.34 36.1 13.2 36.4 330 52 7852 0 0 48 7248 0 0 0 0 0 0 0 0 
137 Chiara 11.3 10.29 129 0.34 32.7 12.5 38.4 142 50 5650 0 0 48 5424 2 226 0 0 0 0 0 0 
138 Di 11.5 9.75 124 0.33 33.6 12.7 37.8 309 47 5405 0 0 43 4945 7 805 3 345 0 0 0 0 
139 Verena 14.0 9.02 116 0.32 35.0 12.9 36.7 272 60 8400 0 0 32 4480 8 1120 0 0 0 0 0 0 
140 Celestine 7.5 9.15 119 0.32 34.4 13.0 37.8 127 45 3375 0 0 46 3450 6 450 2 150 1 75 0 0 
141 Chandra 10.7 9.15 119 0.31 34.0 13.0 38.3 228 43 4601 0 0 45 4815 6 642 5 535 1 107 0 0 
142 Celina 8.7 9.50 121 0.32 33.3 12.7 38.3 220 30 2610 0 0 64 5568 4 348 2 174 0 0 0 0 
143 Sambucco 6.1 7.61 125 0.35 46.0 16.4 35.7 100 50 3050 0 0 40 2440 8 488 1 61 1 61 0 0 
144 Qurin 6.6 6.75 115 0.32 47.3 17.0 36.1 158 50 3300 0 0 35 2310 6 396 9 594 0 0 0 0 
 Table VIII-3 continued 
    Complete blood count Differential haemogram 
N
o
.
 
I
d
e
n
t
i
f
i
c
a
t
i
o
n
 
L
e
u
c
o
c
y
t
e
s
 
E
r
y
t
h
r
o
c
y
t
e
s
 
H
a
e
m
o
g
l
o
b
i
n
 
H
a
e
m
a
t
o
c
r
i
t
 
M
C
V
 
M
C
H
 
M
C
H
C
 
T
h
r
o
m
b
o
c
y
t
e
s
 
S
e
g
m
e
n
t
e
d
 
N
e
u
t
r
o
p
h
i
l
s
 
S
e
g
m
e
n
t
e
d
 
N
e
u
t
r
o
p
h
i
l
s
 
a
b
s
.
 
 
B
a
n
d
 
N
e
u
t
r
o
p
h
i
l
s
 
B
a
n
d
 
N
e
u
t
r
o
p
h
i
l
s
 
a
b
s
.
 
L
y
m
p
h
o
c
y
t
e
s
 
L
y
m
p
h
o
c
y
t
e
s
 
a
b
s
.
 
M
o
n
o
c
y
t
e
s
 
M
o
n
o
c
y
t
e
s
 
a
b
s
.
 
E
o
s
i
n
o
p
h
i
l
s
 
E
o
s
i
n
o
p
h
i
l
s
 
a
b
s
.
 
B
a
s
o
p
h
i
l
s
 
B
a
s
o
p
h
i
l
s
 
a
b
s
.
 
O
t
h
e
r
 
c
e
l
l
s
 
O
t
h
e
r
 
c
e
l
l
s
 
a
b
s
.
 
Reference range 6.0-12.0 G/l 
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/µl 0-3 % 
0-300 
/µl 0 % /µl 
145 La Bamboula 8.5 3.00 53 0.15 51.0 17.7 34.6 72 83 7055 0 0 9 765 8 680 0 0 0 0 0 0 
146 Loretta 5.1 5.00 91 0.25 50.4 18.2 36.1 143 43 2193 0 0 50 2550 4 204 3 153 0 0 0 0 
147 Notje 8.5 6.11 98 0.26 42.1 16.0 38.1 / 45 3825 0 0 50 4250 3 255 1 85 1 85 0 0 
148 Kanif 14.3 8.62 101 0.28 32.6 11.7 35.9 241 36 5148 0 0 60 8580 4 572 0 0 0 0 0 0 
149 Giuliani 13.3 6.83 114 0.32 46.3 16.7 36.1 130 79 10507 0 0 21 2793 0 0 0 0 0 0 0 0 
150 Aragon 30.4 6.88 105 0.29 41.6 15.3 36.7 332 83 25232 0 0 14 4256 1 304 2 608 0 0 0 0 
151 Ronja 5.5 5.80 105 0.29 50.0 18.1 36.2 195 28 1540 ? ? 72 3960 0 0 0 0 0 0 0 0 
152 Merlin 2.6 6.57 115 0.31 47.6 17.5 36.7 121 50 1300 0 0 44 1144 6 156 0 0 0 0 0 0 
153 Kalle 10.2 7.52 118 0.33 43.2 15.7 36.3 115 34 3468 ? ? 62 6324 0 0 4 408 0 0 0 0 
154 Rebana 6.4 7.84 132 0.40 51.3 16.8 32.8 101 59 3776 0 0 34 2176 5 320 2 128 0 0 0 0 
155 Cockney 6.0 6.14 94 0.27 44.1 15.3 34.7 115 56 3360 0 0 39 2340 4 240 1 60 0 0 0 0 
156 Silmoor 4.6 5.75 96 0.27 47.5 16.7 35.2 112 55 2530 ? ? 37 1702 6 276 2 92 0 0 0 0 
157 Lyn's Halast 19.6 4.90 69 0.20 40.0 14.1 35.2 161 74 14504 0 0 18 3528 8 1568 0 0 0 0 0 0 
No. = samples number; MCV = mean corpuscular volume, MCH = mean corpuscular haemoglobin, MCHC = mean corpuscular haemoglobin concentration; blue = decreased, 
orange = increased; yellow = re-sampled horses; / = not determined. 
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VIII.4 Sequence alignments 
On the following pages the corresponding alignments of the phylogenetic trees shown 
in Chapter IV will be presented. 
1. Alignment of 16S rRNA of haemotrophic mycoplasmas. For reasons 
of simplicity only one species of each cluster is shown. 
pp. 194-201 
2. Alignment of 16S rRNA of bovine HM isolates pp. 202-206 
3. Alignment of 16S rRNA of equine HM isolates pp. 207-209 
4. Alignment of 16S rRNA of Mycoplasma suis pp. 210-218 
 
Annotation of sequences is according to the IUPAC nomenclature: A = Adenine, 
C = Cytosine, G = Guanine, T (or U) = Thymine (or Uracil), R =  A or G, Y = C or T, 
S = G or C, W = A or T (U), K = G or T (U), M = A or C, B = C or G or T (U), D = A 
or G or T (U), H = A or C or T (U), V = A or C or G, N = any base, . or - = gap. 
Sequence position is given on the top, on the left and on the right. 
On the left side, species are assigned by an ‘ARB short name’. For explanation of ab-
breviations see Table VIII-4. 
Table VIII-4 Description of the 16S rRNA isolates used in the phylogenetic studies 
ARB Accession Description Host bp 
BacSubti AB042061 Bacillus subtilis  1550 
BacSub76 Z99107 Bacillus subtilis  1550 
CloPe117 CP000246 Clostridium perfringens  1518 
CanMy155 AB558897 CM erythrocervae Cervus nippon 1434 
CanMy157 AB558898 CM erythrocervae Cervus nippon 1434 
MycEryth AF178676 CM erythrodidelphis  Didelphis marsupialis 1453 
CanMyc10 AY383241 CM haematoparvum  Dog 1461 
CanMyc12 AY532390 CM haematoparvum  Dog 1448 
CanMyc50 EF416569 CM haematoparvum Dog 1351 
CanMy131 GQ129112 CM haematoparvum Dog 1310 
CanMy132 GQ129114 CM haematoparvum Dog 1310 
CanMy137 GQ129113 CM haematoparvum Dog 1310 
CanMyc51 EF460765 CM haemobovis  Cattle 1435 
CanMyc52 EF616467 CM haemobovis  Cattle 1391 
CanMyc53 EF616468 CM haemobovis  Cattle 1391 
CanMyc59 EU367965 CM haemobovis  Cattle 1204 
CanMy156 AB558899 CM haemocervae Cervus nippon 1434 
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Table VIII-4 continued 
ARB Accession Description Host bp 
MycHaemo AF306346 CM haemolamae Alpaca 1428 
CanMy122 FN908076 CM haemolamae Llama 1080 
CanMy123 FN908077 CM haemolamae Llama 1071 
CanMy124 FN908078 CM haemolamae Llama 1075 
CanMy125 FN908079 CM haemolamae Llama 1078 
CanMy126 FN908080 CM haemolamae Llama 1070 
CanMy127 FN908081 CM haemolamae Llama 1032 
CanMy128 FN908082 CM haemolamae Llama 1068 
CanMy129 FN908083 CM haemolamae Llama 1080 
CanMy130 FN908084 CM haemolamae Llama 1065 
CanMy153 GU047355 CM haemolamae Alpaca 1421 
CanMycop AF271154 CM haemominutum  Cat 1425 
CanMyco3 AM745338 CM haemominutum Cat 1456 
CanMyco4 AY150974 CM haemominutum Cat 1426 
CanMyco6 AY150979 CM haemominutum Cat 1427 
CanMyco7 AY150980 CM haemominutum Cat 1425 
CanMyco8 AY150981 CM haemominutum Cat 1424 
CanMyco9 AY297712 CM haemominutum  Dog 1480 
CanMyc11 AY529634 CM haemominutum  Cat 1291 
CanMyc13 DQ157141 CM haemominutum Cat 1356 
CanMyc14 DQ157143 CM haemominutum Cat 1359 
CanMyc16 DQ157145 CM haemominutum Cat 1356 
CanMyc17 DQ157146 CM haemominutum Cat 1358 
CanMyc18 DQ157147 CM haemominutum Cat 1356 
CanMyc19 DQ157148 CM haemominutum Cat 1359 
CanMyc20 DQ157149 CM haemominutum Cat 1356 
CanMyc35 DQ825439 CM haemominutum Leopardus tigrinus 1355 
CanMyc36 DQ825440 CM haemominutum Leopardus wiedii 1352 
CanMyc37 DQ825442 CM haemominutum European wildcat 1358 
CanMyc38 DQ825443 CM haemominutum European wildcat 1355 
CanMyc39 DQ825444 CM haemominutum Iberian lynx 1357 
CanMyc40 DQ825445 CM haemominutum Iberian lynx 1358 
CanMyc41 DQ825446 CM haemominutum Iberian lynx 1360 
CanMyc45 DQ825452 CM haemominutum Lion 1356 
CanMyc47 DQ825455 CM haemominutum Lion 1356 
CanMyc48 DQ825456 CM haemominutum Eurasian lynx 1366 
CanMyc49 DQ825457 CM haemominutum Eurasian lynx 1359 
CanMyc54 EU128752 CM haemominutum Cat 1274 
CanMyc57 EU170604 CM haemominutum  Ctenocephalides felis 1268 
CanMyc64 EU839979 CM haemominutum Felis catus 1257 
CanMyc65 EU839980 CM haemominutum Felis catus 1305 
CanMyc66 EU839981 CM haemominutum Felis catus 1305 
CanMyc67 EU839982 CM haemominutum Felis catus 1305 
CanMyc68 EU839983 CM haemominutum Felis catus 1306 
CanMyc69 EU839984 CM haemominutum Felis catus 1306 
CanMyc70 EU839985 CM haemominutum Felis catus 1306 
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Table VIII-4 continued 
ARB Accession Description Host bp 
CanMyc72 FJ004275 CM haemominutum Felis catus 1312 
CanMyc73 U88564 CM haemominutum Cat 1430 
CanMy136 AM691834 CM haemominutum Dog 1457 
CanMyc55 EU165512 CM haemovis Ovis aries 1441 
CanMyc56 EU165513 CM haemovis Ovis aries 1441 
CanMy135 EU828579 CM haemovis Ovis aries 1345 
CanMy133 EU828580 CM haemovis Ovis aries 1345 
CanMy134 EU828581 CM haemovis Ovis aries 1345 
MycSpe87 GU230141 CM haemovis Homo sapiens 1439 
MycSpe88 GU383116 CM haemovis Homo sapiens 1439 
MycSpe78 GU905011 CM haemozalophi Sea lion 1438 
MycSpe79 GU905012 CM haemozalophi Sea lion 1438 
CanMyco2 AF338269 CM kahanei  Saimiri sciureus 1451 
CanMyc21 DQ157150 CM turicensis  Cat 1339 
CanMyc22 DQ157151 CM turicensis  Cat 1336 
CanMyc23 DQ157152 CM turicensis  Cat 1342 
CanMyc24 DQ157153 CM turicensis  Cat 1442 
CanMyc25 DQ157154 CM turicensis  Cat 1342 
CanMyc26 DQ464417 CM turicensis  Cat 1343 
CanMyc27 DQ464418 CM turicensis  Cat 1341 
CanMyc28 DQ464419 CM turicensis  Cat 1340 
CanMyc29 DQ464420 CM turicensis  Cat 1341 
CanMyc30 DQ464421 CM turicensis  Cat 1341 
CanMyc31 DQ464422 CM turicensis  Cat 1341 
CanMyc32 DQ464423 CM turicensis  Cat 1394 
CanMyc33 DQ464424 CM turicensis  Cat 1294 
CanMyc34 DQ464425 CM turicensis  Cat 1294 
CanMyc42 DQ825448 CM turicensis  Leopardus pardali 1306 
CanMyc43 DQ825449 CM turicensis  European wildcat 1341 
CanMyc44 DQ825450 CM turicensis  European wildcat 1341 
CanMyc46 DQ825454 CM turicensis  Lion 1343 
CanMyc60 EU532066 CM turicensis  Cat 1179 
CanMyc61 EU789558 CM turicensis  Cat 1238 
CanMyc62 EU789559 CM turicensis  Cat 1232 
CanMyc63 EU839977 CM turicensis  Felis catus 1292 
CanMyc71 EU861063 CM turicensis  Felis catus 1259 
MycSpe32 AY831867 CM turicensis  Cat 1395 
MycCavip NR_024988 Mycoplasma cavipharyngis Guinea pig 1444 
MycCocco AY171918 Mycoplasma coccoides Mouse 1430 
MycFast3 NR_024987 Mycoplasma fastidiosum Horse 1455 
HmbCanis AF197337 Mycoplasma haemocanis Dog 1397 
HmcCani2 AF407208 Mycoplasma haemocanis Dog 1393 
MycHaem4 AY150973 Mycoplasma haemocanis Dog 1430 
MycHae10 AY529641 Mycoplasma haemocanis Dog 1393 
MycHae23 EF416566 Mycoplasma haemocanis Dog 1330 
MycHae24 EF416567 Mycoplasma haemocanis Dog 1328 
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Table VIII-4 continued 
ARB Accession Description Host bp 
MycHae25 EF416568 Mycoplasma haemocanis Dog 1330 
MycHae33 GQ129115 Mycoplasma haemocanis Dog 1283 
MycHae34 GQ129116 Mycoplasma haemocanis Dog 1283 
MycHae35 GQ129117 Mycoplasma haemocanis Dog 1283 
MycHae36 GQ129118 Mycoplasma haemocanis Dog 1283 
MycHae37 EF416568 Mycoplasma haemocanis Dog 1330 
HmbFelis AF178677 Mycoplasma haemofelis  Cat 1429 
HmbFeli2 AY069948 Mycoplasma haemofelis  Cat 1393 
HmbFeli3 U95297 Mycoplasma haemofelis Cat 1377 
MycHaem2 AF548631 Mycoplasma haemofelis  Cat 1396 
MycHaem3 AY150972 Mycoplasma haemofelis  Cat 1396 
MycHaem5 AY150976 Mycoplasma haemofelis  Cat 1396 
MycHaem6 AY150977 Mycoplasma haemofelis  Cat 1396 
MycHaem7 AY150984 Mycoplasma haemofelis  Cat 1396 
MycHaem8 AY150985 Mycoplasma haemofelis  Cat 1396 
MycHaem9 AY529632 Mycoplasma haemofelis  Cat 1312 
MycHae11 DQ157155 Mycoplasma haemofelis  Cat 1328 
MycHae12 DQ157156 Mycoplasma haemofelis  Cat 1330 
MycHae13 DQ157157 Mycoplasma haemofelis  Cat 1322 
MycHae14 DQ157158 Mycoplasma haemofelis  Cat 1330 
MycHae15 DQ157159 Mycoplasma haemofelis  Cat 1330 
MycHae16 DQ157160 Mycoplasma haemofelis  Cat 1330 
MycHae17 DQ825438 Mycoplasma haemofelis  Leopardus wiedii 1330 
MycHae18 DQ825441 Mycoplasma haemofelis  European wildcat 1329 
MycHae19 DQ825447 Mycoplasma haemofelis  Iberian lynx 1328 
MycHae20 DQ825451 Mycoplasma haemofelis  Lion 1333 
MycHae21 DQ825453 Mycoplasma haemofelis  Lion 1330 
MycHae22 DQ825458 Mycoplasma haemofelis  Eurasian lynx 1331 
MycHae26 EU145745 Mycoplasma haemofelis  Cat 1452 
MycHae27 EU442639 Mycoplasma haemofelis  Felis catus 1207 
MycHae28 EU839978 Mycoplasma haemofelis  Felis catus 1283 
MycHae29 EU930823 Mycoplasma haemofelis  Felis catus 1323 
MycHae30 U88563 Mycoplasma haemofelis  Cat 1402 
MycHae90 NC_014970 Mycoplasma haemofelis  Cat 1429 
HmbMuris U82963 Mycoplasma haemomuris Wild mouse 1401 
MycInso2 EU859974 Mycoplasma insons  1546 
MycoOvis AF338268 Mycoplasma ovis Sheep, goat 1458 
MycoOvi2 EU165509 Mycoplasma ovis Ovis aries 1458 
MycoOvi3 EU165510 Mycoplasma ovis Ovis aries 1458 
MycoOvi4 EU165511 Mycoplasma ovis Ovis aries 1458 
MycoOvi5 EU916726 Mycoplasma ovis Sheep 1080 
MycoOvi6 FJ440328 Mycoplasma ovis Sheep 1079 
MycoOv12 GU230143 Mycoplasma ovis Homo sapiens 1457 
MycoOv13 GU230142 Mycoplasma ovis Homo sapiens 1457 
MycOv14 GU230144 Mycoplasma ovis Homo sapiens 1457 
MycoOv15 EU828582 Mycoplasma ovis Ovis aries 1362 
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Table VIII-4 continued 
ARB Accession Description Host bp 
MycoOv18 AB571119 Mycoplasma ovis Capricornis crispus 993 
MycPneu5 NC_000912 Mycoplasma pneumoniae M129  1513 
MycSpe39 EF424082 Mycoplasma sp. China-1  Buffalo 1434 
MycSpe90 GU124600 Mycoplasma sp. CSL 7666 Sea lion 1438 
MycSpe91 GU124601 Mycoplasma sp. CSL 7755 Sea lion 1438 
MycSpe92 GU124602 Mycoplasma sp. CSL 7750 Sea lion 1438 
MycSpe93 GU124603 Mycoplasma sp. CSL 7783 Sea lion 1438 
MycSpe94 GU124604 Mycoplasma sp. CSL 7873 Sea lion 1438 
MycSpe95 GU124605 Mycoplasma sp. CSL 7881 Sea lion 1438 
MycSpe96 GU124606 Mycoplasma sp. CSL 7758 Sea lion 1438 
MycSpe97 GU124607 Mycoplasma sp. CSL C797 Sea lion 1438 
MycSpe98 GU124608 Mycoplasma sp. CSL C606 Sea lion 1438 
MycSpe99 GU124609 Mycoplasma sp. CSL 7897 Sea lion 1438 
MycSp100 GU124610 Mycoplasma sp. CSL 7801 Sea lion 1438 
MycSp101 GU124611 Mycoplasma sp. CSL 7822 Sea lion 1438 
MycSp102 GU124612 Mycoplasma sp. CSL C795 Sea lion 1438 
MycSp103 GU124613 Mycoplasma sp. CSL 7860 Sea lion 1438 
MycSp104 GU124614 Mycoplasma sp. CSL 7871 Sea lion 1438 
MycSp110 FR668085 Mycoplasma sp. horse 111 Horse 107 
MycSp111 FR668086 Mycoplasma sp. horse 127 Horse 106 
MycSp112 FR668084 Mycoplasma sp. horse 90 Horse 110 
MycSpe16 FN421444 Mycoplasma sp. Horse isolate 30/14 Horse 916 
MycSpe18 FN421445 Mycoplasma sp. Horse isolate 30/7 Horse 880 
MycSpe17 FN421443 Mycoplasma sp. Horse isolate 32/3 Horse 896 
MycSpe66 FN392887 Mycoplasma sp. Isolate BovHM-2 Cattle 978 
MycSpe67 FN392888 Mycoplasma sp. Isolate BovHM-5 Cattle 978 
MycSpe68 FN392889 Mycoplasma sp. Isolate BovHM-7 Cattle 978 
EperSuis AF029394 Mycoplasma suis ‘Zachary’ Sus scrofa 1374 
EperSui2 U88565 Mycoplasma suis ‘Illinois’ Sus scrofa 1436 
MycoSuis AY492086 Mycoplasma suis ‘Guangdong’ Sus scrofa 1468 
MycoSui2 EU603330 Mycoplasma suis  Sus scrofa 1473 
MycoSui3 FJ263943 Mycoplasma suis  Sus scrofa 1473 
MycoSui4 FJ263944 Mycoplasma suis  Sus scrofa 1473 
MycoSui6 FN391022 Mycoplasma suis  Sus scrofa 1479 
MycoSui7 FN391021 Mycoplasma suis  Sus scrofa 1479 
MycoSui9 FN391018 Mycoplasma suis  Wild boar 1009 
MycoSu10 FN391020 Mycoplasma suis  Wild boar 1007 
MycoSu11 FN391019 Mycoplasma suis  Wild boar 1008 
MyocSu12 FN436016 Mycoplasma suis  Wild boar 1008 
MycoSu13 FN436017 Mycoplasma suis  Wild boar 1008 
MycoSu14 FN436018 Mycoplasma suis  Wild boar 1006 
MycoSu15 FN436019 Mycoplasma suis  Wild boar 1002 
MycoSu16 FN436009 Mycoplasma suis  Wild boar 972 
MycoSu17 FN436010 Mycoplasma suis  Wild boar 1009 
MycoSu18 FN436011 Mycoplasma suis  Wild boar 1006 
MycoSu19 FN436012 Mycoplasma suis  Wild boar 1006 
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Table VIII-4 continued 
ARB Accession Description Host bp 
MycoSu20 FN436013 Mycoplasma suis  Wild boar 1005 
MycoSu21 FN436014 Mycoplasma suis  Wild boar 1007 
MycoSu22 FN436015 Mycoplasma suis  Wild boar 1003 
MycoSu34 HQ259257 Mycoplasma suis ‘Zhejiang’ Sus scrofa 1473 
MycoSu35 NC_015153 Mycoplasma suis Sus scrofa 1469 
EpeWenyo AF016546 Mycoplasma wenyonii  Cattle 1394 
MycWenyo AY769937 Mycoplasma wenyonii  Cattle 1399 
MycWeny2 AY946266 Mycoplasma wenyonii  Cattle 1471 
MycWeny3 DQ641256 Mycoplasma wenyonii  Cattle 1334 
MycWeny4 EF221880 Mycoplasma wenyonii  Cattle 1453 
MycWeny5 EU367963 Mycoplasma wenyonii  Cattle 1374 
MycWeny6 EU367964 Mycoplasma wenyonii  Cattle 1249 
MycWeny7 FJ375309 Mycoplasma wenyonii  Cattle 1454 
MycWeny8 FN392885 Mycoplasma wenyonii  Cattle 1083 
MycWeny9 FN392886 Mycoplasma wenyonii  Cattle 1004 
MycWen20 HM538187 Mycoplasma wenyonii  Cattle 1470 
MycWen21 HM538188 Mycoplasma wenyonii  Cattle 1469 
MycWen22 HM538189 Mycoplasma wenyonii  Cattle 1470 
MycWen23 HM538190 Mycoplasma wenyonii  Cattle 1470 
MycWen24 HM538191 Mycoplasma wenyonii  Cattle 1471 
UncMyc20 AY837724 Uncultured Mycoplasma sp.  Mosquito midgut 1457 
UncMyc48 EU888930 Uncultured Mycoplasma sp. Homo sapiens 1214 
UncMyc52 FJ667774 Uncultured Mycoplasma sp.  Capybara 1347 
UncMyc53 FJ824847 Uncultured Mycoplasma sp. Deer 1370 
UncMyc54 FJ667773 Uncultured Mycoplasma sp.  Capybara 1347 
UncMyc55 HQ183731 Uncultured Mycoplasma sp.  Leopoldamys edwardsi  1342 
UncMyc56 HQ183732 Uncultured Mycoplasma sp.  Leopoldamys edwardsi  1360 
UncMyc57 HQ197742 Uncultured Mycoplasma sp.  Mazama nana 1242 
UncMyc58 HQ197743 Uncultured Mycoplasma sp.  Blastoceros dichotomus 1239 
UncMyc59 HQ197744 Uncultured Mycoplasma sp.  Mazama nana 1246 
UncMyc60 HQ197745 Uncultured Mycoplasma sp.  Mazama nana 1242 
UncMyc61 HQ197746 Uncultured Mycoplasma sp.  Blastoceros dichotomus 1248 
UncMyc62 HQ197747 Uncultured Mycoplasma sp.  Blastoceros dichotomus 1252 
UncMyc63 HQ197748 Uncultured Mycoplasma sp.  Mazama americana 1253 
UncMyc64 HQ197749 Uncultured Mycoplasma sp.  Mazama nana 1242 
CM = Candidatus Mycoplasma; isolates sequenced during this study are highlighted in boldface 
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Alignment 16S rRNA of equine HM 
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Alignment 16S rRNA of equine HM 
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VIII.5 Index of manufacturer 
• Applied Biosystems 
• Assistant, Sondheim, Germany 
• BAL-TEC AG, Balzers, Liechtenstein 
• BD Biosciences, Allschwil, Switzerland 
• Chemie Brunschwig AG, Basel, Switzerland 
• Difco, Becton Dickinson AG, Allschwil, Switzerland 
• Erie Scientific Company, Portsmouth, New Hampshire, USA 
• Fluka, Sigma-Aldrich Chemie GmbH, Buchs, Switzerland 
• Gibco, Invitrogen AG, Basel, Switzerland 
• Hoechst, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany 
• Integrated DNA Technologies, Coralville, USA 
• Invitrogen AG, Basel, Switzerland 
• Leica Microsystems, Mannheim, Germany 
• Menzel, Gerhard Menzel Glasbearbeitungswerk GmbH & Co. KG, Braunschweig, 
Germany 
• Merck AG, Zug, Switzerland 
• MWG, Eurofins MWG GmbH, Ebersberg, Germany 
• NEN® Life Science Products, Inc. Boston, USA 
• Oxoid AG, Pratteln, Switzerland 
• Qiagen AG, Hombrechtikon, Switzerland 
• Roche, F. Hoffmann-La Roche AG, Basel, Switzerland 
• Roth, Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
• Shandong, Dako-Diagnostica, Zug, Switzerland 
• Sigma-Aldrich Chemie GmbH, Buchs, Switzerland 
• SIRS-lab GmbH, Jena, Germany 
• synlab.vet GmbH, Geesthacht, Germany 
• Fisher Scientific AG, Wohlen, Switzerland 
• Vacuette, Greiner Bio-One International AG, Kremsmünster, Austria 
• Vadaux Eppendorf, Schönenbuch, Basel, Switzerland 
• Zeiss, Carl Zeiss AG, Feldbach, Switzerland 
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